

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 2015280120 B2

(54) Title
Nuclease-mediated DNA assembly

(51) International Patent Classification(s)
C12N 15/10 (2006.01) **C12N 15/66** (2006.01)
C12N 15/64 (2006.01)

(21) Application No: **2015280120** (22) Date of Filing: **2015.06.23**

(87) WIPO No: **WO15/200334**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/036,983	2014.08.13	US
62/016,400	2014.06.24	US
62/015,809	2014.06.23	US

(43) Publication Date: **2015.12.30**
(44) Accepted Journal Date: **2017.05.25**

(71) Applicant(s)
Regeneron Pharmaceuticals, Inc.

(72) Inventor(s)
Schoenherr, Chris;Mcwhirter, John;Momont, Corey;Macdonald, Lynn;Murphy, Andrew J.;Warshaw, Gregg S.;Rojas, Jose F.;Lai, Ka-Man Venus;Valenzuela, David M.;Montagna, Caitlin

(74) Agent / Attorney
Phillips Ormonde Fitzpatrick, PO Box 323, Collins Street West, VIC, 8007, AU

(56) Related Art
US 2010/035768 A1
GIBSON D.G. et al., Nature Methods, 2009, Vol. 6, pages 343-345
LI M. Z et al., Nature Methods, 2007, Vol. 4, pages 251-256
ZHAO G. et al., Journal of Biosciences, Indian Academy of Sciences, In, 2013, Vol. 38, pages 857-866

(43) International Publication Date
30 December 2015 (30.12.2015)(51) International Patent Classification:
C12N 15/10 (2006.01) *C12N 15/66* (2006.01)
C12N 15/64 (2006.01)(21) International Application Number:
PCT/US2015/037199(22) International Filing Date:
23 June 2015 (23.06.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/015,809 23 June 2014 (23.06.2014) US
62/016,400 24 June 2014 (24.06.2014) US
62/036,983 13 August 2014 (13.08.2014) US(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).(72) Inventors: **SCHOENHERR, Chris**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MCWHIRTER, John**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MOMONT, Corey**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MACDONALD, Lynn**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MURPHY, Andrew, J.**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **WARSHAW, Gregg, S.**; C/o Regeneron Pharmaceuticals, Inc.,777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **ROJAS, Jose, F.**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **LAI, Ka-man, Venus**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **VALENZUELA, David, M.**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MONTAGNA, Caitlin**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).(74) Agents: **RAY, Denise, M.** et al.; Alston & Bird LLP, Bank of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, NC 28280-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: NUCLEASE-MEDIATED DNA ASSEMBLY




FIG. 1

(57) **Abstract:** Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *with amended claims (Art. 19(1))*

— *with sequence listing part of description (Rule 5.2(a))*

Published:

— *with international search report (Art. 21(3))*

Date of publication of the amended claims: 17 March 2016

NUCLEASE-MEDIATED DNA ASSEMBLY

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/015,809, filed June 23, 2014, U.S. Provisional Application No. 62/016,400, filed June 24, 2014, and of U.S. Provisional Application No. 62/036,983, filed August 13, 2014, each of which is hereby incorporated herein in its entirety by reference.

AS A TEXT FILE VIA EFS WEB

[0002] The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file named 461002SEQLIST.TXT, created on June 23, 2015, and having a size of 66KB, and is filed concurrently with the specification. The sequence listing contained in this ASCII formatted document is part of the specification and is herein incorporated by reference in its entirety.

BACKGROUND

[0003] Historically, overlap extension could be used as a means of synthesizing larger double stranded DNA molecules, particularly genes, from overlapping synthetic oligonucleotides. However, these methods could not effectively combine large DNA molecules in a rapid manner. Further, site-specific combination of large nucleic acids using overlapping sequences is often limited by the availability of overlapping sequences at the desired position in the nucleic acids to be combined. Engineered nuclease enzymes designed to target specific DNA sequences have attracted attention as powerful tools for genetic manipulation allowing for targeted gene deletion, replacement, and repair, as well as the insertion of exogenous sequences. However, existing technologies suffer from limited precision, which can lead to unpredictable off-target effects and time consuming multistep reactions.

SUMMARY

[0003a] In one aspect, the present invention provides a method for assembling two or more nucleic acids, comprising:

(a) contacting a first nucleic acid with a first nuclease agent, wherein the first nuclease agent comprises a Cas protein and a guide RNA (gRNA) (gRNA-Cas complex), a zinc finger nuclease, or a Transcription Activator-Like Effector Nuclease (TALEN), wherein

the first nuclease agent cleaves the first nucleic acid at a first target site to produce a first digested nucleic acid with an overlapping end sequence shared by a second nucleic acid;

(b) contacting the first digested nucleic acid and the second nucleic acid with an exonuclease to expose complementary sequences between the first digested nucleic acid and the second nucleic acid; and

(c) assembling the two nucleic acid fragments generated from step (b).

[0003b] In a further aspect, the present invention provides a method for assembling two or more nucleic acids, comprising:

(a) contacting a first nucleic acid with at least one nuclease agent, wherein the at least one nuclease agent comprises a Cas protein and a guide RNA (gRNA) (gRNA-Cas complex), a zinc finger nuclease, or a Transcription Activator-Like Effector Nuclease (TALEN), wherein the at least one nuclease agent cleaves the first nucleic acid at a first target site to generate a first digested nucleic acid;

(b) contacting the first digested nucleic acid with a second nucleic acid, a joiner oligo, and an exonuclease, wherein the joiner oligo comprises:

(i) a first complementary sequence that is complementary to the first digested nucleic acid;

(ii) a spacer; and

(iii) a second complementary sequence that is complementary to the second nucleic acid; wherein the exonuclease exposes the first and second complementary sequences; and

(c) assembling the joiner oligo with the first digested nucleic acid and the second nucleic acid.

[0003c] Methods are provided herein for assembling nucleic acids having overlapping sequences. Such methods comprise a method for assembling at least two nucleic acids, comprising: (a) contacting a first nucleic acid with a first nuclease agent, wherein the first nuclease agent cleaves the first nucleic acid at a first target site to produce a first digested nucleic acid with overlapping end sequences between the first digested nucleic acid and a

second nucleic acid; (b) contacting the first digested nucleic acid and the second nucleic acid with an exonuclease to expose complementary sequences between the first digested nucleic acid and the second nucleic acid; and (c) assembling the two nucleic acid fragments generated from step (b). In some such methods step (c) further comprises: (i) annealing the exposed complementary sequences; (ii) extending 3' ends of the annealed complementary sequences; and (iii) ligating the first and the second nucleic acid.

[0004] In some of the methods step (a) further comprises contacting the second nucleic acid with a second nuclease agent, wherein the second nucleic acid does not comprise the overlapping end sequence, and the second nuclease agent cleaves the second nucleic acid at a second target site to produce a second digested nucleic acid with the overlapping end sequences between the first digested nucleic acid and the second digested nucleic acid, and wherein the second nucleic acid of step (b) is the second digested nucleic acid. In some of the methods, the overlapping end sequence ranges from 20 bp to 200 bp long.

[0005] In some of the methods, at least one of the first or second nuclease agent comprises a Cas protein and a guide RNA (gRNA) (gRNA-Cas complex) that targets the first or the second target site. For example, the Cas protein can be a Cas9 protein. The Cas9 protein may comprise a RuvC domain and a HNH domain, at least one of which lacks endonuclease activity. In some embodiments, the gRNA comprises a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA). The first target site and/or second target site can be flanked by a Protospacer Adjacent Motif (PAM) sequence. In some of the methods the nuclease agent comprises a zinc finger nuclease or a Transcription Activator-Like Effector Nuclease (TALEN).

[0006] In some of the methods the first, the second, or both nucleic acids are from a bacterial artificial chromosome. The bacterial artificial chromosome can comprise a human DNA, a rodent DNA, a synthetic DNA, or a combination thereof. The bacterial artificial chromosome can comprise a human sequence.

[0007] The methods disclosed herein include a method for assembling at least two nucleic acids, comprising: (a) contacting a first nucleic acid with a first nuclease agent and a second nuclease agent to produce a first digested nucleic acid, wherein the first nuclease agent generates a nick on a first strand of the first nucleic acid at a first target site, and the second nuclease agent generates a nick on a second strand of the first nucleic acid at a second target site, to produce a first digested nucleic acid comprising 5' or 3' overhanging sequence at one of its ends; (b) annealing the first digested nucleic acid and a second nucleic acid

comprising a complementary sequence to the 5' or 3' overhanging sequence; and (c) ligating the first digested nucleic acid and the second nucleic acid. In some of the methods, step (b) further comprises extending the 3' end of the first strand using the second strand as a template and extending the 3' end of the second strand based using the first strand as a template. In some of the methods, the first target site is separated by at least 4 bp from the second target site.

[0008] In some of the methods, at least one of the first or second nuclease agent comprises a Cas9 protein and a guide RNA (gRNA) (gRNA-Cas complex) that targets the first or the second target site. The gRNA can comprise a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA). In some of the methods, at least one of the first target site and second target site is flanked by a Protospacer Adjacent Motif (PAM) sequence. The Cas9 protein can comprise a RuvC domain and a HNH domain, one of which lacks endonuclease activity.

[0009] In some of the methods, the second nucleic acid does not comprise the complementary sequence to the 5' or 3' overhanging sequence of the first digested nucleic acid, and step (a) further comprises contacting the first digested nucleic acid and the second digested nucleic acid with a joiner oligo, wherein the joiner oligo comprises: (i) a first complementary sequence to the 5' or 3' overhanging sequence of the first digested nucleic acid; and (ii) a second complementary sequence to the 5' or 3' overhanging sequence of the second digested nucleic acid. In some methods, the first, the second, or both nucleic acids are derived from a bacterial artificial chromosome. The bacterial artificial chromosome can comprise a human DNA, a rodent DNA, a synthetic DNA, or a combination thereof. The bacterial artificial chromosome can comprise a human polynucleotide sequence. In some methods, the second nucleic acid comprises a bacterial artificial chromosome.

[0010] Methods provided also include a method for assembling two or more nucleic acid fragments, comprising: (a) contacting a first nucleic acid with at least one nuclease agent to generate a first digested nucleic acid; (b) contacting the first digested nucleic acid with a second nucleic acid, a joiner oligo, and an exonuclease, wherein the joiner oligo comprises: (i) a first complementary sequence that is complementary to the first digested nucleic acid; (ii) a spacer; and (iii) a second complementary sequence that is complementary to the second nucleic acid; wherein the exonuclease exposes the first and second complementary sequences; and (c) assembling the joiner oligo with the first digested nucleic acid and the second nucleic acid. In some such methods the assembling in step (c) comprises: (i)

annealing the first complementary sequence of the joiner oligo to the first digested nucleic acid and the second complementary sequence of the joiner oligo to the second nucleic acid; and (ii) ligating the joiner oligo to the first digested nucleic acid and the second nucleic acid.

[0011] In some methods the first complementary sequence and the second complementary sequence of the joiner oligo comprise between 15 and 120 complementary bases. In some methods, the spacer of the joiner oligo comprises non-complementary nucleic acids. In some embodiments, the first digested nucleic acid is seamlessly assembled to the second nucleic acid.

[0012] In some methods, the nuclease agent is designed to cleave an at least 20 bp fragment from the end of the first nucleic acid at which the seamless assembly will occur, wherein, the spacer of the joiner oligo comprises a sequence identical to said at least 20 bp fragment, wherein no nucleic acid bases are present between the first complementary sequence and the at least 20 bp fragment, and no nucleic acid bases are present between the second complementary sequence and the at least 20 bp fragment, such that assembly of said first nucleic acid with said joiner oligo and said second nucleic acid reconstitutes the at least 20 bp fragment and seamlessly assembles the first and second nucleic acid. In some methods, the same method is performed with an at least 20 bp fragment from the second nucleic acid as the spacer sequence. In some methods, the spacer comprises from about 20 bp to about 120 bp. In some methods, the second nucleic acid is contacted with a second nuclease agent and an exonuclease, wherein the second nuclease agent cleaves the second nucleic acid to produce a second digested nucleic acid comprising a nucleotide sequence that is complementary to the second complementary sequence of the joiner oligo, wherein the first digested nucleic acid is assembled to the second digested nucleic acid. In some methods, the second nucleic acid is contacted with a restriction enzyme or meganuclease and an exonuclease, wherein the restriction enzyme or meganuclease cleaves the second nucleic acid to produce a second digested nucleic acid comprising a nucleotide sequence that is complementary to the second complementary sequence in the joiner oligo, wherein the first digested nucleic acid is assembled to the second digested nucleic acid. In some methods, the 3' end of the first and/or the second digested nucleic acids is extended in step (b). The joiner oligo can be assembled to said first nucleic acid and said second nucleic acid in the same reaction or sequentially. In some methods, the first, the second, or both nucleic acids are derived from a bacterial artificial chromosome, at least 10 kb, and/or comprise a human DNA, rodent DNA, a synthetic DNA, or a combination thereof.

[0013] In some of the methods, the at least one nuclease agent or second nuclease agent comprises a Cas protein and a guide RNA (gRNA) (gRNA-Cas complex) that targets the first or the second target site. For example, the Cas protein can be a Cas9 protein. The Cas9 protein may comprise a RuvC domain and a HNH domain, at least one of which lacks endonuclease activity. In some embodiments, the gRNA comprises a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA). The first target site and/or second target site can be flanked by a Protospacer Adjacent Motif (PAM) sequence. In some of the methods the at least one nuclease agent and/or the second nuclease agent comprises a zinc finger nuclease or a Transcription Activator-Like Effector Nuclease (TALEN).

[0014] In some embodiments, the joiner oligo comprises a gBlock. In some such methods, the gBlock does not comprise a selection cassette.

[0015] Methods are further provided for assembling two or more nucleic acids, comprising: (a) contacting a first nucleic acid with at least one nuclease agent to generate a first digested nucleic acid; (b) contacting a second nucleic acid with a second nuclease agent to generate a second digested nucleic acid; (c) contacting the first digested nucleic acid and the second digested nucleic acid with a joiner oligo and an exonuclease, wherein the joiner oligo comprises: (i) a first complementary sequence that is complementary to the first digested nucleic acid; (ii) a spacer; and (iii) a second complementary sequence that is complementary to the second digested nucleic acid; wherein the exonuclease exposes the first and second complementary sequences; and (d) assembling the joiner oligo with the first digested nucleic acid and the second nucleic acid.

[0016] Methods are provided herein for assembling nucleic acids having overlapping sequences. Such methods comprise a method for assembling at least two nucleic acid fragments, comprising (a) contacting a first and a second nucleic acid comprising overlapping sequences with at least one gRNA-Cas complex and an exonuclease, thereby generating two digested nucleic acid fragments comprising complementary sequences at one of their ends; (b) assembling the two nucleic acid fragments generated from step (a). In some methods, the at least one gRNA-Cas complex cleaves the first nucleic acid at a first target site to produce a first digested nucleic acid comprising complementary end sequences between the first digested nucleic acid and the second nucleic acid. In certain methods, step (b) further comprises: (i) annealing the exposed complementary sequences; (ii) extending 3' ends of the annealed complementary sequences; and (iii) ligating the first and the second nucleic acid. In some methods, step (a) further comprises contacting the second nucleic acid with a second

gRNA-Cas complex, wherein the second nucleic acid does not comprise the overlapping end sequence, and the second gRNA-Cas complex cleaves the second nucleic acid to produce a second digested nucleic acid comprising the overlapping end sequences between the first digested nucleic acid and the second digested nucleic acid. For example, the gRNA-Cas complex comprises a Cas9 protein. The Cas9 protein can comprise a RuvC domain and a HNH domain, at least one of which lacks endonuclease activity. In some methods, the overlapping sequence ranges from 20 bp to 200 bp long. The method of any one of claims 1-7, wherein the first, the second, or both nucleic acids are from a bacterial artificial chromosome. In some methods, the bacterial artificial chromosome comprises a human DNA, a rodent DNA, a synthetic DNA, or a combination thereof. The bacterial artificial chromosome can comprise a human sequence.

[0017] Methods provided also include a method for assembling two or more nucleic acid fragments, comprising: (a) exposing a first and a second nucleic acid to at least one gRNA-Cas complex to generate a first and a second digested nucleic acids comprising a 5' or 3' overhanging sequence at one of their ends; (b) assembling the two nucleic acid fragments generated from step (a). In some methods, assembling step (b) comprises: (i) annealing the 5' and 3' overhanging sequences; and (ii) ligating the first digested nucleic acid and the second digested nucleic acid. In some methods, the 5' and/or 3' overhanging sequences comprise at least 4 complementary bases. In some methods, step (b) further comprises extending the 3' end of the first and the second digested nucleic acids. In some methods, the second nucleic acid does not comprise a complementary sequence to the 5' or 3' overhanging sequence of the first digested nucleic acid, and step (a) further comprises contacting the first digested nucleic acid and the second digested nucleic acid with a joiner oligo, wherein the joiner oligo comprises: (i) a first complementary sequence to the 5' or 3' overhanging sequence of the first digested nucleic acid; and (ii) a second complementary sequence to the 5' or 3' overhanging sequence of the second digested nucleic acid. In some methods, the gRNA-Cas protein complex comprises a Cas9 protein comprising a RuvC domain and a HNH domain, one of which lacks endonuclease activity. In some methods the gRNA-Cas complex is provided separately as a crRNA, tracrRNA, and Cas protein. In some methods, the first and the second nucleic acids comprise a Protospacer Adjacent Motif (PAM) sequence. In some methods, the first, the second, or both nucleic acids are derived from a bacterial artificial chromosome. In some methods, the bacterial artificial chromosome comprises a human DNA, a rodent DNA, a synthetic DNA, or a combination thereof. For example, the bacterial artificial chromosome can comprise a human polynucleotide sequence.

[0018] Methods are further provided for assembling two or more nucleic acids, comprising: (a) contacting a first nucleic acid with at least one gRNA-Cas complex to generate a first digested nucleic acid; and (b) contacting the first digested nucleic acid with a second nucleic acid, a joiner oligo, and an exonuclease, wherein the joiner oligo comprises: (i) a first complementary sequence that is complementary to the first digested nucleic acid; (ii) a spacer; and (iii) a second complementary sequence that is complementary to the second nucleic acid; wherein the exonuclease exposes the first and second complementary sequences; and (c) assembling the joiner oligo with the first digested nucleic acid and the second nucleic acid. In some methods assembling step (c) comprises (i) annealing the first complementary sequence of the joiner oligo to the first digested nucleic acid and the second complementary sequence of the joiner oligo to the second nucleic acid; and (ii) ligating the joiner oligo to the first digested nucleic acid and the second nucleic acid. In some methods the first complementary sequence and the second complementary sequence of the joiner oligo comprise between 15 and 120 complementary bases. In some methods, the spacer of the joiner oligo comprises non-complementary nucleic acids.

[0019] Using the joiner oligo, the first digested nucleic acid can be seamlessly assembled to the second nucleic acid. In some methods, the gRNA-Cas complex is designed to cleave an at least 20 bp fragment from the end of the first nucleic acid at which the seamless assembly will occur, wherein, the spacer of the joiner oligo comprises a sequence identical to said at least 20 bp fragment, wherein no nucleic acid bases are present between the first complementary sequence and the at least 20 bp fragment, and no nucleic acid bases are present between the second complementary sequence and the at least 20 bp fragment, such that assembly of said first nucleic acid with said joiner oligo and said second nucleic acid reconstitutes the at least 20 bp fragment and seamlessly assembles the first and second nucleic acid. In some methods, the same method is performed with an at least 20 bp fragment from the second nucleic acid as the spacer sequence. In some methods, the spacer comprises from about 20 bp to about 120 bp. In some methods, the second nucleic acid is contacted with a second gRNA-Cas complex and an exonuclease, wherein the second gRNA-Cas complex cleaves the second nucleic acid to produce a second digested nucleic acid comprising a nucleotide sequence that is complementary to the second complementary sequence of the joiner oligo, wherein the first digested nucleic acid is assembled to the second digested nucleic acid. In some methods, the second nucleic acid is contacted with a restriction enzyme or meganuclease and an exonuclease, wherein the restriction enzyme or meganuclease cleaves the second nucleic acid to produce a second digested nucleic acid comprising a

nucleotide sequence that is complementary to the second complementary sequence in the joiner oligo, wherein the first digested nucleic acid is assembled to the second digested nucleic acid. In some methods, the 3' end of the first and/or the second digested nucleic acids is extended in step (b). The joiner oligo can be assembled to said first nucleic acid and said second nucleic acid in the same reaction or sequentially. In some methods, the gRNA-Cas complex comprises a Cas9 protein. In some methods, the first, the second, or both nucleic acids are derived from a bacterial artificial chromosome, at least 10 kb, and/or comprise a human DNA, rodent DNA, a synthetic DNA, or a combination thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] FIG. 1 shows assembly of a BAC to a PCR product having overlaps designed to be specific for the BAC. 50 bp overlaps were added to the HYG cassette by PCR.

[0021] FIG. 2 shows assembly of two BACs having overlapping sequences using two Cas9 target sites on each BAC. The process of assembly using the method disclosed herein took 2 days.

[0022] FIG. 3 shows assembly of two BACs with overlapping sequences using traditional methods. The process of assembly using traditional methods took 4 weeks.

[0023] FIG. 4 shows the cloning efficiencies of Cas9/isothermal assembly method and the time required for BAC cloning steps.

[0024] FIG. 5 shows the construction of a large targeting vector (LTVEC) using CRISPR/Cas9 system and isothermal assembly. DNA fragments cleaved with CRISPR/Cas9 were seamlessly assembled using one or more joiner oligos and isothermal assembly.

[0025] FIG. 6 shows the strategy for using linkers (joiner oligos) for seamlessly assembling nucleic acids after Cas9 cleavage. A gRNA/Cas9 complex is designed to cleave a target site located 5' upstream of an area of interest (arrow) to generate a first Cas9-digested DNA fragment (5' DNA). The deleted portion of the 5' DNA (slashed box) is then used as a spacer between the 5' and 3' overlapping sequences in a joiner oligo. Three components are assembled in the isothermal assembly reaction: (a) a first Cas9-digested DNA fragment (5' DNA); (b) a joiner oligo; and (c) a second DNA fragment (3' DNA). The joiner oligo comprises from 5' to 3': (1) an overlapping sequence with 5' DNA, (2) a spacer containing the deleted portion of the first digested fragment, and (3) an overlapping sequence with 3' DNA. The deleted portion of the 5'DNA is reconstituted during the assembly step.

[0026] FIG. 7 shows the construction of a DNA vector using CRISPR/Cas9 system and isothermal assembly.

[0027] FIG. 8 shows the construction of a large targeting vector using CRISPR/Cas9 system and isothermal assembly.

[0028] FIG. 9 shows the construction of a targeting vector for replacement of a portion of a BAC vector with a cassette using isothermal assembly and two linkers (joiner oligos). The results of various ratios of mBAC to fragments or linkers are presented in panels #1, #2, #3, and #4.

[0029] FIG. 10 shows the sequence confirmation of seamless assembly across both junctions of the assembly reaction between an mBAC (BAC ID: RP23-399M19) and a cassette using two linkers.

[0030] FIG. 11 shows the assembly of two mBACs using Cas9 and isothermal assembly. Assembly between the bMQ50f19 vector and the cassette comprising a hygromycin resistance gene ubiquitin promoter was seamless.

[0031] FIG. 12 shows the sequence confirmation of seamless assembly at linker 1, and sequence confirmation of assembly that was intentionally not seamless at linker 2 and linker 3.

[0032] FIG. 13 shows the insertion of large human gene fragments onto a mBAC using four linkers and isothermal assembly. Cas9 cleaved hGene fragment A from hBAC1, hGene Fragment B from hBAC2, and mBAC to remove mGene fragments.

[0033] FIG. 14 shows the insertion of human sequence into a BAC vector using Cas9 and Isothermal Assembly.

[0034] FIG. 15 shows the insertion of a gBlock comprising a meganuclease site using Cas9 and Isothermal Assembly. FIG. 15A shows the insertion of a gBlock comprising a PI-SeeI site; and FIG. 15B shows the insertion of a gBlock comprising a MauBI site.

[0035] FIG. 16 illustrates an example of direct humanization of a targeting vector using three joiner oligos, Cas9, and isothermal assembly.

[0036] FIG. 17 illustrates an example of indirect humanization of a targeting vector using a donor with up and down joiner oligos, Cas9, and isothermal assembly.

[0037] FIG. 18 illustrates an example of introducing a point mutation using Cas9 and Isothermal Assembly.

[0038] FIG. 19 illustrates an example of BAC trimming by Cas9 and isothermal assembly. In this example, the trimming removes the Ori sequence. The Ori sequence is re-inserted in the vector using two joiner oligos and isothermal assembly.

DETAILED DESCRIPTION

I. Definitions

[0039] The terms “protein,” “polypeptide,” and “peptide,” used interchangeably herein, include polymeric forms of amino acids of any length, including coded and non-coded amino acids and chemically or biochemically modified or derivatized amino acids. The terms also include polymers that have been modified, such as polypeptides having modified peptide backbones.

[0040] The terms “nucleic acid” and “polynucleotide,” used interchangeably herein, include polymeric forms of nucleotides of any length, including ribonucleotides, deoxyribonucleotides, or analogs or modified versions thereof. They include single-, double-, and multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, and polymers comprising purine bases, pyrimidine bases, or other natural, chemically modified, biochemically modified, non-natural, or derivatized nucleotide bases.

[0041] “Codon optimization” generally includes a process of modifying a nucleic acid sequence for enhanced expression in particular host cells by replacing at least one codon of the native sequence with a codon that is more frequently or most frequently used in the genes of the host cell while maintaining the native amino acid sequence. For example, a nucleic acid encoding a Cas protein can be modified to substitute codons having a higher frequency of usage in a given prokaryotic or eukaryotic cell, including a bacterial cell, a yeast cell, a human cell, a non-human cell, a mammalian cell, a rodent cell, a mouse cell, a rat cell, a hamster cell, or any other host cell, as compared to the naturally occurring nucleic acid sequence. Codon usage tables are readily available, for example, at the “Codon Usage Database.” These tables can be adapted in a number of ways. See Nakamura *et al.* (2000) *Nucleic Acids Research* 28:292. Computer algorithms for codon optimization of a particular sequence for expression in a particular host are also available (see, e.g., Gene Forge).

[0042] “Operable linkage” or being “operably linked” includes juxtaposition of two or more components (e.g., a promoter and another sequence element) such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. For example, a promoter can be operably linked to a coding sequence if the promoter controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors.

[0043] "Complementarity" of nucleic acids means that a nucleotide sequence in one strand of nucleic acid, due to orientation of its nucleobase groups, forms hydrogen bonds with another sequence on an opposing nucleic acid strand. The complementary bases in DNA are typically A with T and C with G. In RNA, they are typically C with G and U with A. Complementarity can be perfect or substantial/sufficient. Perfect complementarity between two nucleic acids means that the two nucleic acids can form a duplex in which every base in the duplex is bonded to a complementary base by Watson-Crick pairing. "Substantial" or "sufficient" complementary means that a sequence in one strand is not completely and/or perfectly complementary to a sequence in an opposing strand, but that sufficient bonding occurs between bases on the two strands to form a stable hybrid complex in set of hybridization conditions (e.g., salt concentration and temperature). Such conditions can be predicted by using the sequences and standard mathematical calculations to predict the Tm of hybridized strands, or by empirical determination of Tm by using routine methods. Tm includes the temperature at which a population of hybridization complexes formed between two nucleic acid strands are 50% denatured. At a temperature below the Tm, formation of a hybridization complex is favored, whereas at a temperature above the Tm, melting or separation of the strands in the hybridization complex is favored. Tm may be estimated for a nucleic acid having a known G+C content in an aqueous 1 M NaCl solution by using, e.g., $Tm=81.5+0.41(\% G+C)$, although other known Tm computations take into account nucleic acid structural characteristics.

[0044] "Hybridization condition" includes the cumulative environment in which one nucleic acid strand bonds to a second nucleic acid strand by complementary strand interactions and hydrogen bonding to produce a hybridization complex. Such conditions include the chemical components and their concentrations (e.g., salts, chelating agents, formamide) of an aqueous or organic solution containing the nucleic acids, and the temperature of the mixture. Other factors, such as the length of incubation time or reaction chamber dimensions may contribute to the environment. See, e.g., Sambrook *et al.*, Molecular Cloning, A Laboratory Manual, 2.sup.nd ed., pp. 1.90-1.91, 9.47-9.51, 1 1.47-11.57 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

[0045] Hybridization requires that the two nucleic acids contain complementary sequences, although mismatches between bases are possible. The conditions appropriate for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of complementation between two nucleotide sequences, the greater the value of the melting

temperature (T_m) for hybrids of nucleic acids having those sequences. For hybridizations between nucleic acids with short stretches of complementarity (e.g. complementarity over 35 or fewer, 30 or fewer, 25 or fewer, 22 or fewer, 20 or fewer, or 18 or fewer nucleotides) the position of mismatches becomes important (see Sambrook *et al.*, *supra*, 11.7-11.8).

Typically, the length for a hybridizable nucleic acid is at least about 10 nucleotides.

Illustrative minimum lengths for a hybridizable nucleic acid include at least about 15 nucleotides, at least about 20 nucleotides, at least about 22 nucleotides, at least about 25 nucleotides, and at least about 30 nucleotides. Furthermore, the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the region of complementation and the degree of complementation.

[0046] The sequence of polynucleotide need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, a polynucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). A polynucleotide (e.g., gRNA) can comprise at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, a gRNA in which 18 of 20 nucleotides are complementary to a target region, and would therefore specifically hybridize, would represent 90% complementarity. In this example, the remaining noncomplementary nucleotides may be clustered or interspersed with complementary nucleotides and need not be contiguous to each other or to complementary nucleotides.

[0047] Percent complementarity between particular stretches of nucleic acid sequences within nucleic acids can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410; Zhang and Madden (1997) *Genome Res.* 7:649-656) or by using the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489).

[0048] The methods and compositions provided herein employ a variety of different components. It is recognized throughout the description that some components can have active variants and fragments. Such components include, for example, Cas proteins, CRISPR RNAs, tracrRNAs, and guide RNAs. Biological activity for each of these components is described elsewhere herein.

[0049] "Sequence identity" or "identity" in the context of two polynucleotides or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity." Means for making this adjustment are well known to those of skill in the art. Typically, this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California).

[0050] "Percentage of sequence identity" includes the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

[0051] Unless otherwise stated, sequence identity/similarity values include the value obtained using GAP Version 10 using the following parameters: % identity and % similarity for a nucleotide sequence using GAP Weight of 50 and Length Weight of 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for an amino acid sequence using GAP Weight of 8 and Length Weight of 2, and the BLOSUM62 scoring matrix; or any equivalent program thereof. "Equivalent program" includes any sequence comparison program that, for any two sequences in question, generates an alignment having identical

nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10.

[0052] Compositions or methods “comprising” or “including” one or more recited elements may include other elements not specifically recited. For example, a composition that “comprises” or “includes” a protein may contain the protein alone or in combination with other ingredients.

[0053] Designation of a range of values includes all integers within or defining the range, and all subranges defined by integers within the range.

[0054] Unless otherwise apparent from the context, the term “about” encompasses values within a standard margin of error of measurement (e.g., SEM) of a stated value.

[0055] The singular forms of the articles “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a Cas protein” or “at least one Cas protein” can include a plurality of Cas proteins, including mixtures thereof.

II. General

[0056] Traditional methods of assembling nucleic acids employ time consuming steps of conventional enzymatic digestion with restriction enzymes, cloning of the nucleic acids, and ligating nucleic acids together (see, FIG. 3 and FIG. 4 for an illustration of traditional methods and timeline). These methods are made more difficult when large fragments or vectors are being assembled together. The methods provided herein take advantage of the malleable target specificity of nucleases (e.g., guide RNAs and Cas9 nucleases) to convert nucleic acids into a form suitable for use in rapid assembly reactions.

[0057] Provided herein are methods for assembling at least two nucleic acids using nuclease agents directed to specific target sites, such as by guide RNA (gRNA) (e.g., Cas protein directed to specific target sites by guide RNA (gRNA)). Site directed nuclease agents, for example, guide RNA-directed Cas proteins, allow rapid and efficient combination of nucleic acids by selecting and manipulating the end sequences generated by their endonuclease activity. The methods provided herein combine a first polynucleotide with a nuclease agent (e.g., a gRNA-Cas complex) specific for a desired target site and an exonuclease. The target site can be chosen such that when the nuclease cleaves the nucleic acid, the resulting ends created by the cleavage have regions complementary to the ends of the second nucleic acid (e.g., overlapping ends). These complementary ends can then be assembled to yield a single assembled nucleic acid. Because the nuclease agent (e.g., gRNA-

Cas complex) is specific for an individual target site, the present method allows for modification of nucleic acids in a precise site-directed manner. The present method further takes advantage of nuclease agent, for example, a gRNA-Cas complex, specificity by utilizing rapid and efficient assembly methods specially designed for combining overlapping nucleic acid ends generated by nuclease cleavage or designed and synthesized for the assembly reaction. For example, by selecting a nuclease agent (e.g., a gRNA-Cas complex) specific for a target site such that, on cleavage, end sequences complementary to those of a second nucleic acid are produced, isothermal assembly can be used to assemble the resulting digested nucleic acid. Thus, by selecting nucleic acids and nuclease agents (e.g., gRNA-Cas complexes) that result in overlapping end sequences, nucleic acids can be assembled by rapid combinatorial methods to produce the final assembled nucleic acid in a fast and efficient manner. Alternatively, nucleic acids not having complementary ends can be assembled with joiner oligos designed to have complementary ends to each nucleic acid. By using the joiner oligos, two or more nucleic acids can be seamlessly assembled, thereby reducing unnecessary sequences in the resulting assembled nucleic acid.

III. Nuclease Agent

[0058] The present methods employ a nuclease agent for site-directed cleavage of polynucleotides. Specifically, endonuclease cleavage of polynucleotides at an identified target site produces a digested polynucleotide with ends that can then be joined to a second polynucleotide to assemble two or more polynucleotides in a site-specific manner.

[0059] "Nuclease agent" includes molecules which possesses activity for DNA cleavage. Particular examples of nuclease agents for use in the methods disclosed herein include RNA-guided CRISPR-Cas9 system, zinc finger proteins, meganucleases, TAL domains, TALENs, yeast assembly, recombinases, leucine zippers, CRISPR/Cas, endonucleases, and other nuclease agents known to those in the art. Nuclease agents can be selected or designed for specificity in cleaving at a given target site. For example, nuclease agents can be selected for cleavage at a target site that creates overlapping ends between the cleaved polynucleotide and a different polynucleotide. Nuclease agents having both protein and RNA elements as in CRISPR-Cas9 can be supplied with the agents already complexed as a nuclease agent, or can be supplied with the protein and RNA elements separate, in which case they complex to form a nuclease agent in the reaction mixtures described herein.

[0060] The term "recognition site for a nuclease agent" includes a DNA sequence at which a nick or double-strand break is induced by a nuclease agent. The recognition site for

a nuclease agent can be endogenous (or native) to the cell or the recognition site can be exogenous to the cell. In specific embodiments, the recognition site is exogenous to the cell and thereby is not naturally occurring in the genome of the cell. In still further embodiments, the recognition site is exogenous to the cell and to the polynucleotides of interest that one desires to be positioned at the target locus. In further embodiments, the exogenous or endogenous recognition site is present only once in the genome of the host cell. In specific embodiments, an endogenous or native site that occurs only once within the genome is identified. Such a site can then be used to design nuclease agents that will produce a nick or double-strand break at the endogenous recognition site.

[0061] The length of the recognition site can vary, and includes, for example, recognition sites that are about 30-36 bp for a zinc finger nuclease (ZFN) pair (*i.e.*, about 15-18 bp for each ZFN), about 36 bp for a Transcription Activator-Like Effector Nuclease (TALEN), or about 20 bp for a CRISPR/Cas9 guide RNA.

[0062] Active variants and fragments of the exemplified recognition sites are also provided. Such active variants can comprise at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the given recognition site, wherein the active variants retain biological activity and hence are capable of being recognized and cleaved by a nuclease agent in a sequence-specific manner. Assays to measure the double-strand break of a recognition site by a nuclease agent are known in the art (e.g., TaqMan® qPCR assay, Frendewey D. *et al.*, Methods in Enzymology, 2010, 476:295-307, which is incorporated by reference herein in its entirety).

[0063] In specific embodiments, the recognition site is positioned within the polynucleotide encoding the selection marker. Such a position can be located within the coding region of the selection marker or within the regulatory regions, which influence the expression of the selection marker. Thus, a recognition site of the nuclease agent can be located in an intron of the selection marker, a promoter, an enhancer, a regulatory region, or any non-protein-coding region of the polynucleotide encoding the selection marker. In specific embodiments, a nick or double-strand break at the recognition site disrupts the activity of the selection marker. Methods to assay for the presence or absence of a functional selection marker are known.

[0064] Any nuclease agent that induces a nick or double-strand break into a desired recognition site can be used in the methods and compositions disclosed herein. A naturally-occurring or native nuclease agent can be employed so long as the nuclease agent induces a nick or double-strand break in a desired recognition site. Alternatively, a modified or

engineered nuclease agent can be employed. An “engineered nuclease agent” comprises a nuclease that is engineered (modified or derived) from its native form to specifically recognize and induce a nick or double-strand break in the desired recognition site. Thus, an engineered nuclease agent can be derived from a native, naturally-occurring nuclease agent or it can be artificially created or synthesized. The modification of the nuclease agent can be as little as one amino acid in a protein cleavage agent or one nucleotide in a nucleic acid cleavage agent. In some embodiments, the engineered nuclease induces a nick or double-strand break in a recognition site, wherein the recognition site was not a sequence that would have been recognized by a native (non-engineered or non-modified) nuclease agent. Producing a nick or double-strand break in a recognition site or other DNA can be referred to herein as “cutting” or “cleaving” the recognition site or other DNA.

[0065] These breaks can then be repaired by the cell in one of two ways: non-homologous end joining and homology-directed repair (homologous recombination). In non-homologous end joining (NHEJ), the double-strand breaks are repaired by direct ligation of the break ends to one another. As such, no new nucleic acid material is inserted into the site, although some nucleic acid material may be lost, resulting in a deletion. In homology-directed repair, a donor polynucleotide with homology to the cleaved target DNA sequence can be used as a template for repair of the cleaved target DNA sequence, resulting in the transfer of genetic information from the donor polynucleotide to the target DNA. Therefore, new nucleic acid material may be inserted/copied into the site. The modifications of the target DNA due to NHEJ and/or homology-directed repair can be used for gene correction, gene replacement, gene tagging, transgene insertion, nucleotide deletion, gene disruption, gene mutation, etc.

[0066] In one embodiment, the nuclease agent is a Transcription Activator-Like Effector Nuclease (TALEN). TAL effector nucleases are a class of sequence-specific nucleases that can be used to make double-strand breaks at specific target sequences in the genome of a prokaryotic or eukaryotic organism. TAL effector nucleases are created by fusing a native or engineered transcription activator-like (TAL) effector, or functional part thereof, to the catalytic domain of an endonuclease, such as, for example, *FokI*. The unique, modular TAL effector DNA binding domain allows for the design of proteins with potentially any given DNA recognition specificity. Thus, the DNA binding domains of the TAL effector nucleases can be engineered to recognize specific DNA target sites and thus, used to make double-strand breaks at desired target sequences. *See, WO 2010/079430; Morbitzer et al. (2010) PNAS 10.1073/pnas.1013133107; Scholze & Boch (2010) Virulence 1:428-432;*

Christian *et al.* *Genetics* (2010) 186:757-761; Li *et al.* (2010) *Nuc. Acids Res.* (2010) doi:10.1093/nar/gkq704; and Miller *et al.* (2011) *Nature Biotechnology* 29:143–148; all of which are herein incorporated by reference.

[0067] Examples of suitable TAL nucleases, and methods for preparing suitable TAL nucleases, are disclosed, *e.g.*, in US Patent Application No. 2011/0239315 A1, 2011/0269234 A1, 2011/0145940 A1, 2003/0232410 A1, 2005/0208489 A1, 2005/0026157 A1, 2005/0064474 A1, 2006/0188987 A1, and 2006/0063231 A1 (each hereby incorporated by reference). In various embodiments, TAL effector nucleases are engineered that cut in or near a target nucleic acid sequence in, *e.g.*, a genomic locus of interest, wherein the target nucleic acid sequence is at or near a sequence to be modified by a targeting vector. The TAL nucleases suitable for use with the various methods and compositions provided herein include those that are specifically designed to bind at or near target nucleic acid sequences to be modified by targeting vectors as described herein.

[0068] In one embodiment, each monomer of the TALEN comprises 33-35 TAL repeats that recognize a single base pair via two hypervariable residues. In one embodiment, the nuclease agent is a chimeric protein comprising a TAL repeat-based DNA binding domain operably linked to an independent nuclease. In one embodiment, the independent nuclease is a FokI endonuclease. In one embodiment, the nuclease agent comprises a first TAL-repeat-based DNA binding domain and a second TAL-repeat-based DNA binding domain, wherein each of the first and the second TAL-repeat-based DNA binding domain is operably linked to a FokI nuclease subunit, wherein the first and the second TAL-repeat-based DNA binding domain recognize two contiguous target DNA sequences in each strand of the target DNA sequence separated by a spacer sequence of varying length (12-20 bp), and wherein the FokI nuclease subunits dimerize to create an active nuclease that makes a double strand break at a target sequence.

[0069] The nuclease agent employed in the various methods and compositions disclosed herein can further comprise a zinc-finger nuclease (ZFN). In one embodiment, each monomer of the ZFN comprises 3 or more zinc finger-based DNA binding domains, wherein each zinc finger-based DNA binding domain binds to a 3 bp subsite. In other embodiments, the ZFN is a chimeric protein comprising a zinc finger-based DNA binding domain operably linked to an independent nuclease. In one embodiment, the independent endonuclease is a FokI endonuclease. In one embodiment, the nuclease agent comprises a first ZFN and a second ZFN, wherein each of the first ZFN and the second ZFN is operably linked to a FokI nuclease subunit, wherein the first and the second ZFN recognize two

contiguous target DNA sequences in each strand of the target DNA sequence separated by about 5-7 bp spacer, and wherein the FokI nuclease subunits dimerize to create an active nuclease that makes a double strand break. See, for example, US20060246567; US20080182332; US20020081614; US20030021776; WO/2002/057308A2; US20130123484; US20100291048; WO/2011/017293A2; and Gaj *et al.* (2013) *Trends in Biotechnology*, 31(7):397-405, each of which is herein incorporated by reference.

[0070] In one embodiment of the methods provided herein, the nuclease agent comprises (a) a chimeric protein comprising a zinc finger-based DNA binding domain fused to a FokI endonuclease; or, (b) a chimeric protein comprising a Transcription Activator-Like Effector Nuclease (TALEN) fused to a FokI endonuclease.

[0071] In still another embodiment, the nuclease agent is a meganuclease. Meganucleases have been classified into four families based on conserved sequence motifs, the families are the LAGLIDADG (SEQ ID NO: 16), GIY-YIG, H-N-H, and His-Cys box families. These motifs participate in the coordination of metal ions and hydrolysis of phosphodiester bonds. HEases are notable for their long recognition sites, and for tolerating some sequence polymorphisms in their DNA substrates. Meganuclease domains, structure and function are known, see for example, Guhan and Muniyappa (2003) *Crit Rev Biochem Mol Biol* 38:199-248; Lucas *et al.*, (2001) *Nucleic Acids Res* 29:960-9; Jurica and Stoddard, (1999) *Cell Mol Life Sci* 55:1304-26; Stoddard, (2006) *Q Rev Biophys* 38:49-95; and Moure *et al.*, (2002) *Nat Struct Biol* 9:764. In some examples a naturally occurring variant, and/or engineered derivative meganuclease is used. Methods for modifying the kinetics, cofactor interactions, expression, optimal conditions, and/or recognition site specificity, and screening for activity are known, see for example, Epinat *et al.*, (2003) *Nucleic Acids Res* 31:2952-62; Chevalier *et al.*, (2002) *Mol Cell* 10:895-905; Gimble *et al.*, (2003) *Mol Biol* 334:993-1008; Seligman *et al.*, (2002) *Nucleic Acids Res* 30:3870-9; Sussman *et al.*, (2004) *J Mol Biol* 342:31-41; Rosen *et al.*, (2006) *Nucleic Acids Res* 34:4791-800; Chames *et al.*, (2005) *Nucleic Acids Res* 33:e178; Smith *et al.*, (2006) *Nucleic Acids Res* 34:e149; Gruen *et al.*, (2002) *Nucleic Acids Res* 30:e29; Chen and Zhao, (2005) *Nucleic Acids Res* 33:e154; WO2005105989; WO2003078619; WO2006097854; WO2006097853; WO2006097784; and WO2004031346.

[0072] Any meganuclease can be used herein, including, but not limited to, I-SceI, I-SceII, I-SceIII, I-SceIV, I-SceV, I-SceVI, I-SceVII, I-CeuI, I-CeuAIIP, I-CreI, I-CrepsbIP, I-CrepsbIIP, I-CrepsbIIIP, I-CrepsbIVP, I-TliI, I-PpoI, PI-PspI, F-SceI, F-SceII, F-SvuI, F-TevI, F-TevII, I-AmaI, I-AniI, I-ChuI, I-CmoeI, I-CpaI, I-CpaII, I-CsmI, I-CvuI, I-CvuAIP,

I-DdiI, I-DdiII, I-DirI, I-DmoI, I-HmuI, I-HmuII, I-HsNIP, I-LlaI, I-MsoI, I-NaaI, I-NanI, I-NcIIP, I-NgrIP, I-NitI, I-NjaI, I-Nsp236IP, I-PakI, I-PboIP, I-PcuIP, I-PcuAI, I-PcuVI, I-PgrIP, I-PobIP, I-PorI, I-PorIIP, I-PbpIP, I-SpBetaIP, I-ScaI, I-SexIP, I-SneIP, I-Spomi, I-SpomCP, I-SpomIP, I-SpomIIP, I-SquIP, I-Ssp6803I, I-SthPhiJP, I-SthPhiST3P, I-SthPhiSTe3bP, I-TdeIP, I-TevI, I-TevII, I-TevIII, I-UarAP, I-UarHGPAIP, I-UarHGPA13P, I-VinIP, I-ZbiIP, PI-MtuI, PI-MtuHIP PI-MtuHIIIP, PI-PfuI, PI-PfuII, PI-PkoI, PI-PkoII, PI-Rma43812IP, PI-SpBetaIP, PI-SceI, PI-TfuI, PI-TfuII, PI-ThyI, PI-TliI, PI-TliII, or any active variants or fragments thereof.

[0073] In one embodiment, the meganuclease recognizes double-stranded DNA sequences of 12 to 40 base pairs. In one embodiment, the meganuclease recognizes one perfectly matched target sequence in the genome. In one embodiment, the meganuclease is a homing nuclease. In one embodiment, the homing nuclease is a LAGLIDADG (SEQ ID NO: 16) family of homing nuclease. In one embodiment, the LAGLIDADG (SEQ ID NO: 16) family of homing nuclease is selected from I-SceI, I-CreI, and I-DmoI.

[0074] Nuclease agents can further comprise restriction endonucleases (restriction enzymes), which include Type I, Type II, Type III, and Type IV endonucleases. Type I and Type III restriction endonucleases recognize specific recognition sites, but typically cleave at a variable position from the nuclease binding site, which can be hundreds of base pairs away from the cleavage site (recognition site). In Type II systems the restriction activity is independent of any methylase activity, and cleavage typically occurs at specific sites within or near to the binding site. Most Type II enzymes cut palindromic sequences, however Type IIa enzymes recognize non-palindromic recognition sites and cleave outside of the recognition site, Type IIb enzymes cut sequences twice with both sites outside of the recognition site, and Type IIc enzymes recognize an asymmetric recognition site and cleave on one side and at a defined distance of about 1-20 nucleotides from the recognition site. Type IV restriction enzymes target methylated DNA. Restriction enzymes are further described and classified, for example in the REBASE database (webpage at rebase.neb.com; Roberts *et al.*, (2003) *Nucleic Acids Res* 31:418-20), Roberts *et al.*, (2003) *Nucleic Acids Res* 31:1805-12, and Belfort *et al.*, (2002) in *Mobile DNA II*, pp. 761-783, Eds. Craigie *et al.*, (ASM Press, Washington, DC). In specific embodiments, at least two endonuclease enzymes can be selected as the nuclease agents wherein the enzymes create compatible, or complementary, sticky ends.

[0075] The nuclease agent employed in the various methods and compositions can also comprise a CRISPR/Cas system. Such systems can employ a Cas9 nuclease, which in

some instances, is codon-optimized for the desired cell type in which it is to be expressed. The system further employs a fused crRNA-tracrRNA construct that functions with the codon-optimized Cas9. This single RNA is often referred to as a guide RNA or gRNA. Within a gRNA, the crRNA portion is identified as the ‘target sequence’ for the given recognition site and the tracrRNA is often referred to as the ‘scaffold’. This system has been shown to function in a variety of eukaryotic and prokaryotic cells. Briefly, a short DNA fragment containing the target sequence is inserted into a guide RNA expression plasmid. The gRNA expression plasmid comprises the target sequence (in some embodiments around 20 nucleotides), a form of the tracrRNA sequence (the scaffold) as well as a suitable promoter that is active in the cell and necessary elements for proper processing in eukaryotic cells. Many of the systems rely on custom, complementary oligos that are annealed to form a double stranded DNA and then cloned into the gRNA expression plasmid. The gRNA expression cassette and the Cas9 expression cassette are then introduced into the cell. See, for example, Mali P et al. (2013) *Science* 2013 Feb 15; 339 (6121):823-6; Jinek M et al. *Science* 2012 Aug 17;337(6096):816-21; Hwang WY et al. *Nat Biotechnol* 2013 Mar;31(3):227-9; Jiang W et al. *Nat Biotechnol* 2013 Mar;31(3):233-9; and, Cong L et al. *Science* 2013 Feb 15;339(6121):819-23, each of which is herein incorporated by reference.

[0076] The methods and compositions disclosed herein can utilize Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) systems or components of such systems to modify a genome within a cell. CRISPR/Cas systems include transcripts and other elements involved in the expression of, or directing the activity of, Cas genes. A CRISPR/Cas system can be a type I, a type II, or a type III system. The methods and compositions disclosed herein employ CRISPR/Cas systems by utilizing CRISPR complexes (comprising a guide RNA (gRNA) complexed with a Cas protein) for site-directed cleavage of nucleic acids.

[0077] Some CRISPR/Cas systems used in the methods disclosed herein are non-naturally occurring. A “non-naturally occurring” system includes anything indicating the involvement of the hand of man, such as one or more components of the system being altered or mutated from their naturally occurring state, being at least substantially free from at least one other component with which they are naturally associated in nature, or being associated with at least one other component with which they are not naturally associated. For example, some CRISPR/Cas systems employ non-naturally occurring CRISPR complexes comprising a gRNA and a Cas protein that do not naturally occur together.

[0078] Active variants and fragments of nuclease agents (i.e. an engineered nuclease agent) are also provided. Such active variants can comprise at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the native nuclease agent, wherein the active variants retain the ability to cut at a desired recognition site and hence retain nick or double-strand-break-inducing activity. For example, any of the nuclease agents described herein can be modified from a native endonuclease sequence and designed to recognize and induce a nick or double-strand break at a recognition site that was not recognized by the native nuclease agent. Thus, in some embodiments, the engineered nuclease has a specificity to induce a nick or double-strand break at a recognition site that is different from the corresponding native nuclease agent recognition site. Assays for nick or double-strand-break-inducing activity are known and generally measure the overall activity and specificity of the endonuclease on DNA substrates containing the recognition site.

IV. CRISPR/Cas Systems (gRNA-Cas complex)

[0079] The present methods can employ a CRISPR/Cas system (e.g., gRNA-Cas complex) for site-directed cleavage of nucleic acids. Specifically, Cas cleavage of nucleic acids directed by gRNA to an identified target site produces a digested nucleic acid with ends that can then be joined to a second nucleic acid to assemble two or more nucleic acids in a site-specific manner.

[0080] A "gRNA-Cas complex" includes a complex of a Cas protein with a gRNA. The gRNA can be designed or selected to direct Cas cleavage to a target site that creates overlapping ends between the cleaved nucleic acid and a different nucleic acid. The gRNA-Cas complex can be supplied with the agents already complexed, or can be supplied with the protein and RNA elements separate, in which case they complex to form a gRNA-Cas complex in the methods and reaction mixtures described herein.

A. Cas RNA-Guided Endonucleases

[0081] Cas proteins generally comprise at least one RNA recognition or binding domain. Such domains can interact with guide RNAs (gRNAs, described in more detail below). Cas proteins can also comprise nuclease domains (e.g., DNase or RNase domains), DNA binding domains, helicase domains, protein-protein interaction domains, dimerization domains, and other domains. A nuclease domain possesses catalytic activity for nucleic acid cleavage. Cleavage includes the breakage of the covalent bonds of a nucleic acid molecule.

Cleavage can produce blunt ends or staggered ends, and it can be single-stranded or double-stranded.

[0082] Examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (Csn1 or Csx12), Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (CasA), Cse2 (CasB), Cse3 (CasE), Cse4 (CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966, and homologs or modified versions thereof.

[0083] Any Cas protein that induces a nick or double-strand break into a desired recognition site can be used in the methods and compositions disclosed herein. A naturally-occurring or native Cas protein can be employed so long as the Cas protein induces double-strand break at a desired recognition site. Alternatively, a modified or engineered Cas protein can be employed. An “engineered Cas protein” comprises a Cas protein that is engineered (modified or derived) from its native form to specifically recognize and induce a nick or double-strand break in the desired recognition site. Thus, an engineered Cas protein can be derived from a native, naturally-occurring Cas protein or it can be artificially created or synthesized.

[0084] In particular embodiments, the Cas protein is Cas9. Cas9 proteins typically share four key motifs with a conserved architecture. Motifs 1, 2, and 4 are RuvC-like motifs, and motif 3 is an HNH motif. The nuclease activity of Cas9 cleaves target DNA to produce double strand breaks. These breaks can then be repaired by the cell in one of two ways: non-homologous end joining and homology-directed repair (homologous recombination). In non-homologous end joining (NHEJ), the double-strand breaks are repaired by direct ligation of the break ends to one another. As such, no new nucleic acid material is inserted into the site, although some nucleic acid material may be lost, resulting in a deletion. In homology-directed repair, a donor polynucleotide with homology to the cleaved target DNA sequence can be used as a template for repair of the cleaved target DNA sequence, resulting in the transfer of genetic information from the donor polynucleotide to the target DNA. Therefore, new nucleic acid material may be inserted/copied into the site. The modifications of the target DNA due to NHEJ and/or homology-directed repair can be used for gene correction, gene replacement, gene tagging, transgene insertion, nucleotide deletion, gene disruption, gene mutation, etc.

[0085] Cas proteins can be from a type II CRISPR/Cas system. For example, the Cas protein can be a Cas9 protein or be derived from a Cas9 protein. Cas9 proteins typically share four key motifs with a conserved architecture. Motifs 1, 2, and 4 are RuvC-like motifs, and motif 3 is an HNH motif. The Cas9 protein can be from, for example, *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptococcus* sp., *Staphylococcus aureus*, *Nocardiopsis dassonvillei*, *Streptomyces pristinaespiralis*, *Streptomyces viridochromogenes*, *Streptomyces viridochromogenes*, *Streptosporangium roseum*, *Streptosporangium roseum*, *Alicyclobacillus acidocaldarius*, *Bacillus pseudomycoides*, *Bacillus selenitireducens*, *Exiguobacterium sibiricum*, *Lactobacillus delbrueckii*, *Lactobacillus salivarius*, *Microscilla marina*, *Burkholderiales bacterium*, *Polaromonas naphthalenivorans*, *Polaromonas* sp., *Crocospaera watsonii*, *Cyanothece* sp., *Microcystis aeruginosa*, *Synechococcus* sp., *Acetohalobium arabaticum*, *Ammonifex degensii*, *Caldicelulosiruptor beccii*, *Candidatus Desulforudis*, *Clostridium botulinum*, *Clostridium difficile*, *Finegoldia magna*, *Natranaerobius thermophilus*, *Pelotomaculum thermopropionicum*, *Acidithiobacillus caldus*, *Acidithiobacillus ferrooxidans*, *Allochromatium vinosum*, *Marinobacter* sp., *Nitrosococcus halophilus*, *Nitrosococcus watsoni*, *Pseudoalteromonas haloplanktis*, *Ktedonobacter racemifer*, *Methanohalobium evestigatum*, *Anabaena variabilis*, *Nodularia spumigena*, *Nostoc* sp., *Arthospira maxima*, *Arthospira platensis*, *Arthospira* sp., *Lyngbya* sp., *Microcoleus chthonoplastes*, *Oscillatoria* sp., *Petrotoga mobilis*, *Thermosiphon africanus*, or *Acaryochloris marina*. Additional examples of the Cas9 family members are described in WO 2014/131833, herein incorporated by reference in its entirety. Cas9 protein from *S. pyogenes* or derived therefrom is a preferred enzyme. Cas9 protein from *S. pyogenes* is assigned SwissProt accession number Q99ZW2.

[0086] Cas proteins can be wild type proteins (i.e., those that occur in nature), modified Cas proteins (i.e., Cas protein variants), or fragments of wild type or modified Cas proteins. Cas proteins can also be active variants or fragments of wild type or modified Cas proteins. Active variants or fragments can comprise at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the wild type or modified Cas protein or a portion thereof, wherein the active variants retain the ability to cut at a desired cleavage site and hence retain nick-inducing or double-strand-break-inducing activity. Assays for nick-inducing or double-strand-break-inducing activity are known and generally measure the overall activity and specificity of the Cas protein on DNA substrates containing the cleavage site.

[0087] Cas proteins can be modified to increase or decrease nucleic acid binding affinity, nucleic acid binding specificity, and/or enzymatic activity. Cas proteins can also be modified to change any other activity or property of the protein, such as stability. For example, one or more nuclease domains of the Cas protein can be modified, deleted, or inactivated, or a Cas protein can be truncated to remove domains that are not essential for the function of the protein or to optimize (e.g., enhance or reduce) the activity of the Cas protein.

[0088] Some Cas proteins comprise at least two nuclease domains, such as DNase domains. For example, a Cas9 protein can comprise a RuvC-like nuclease domain and an HNH-like nuclease domain. The RuvC and HNH domains can each cut a different strand of double-stranded DNA to make a double-stranded break in the DNA. See, e.g., Jinek *et al.* (2012) *Science* 337:816-821, hereby incorporated by reference in its entirety.

[0089] One or both of the nuclease domains can be deleted or mutated so that they are no longer functional or have reduced nuclease activity. If one of the nuclease domains is deleted or mutated, the resulting Cas protein (e.g., Cas9) can be referred to as a nickase and can generate a single-strand break at a CRISPR RNA recognition sequence within a double-stranded DNA but not a double-strand break (i.e., it can cleave the complementary strand or the non-complementary strand, but not both). If both of the nuclease domains are deleted or mutated, the resulting Cas protein (e.g., Cas9) will have a reduced ability to cleave both strands of a double-stranded DNA. An example of a mutation that converts Cas9 into a nickase is a D10A (aspartate to alanine at position 10 of Cas9) mutation in the RuvC domain of Cas9 from *S. pyogenes*. Likewise, H939A (histidine to alanine at amino acid position 839) or H840A (histidine to alanine at amino acid position 840) in the HNH domain of Cas9 from *S. pyogenes* can convert the Cas9 into a nickase. Other examples of mutations that convert Cas9 into a nickase include the corresponding mutations to Cas9 from *S. thermophilus*. See, e.g., Sapranauskas *et al.* (2011) *Nucleic Acids Research* 39:9275-9282 and WO 2013/141680, each of which is herein incorporated by reference in its entirety. Such mutations can be generated using methods such as site-directed mutagenesis, PCR-mediated mutagenesis, or total gene synthesis. Examples of other mutations creating nickases can be found, for example, in WO/2013/176772A1 and WO/2013/142578A1, each of which is herein incorporated by reference.

[0090] Cas proteins can also be fusion proteins. For example, a Cas protein can be fused to a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. See WO 2014/089290, incorporated herein by reference in its entirety. Cas proteins can also be fused to a heterologous polypeptide

providing increased or decreased stability. The fused domain or heterologous polypeptide can be located at the N-terminus, the C-terminus, or internally within the Cas protein.

[0091] A Cas protein can be fused to a heterologous polypeptide that provides for subcellular localization. Such heterologous peptides include, for example, a nuclear localization signal (NLS) such as the SV40 NLS for targeting to the nucleus, a mitochondrial localization signal for targeting to the mitochondria, an ER retention signal, and the like. See, e.g., Lange *et al.* (2007) *J. Biol. Chem.* 282:5101-5105. Such subcellular localization signals can be located at the N-terminus, the C-terminus, or anywhere within the Cas protein. An NLS can comprise a stretch of basic amino acids, and can be a monopartite sequence or a bipartite sequence.

[0092] Cas proteins can also be linked to a cell-penetrating domain. For example, the cell-penetrating domain can be derived from the HIV-1 TAT protein, the TLM cell-penetrating motif from human hepatitis B virus, MPG, Pep-1, VP22, a cell penetrating peptide from Herpes simplex virus, or a polyarginine peptide sequence. See, for example, WO 2014/089290, herein incorporated by reference in its entirety. The cell-penetrating domain can be located at the N-terminus, the C-terminus, or anywhere within the Cas protein.

[0093] Cas proteins can also comprise a heterologous polypeptide for ease of tracking or purification, such as a fluorescent protein, a purification tag, or an epitope tag. Examples of fluorescent proteins include green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, eGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreen1), yellow fluorescent proteins (e.g., YFP, eYFP, Citrine, Venus, YPet, PhiYFP, ZsYellow1), blue fluorescent proteins (e.g. eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire), cyan fluorescent proteins (e.g. eCFP, Cerulean, CyPet, AmCyan1, Midoriishi-Cyan), red fluorescent proteins (mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRed1, AsRed2, eqFP611, mRaspberry, mStrawberry, Jred), orange fluorescent proteins (mOrange, mKO, Kusabira-Orange, Monomeric Kusabira-Orange, mTangerine, tdTomato), and any other suitable fluorescent protein. Examples of tags include glutathione-S-transferase (GST), chitin binding protein (CBP), maltose binding protein, thioredoxin (TRX), poly(NANP), tandem affinity purification (TAP) tag, myc, AcV5, AU1, AU5, E, ECS, E2, FLAG, hemagglutinin (HA), nus, Softag 1, Softag 3, Strep, SBP, Glu-Glu, HSV, KT3, S, S1, T7, V5, VSV-G, histidine (His), biotin carboxyl carrier protein (BCCP), and calmodulin.

[0094] In some embodiments, the Cas protein can be modified such that the resulting nuclease activity is altered. Certain mutations in Cas can reduce the ability of the nuclease to

cleave both the complementary and the non-complementary strands of the target DNA. For example, Cas proteins can be mutated in known positions such that nuclease activity is limited to cleavage of either the complementary strand or the non-complementary strand. Specifically, Cas9 having a D10A (aspartate to alanine at amino acid position 10 of Cas9) mutation can cleave the complementary strand of the target DNA but has reduced ability to cleave the non-complementary strand of the target DNA. In some embodiments, Cas9 having a H840A (histidine to alanine at amino acid position 840) mutation can cleave the non-complementary strand of the target DNA but has reduced ability to cleave the complementary strand of the target DNA. The nuclease activity of Cas9 having either a D10A or H840A mutation would result in a single strand break (SSB) instead of a DSB. Other residues can be mutated to achieve the same effect (*i.e.* inactivate one or the other nuclease portions). As non-limiting examples, residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or A987 (*i.e.*, substituted). Further, substitute amino acids other than alanine can be suitable. In some embodiments when a nuclease has reduced activity (*e.g.*, when a Cas9 protein has a D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or a A987 mutation, such as D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and/or D986A), the nuclease can still bind to target DNA in a site-specific manner because it is still guided to a target DNA sequence by a gRNA) as long as it retains the ability to interact with the gRNA.

[0095] In some embodiments, Cas is altered such that the nuclease does not cleave either the complementary or non-complementary strand of target DNA. For example, Cas9 with both the D10A and the H840A mutations has a reduced ability to cleave both the complementary and the non-complementary strands of the target DNA. Other residues can be mutated to achieve the same effect (*i.e.*, inactivate one or the other nuclease portions). As non-limiting examples, residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or can be substituted in order to substantially eliminate nuclease activity. Further, mutations other than alanine substitutions can be suitable.

[0096] The terms "target site" or "target sequence" can be used interchangeably and include nucleic acid sequences present in a target DNA to which a DNA-targeting segment of a gRNA will bind, provided sufficient conditions for binding exist. For example, the target site (or target sequence) within a target DNA is targeted by (or is bound by, or hybridizes with, or is complementary to) the Cas protein or gRNA. Suitable DNA/RNA binding conditions include physiological conditions normally present in a cell. Other suitable DNA/RNA binding conditions (*e.g.*, conditions in a cell-free system) are known in the art.

(see, *e.g.*, Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook *et al.*, Harbor Laboratory Press 2001)). The strand of the target DNA that is complementary to and hybridizes with the Cas protein or gRNA is referred to as the "complementary strand" and the strand of the target DNA that is complementary to the "complementary strand" (and is therefore not complementary to the Cas protein or gRNA) is referred to as the "noncomplementary strand" or "template strand".

[0097] The Cas protein may cleave the nucleic acid at a site within the target sequence or outside of the target sequence. The "cleavage site" includes the position of a nucleic acid wherein a Cas protein produces a single-strand break or a double-strand break. If the Cas protein produces a double-strand break, the cleavage site can be at the same position on both strands of the nucleic acid (producing blunt ends) or can be at different sites on each strand (producing sticky or cohesive ends). Sticky ends can also be produced by using two Cas proteins which produce a single-strand break at cleavage sites on each strand. Site-specific cleavage of target DNA by Cas9 can occur at locations determined by both (i) base-pairing complementarity between the guide RNA and the target DNA; and (ii) a short motif, referred to as the protospacer adjacent motif (PAM), in the target DNA. For example, the cleavage site of Cas9 can be about 1 to about 10 or about 2 to about 5 base pairs (*e.g.*, 3 base pairs) upstream of the PAM sequence. In some embodiments (*e.g.*, when Cas9 from *S. pyogenes*, or a closely related Cas9, is used), the PAM sequence of the non-complementary strand can be 5'-XGG-3', where X is any DNA nucleotide and X is immediately 3' of the target sequence of the non-complementary strand of the target DNA. As such, the PAM sequence of the complementary strand would be 5'-CCY-3', where Y is any DNA nucleotide and Y is immediately 5' of the target sequence of the complementary strand of the target DNA. In some such embodiments, X and Y can be complementary and the X-Y base pair can be any basepair (*e.g.*, X=C and Y=G; X=G and Y=C; X=A and Y=T, X=T and Y=A).

[0098] Cas proteins can be provided in any form. For example, a Cas protein can be provided in the form of a protein, such as a Cas protein complexed with a gRNA. Alternatively, a Cas protein can be provided in the form of a nucleic acid encoding the Cas protein, such as an RNA (*e.g.*, messenger RNA (mRNA)) or DNA. Optionally, the nucleic acid encoding the Cas protein can be codon optimized for efficient translation into protein in a particular cell or organism. For example, the nucleic acid encoding the Cas protein can be modified to substitute codons having a higher frequency of usage in a bacterial cell, a yeast cell, a human cell, a non-human cell, a mammalian cell, a rodent cell, a mouse cell, a rat cell, or any other host cell of interest, as compared to the naturally occurring polynucleotide

sequence. When a nucleic acid encoding the Cas protein is introduced into the cell, the Cas protein can be transiently, conditionally, or constitutively expressed in the cell.

[0099] Nucleic acids encoding Cas proteins can be stably integrated in the genome of the cell and operably linked to a promoter active in the cell. Alternatively, nucleic acids encoding Cas proteins can be operably linked to a promoter in an expression construct. Expression constructs include any nucleic acid constructs capable of directing expression of a gene or other nucleic acid sequence of interest (e.g., a Cas gene) and which can transfer such a nucleic acid sequence of interest to a target cell. For example, the nucleic acid encoding the Cas protein can be in the targeting vector comprising the nucleic acid insert and/or a vector comprising the DNA encoding the gRNA, or it can be in a vector or a plasmid that is separate from the targeting vector comprising the nucleic acid insert and/or separate from a vector comprising the DNA encoding the gRNA. Promoters that can be used in an expression construct include, for example, promoters active in a pluripotent rat, eukaryotic, mammalian, non-human mammalian, human, rodent, mouse, or hamster cell. Such promoters can be, for example, conditional promoters, inducible promoters, constitutive promoters, or tissue-specific promoters. Examples of other promoters are described elsewhere herein.

B. Guide RNAs (gRNAs)

[00100] A "guide RNA" or "gRNA" includes a RNA molecule that binds to a Cas protein and targets the Cas protein to a specific location within a target DNA. Guide RNAs (gRNA) can comprise two segments, a "DNA-targeting segment" and a "protein-binding segment." "Segment" includes a segment, section, or region of a molecule, such as a contiguous stretch of nucleotides in an RNA. Some gRNAs comprise two separate RNA molecules: an "activator-RNA" and a "targeter-RNA". Other gRNAs are a single RNA molecule (single RNA polynucleotide), which can also be called a "single-molecule gRNA," a "single-guide RNA," or an "sgRNA." See, e.g., WO/2013/176772A1, WO/2014/065596A1, WO/2014/089290A1, WO/2014/093622A2, WO/2014/099750A2, WO/2013142578A1, and WO 2014/131833A1, each of which is herein incorporated by reference. The terms "guide RNA" and "gRNA" include both double-molecule gRNAs and single-molecule gRNAs.

[00101] An exemplary two-molecule gRNA comprises a crRNA-like ("CRISPR RNA" or "targeter-RNA" or "crRNA" or "crRNA repeat") molecule and a corresponding tracrRNA-like ("trans-acting CRISPR RNA" or "activator-RNA" or "tracrRNA" or "scaffold") molecule. A crRNA comprises both the DNA-targeting segment (single-stranded) of the gRNA and a stretch of nucleotides that forms one half of the dsRNA duplex of the protein-binding segment of the gRNA. A corresponding tracrRNA (activator-RNA) comprises a

stretch of nucleotides that forms the other half of the dsRNA duplex of the protein-binding segment of the gRNA. A stretch of nucleotides of a crRNA are complementary to and hybridize with a stretch of nucleotides of a tracrRNA to form the dsRNA duplex of the protein-binding domain of the gRNA. As such, each crRNA can be said to have a corresponding tracrRNA. The crRNA additionally provides the single stranded DNA-targeting segment. Accordingly, a gRNA comprises a sequence that hybridizes to a target sequence, and a tracrRNA.

[00102] The crRNA and the corresponding tracrRNA (as a corresponding pair) hybridize to form a gRNA. The crRNA additionally provides the single-stranded DNA-targeting segment that hybridizes to a CRISPR RNA recognition sequence. If used for modification within a cell, the exact sequence of a given crRNA or tracrRNA molecule can be designed to be specific to the species in which the RNA molecules will be used. See, for example, Mali P *et al.* (2013) *Science* 2013 Feb 15;339(6121):823-6; Jinek M *et al.* *Science* 2012 Aug 17;337(6096):816-21; Hwang WY *et al.* *Nat Biotechnol* 2013 Mar;31(3):227-9; Jiang W *et al.* *Nat Biotechnol* 2013 Mar;31(3):233-9; and, Cong L *et al.* *Science* 2013 Feb 15;339(6121):819-23, each of which is herein incorporated by reference.

[00103] The DNA-targeting segment (crRNA) of a given gRNA comprises a nucleotide sequence that is complementary to a sequence in a target DNA. The DNA-targeting segment of a gRNA interacts with a target DNA in a sequence-specific manner via hybridization (*i.e.*, base pairing). As such, the nucleotide sequence of the DNA-targeting segment may vary and determines the location within the target DNA with which the gRNA and the target DNA will interact. The DNA-targeting segment of a subject gRNA can be modified to hybridize to any desired sequence within a target DNA. Naturally occurring crRNAs differ depending on the Cas9 system and organism but often contain a targeting segment of between 21 to 72 nucleotides length, flanked by two direct repeats (DR) of a length of between 21 to 46 nucleotides (see, e.g., WO2014/131833). In the case of *S. pyogenes*, the DRs are 36 nucleotides long and the targeting segment is 30 nucleotides long. The 3' located DR is complementary to and hybridizes with the corresponding tracrRNA, which in turn binds to the Cas9 protein.

[00104] The DNA-targeting segment can have a length of from about 12 nucleotides to about 100 nucleotides. For example, the DNA-targeting segment can have a length of from about 12 nucleotides (nt) to about 80 nt, from about 12 nt to about 50 nt, from about 12 nt to about 40 nt, from about 12 nt to about 30 nt, from about 12 nt to about 25 nt, from about 12 nt to about 20 nt, or from about 12 nt to about 19 nt. Alternatively, the DNA-targeting

segment can have a length of from about 19 nt to about 20 nt, from about 19 nt to about 25 nt, from about 19 nt to about 30 nt, from about 19 nt to about 35 nt, from about 19 nt to about 40 nt, from about 19 nt to about 45 nt, from about 19 nt to about 50 nt, from about 19 nt to about 60 nt, from about 19 nt to about 70 nt, from about 19 nt to about 80 nt, from about 19 nt to about 90 nt, from about 19 nt to about 100 nt, from about 20 nt to about 25 nt, from about 20 nt to about 30 nt, from about 20 nt to about 35 nt, from about 20 nt to about 40 nt, from about 20 nt to about 45 nt, from about 20 nt to about 50 nt, from about 20 nt to about 60 nt, from about 20 nt to about 70 nt, from about 20 nt to about 80 nt, from about 20 nt to about 90 nt, or from about 20 nt to about 100 nt.

[00105] The nucleotide sequence of the DNA-targeting segment that is complementary to a nucleotide sequence (CRISPR RNA recognition sequence) of the target DNA can have a length at least about 12 nt. For example, the DNA-targeting sequence (e.g., the sequence within the DNA-targeting segment that is complementary to a CRISPR RNA recognition sequence within the target DNA) can have a length at least about 12 nt, at least about 15 nt, at least about 18 nt, at least about 19 nt, at least about 20 nt, at least about 25 nt, at least about 30 nt, at least about 35 nt, or at least about 40 nt. Alternatively, the DNA-targeting sequence of the DNA-targeting segment that is complementary to a target sequence of the target DNA can have a length of from about 12 nucleotides (nt) to about 80 nt, from about 12 nt to about 50 nt, from about 12 nt to about 45 nt, from about 12 nt to about 40 nt, from about 12 nt to about 35 nt, from about 12 nt to about 30 nt, from about 12 nt to about 25 nt, from about 12 nt to about 20 nt, from about 12 nt to about 19 nt, from about 19 nt to about 20 nt, from about 19 nt to about 25 nt, from about 19 nt to about 30 nt, from about 19 nt to about 35 nt, from about 19 nt to about 40 nt, from about 19 nt to about 45 nt, from about 19 nt to about 50 nt, from about 19 nt to about 60 nt, from about 20 nt to about 25 nt, from about 20 nt to about 30 nt, from about 20 nt to about 35 nt, from about 20 nt to about 40 nt, from about 20 nt to about 45 nt, from about 20 nt to about 50 nt, or from about 20 nt to about 60 nt. The nucleotide sequence (the DNA-targeting sequence) of the DNA-targeting segment that is complementary to a nucleotide sequence (target sequence) of the target DNA can have a length at least about 12 nt. In some cases, the DNA-targeting sequence can have a length of at least about 20 nt.

[00106] TracrRNAs can be in any form (e.g., full-length tracrRNAs or active partial tracrRNAs) and of varying lengths. They can include primary transcripts or processed forms. For example, tracrRNAs (as part of a single-guide RNA or as a separate molecule as part of a two-molecule gRNA) may comprise or consist of all or a portion of a wild-type tracrRNA sequence (e.g., about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more

nucleotides of a wild-type tracrRNA sequence). Examples of wild-type tracrRNA sequences from *S. pyogenes* include 171-nucleotide, 89-nucleotide, 75-nucleotide, and 65-nucleotide versions. See, for example, Deltcheva *et al.* (2011) *Nature* 471:602-607; WO 2014/093661, each of which is incorporated herein by reference in their entirety. Examples of tracrRNAs within single-guide RNAs (sgRNAs) include the tracrRNA segments found within +48, +54, +67, and +85 versions of sgRNAs, where “+n” indicates that up to the +n nucleotide of wild-type tracrRNA is included in the sgRNA. See US 8,697,359, incorporated herein by reference in its entirety.

[00107] The percent complementarity between the DNA-targeting sequence and the CRISPR RNA recognition sequence within the target DNA can be at least 60% (e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%). The percent complementarity between the DNA-targeting sequence and the CRISPR RNA recognition sequence within the target DNA is 100% over the seven contiguous 5'-most nucleotides of the target sequence of the complementary strand of the target DNA. In certain embodiments, the percent complementarity between the DNA-targeting sequence and the CRISPR RNA recognition sequence within the target DNA can be at least 60% over about 20 contiguous nucleotides. As an example, the percent complementarity between the DNA-targeting sequence and the CRISPR RNA recognition sequence within the target DNA is 100% over the fourteen contiguous nucleotides at the 5'-most end of the CRISPR RNA recognition sequence within the complementary strand of the target DNA and as low as 0% over the remainder. In such a case, the DNA-targeting sequence can be considered to be 14 nucleotides in length. As another example, the percent complementarity between the DNA-targeting sequence and the CRISPR RNA recognition sequence within the target DNA is 100% over the seven contiguous nucleotides at the 5'-most end of the CRISPR RNA recognition sequence within the complementary strand of the target DNA and as low as 0% over the remainder. In such a case, the DNA-targeting sequence can be considered to be 7 nucleotides in length.

[00108] Complementarity of nucleic acids means that a nucleotide sequence in one strand of nucleic acid, due to orientation of its nucleobase groups, hydrogen bonds to another sequence on an opposing nucleic acid strand. The complementary bases typically are, in DNA: A with T and C with G, and, in RNA: C with G, and U with A. Complementarity can be perfect or substantial/sufficient. Perfect complementarity between two nucleic acids means that the two nucleic acids can form a duplex in which every base in the duplex is bonded to a complementary base by Watson-Crick pairing. "Substantial" or "sufficient" complementary

means that a sequence in one strand is not completely and/or perfectly complementary to a sequence in an opposing strand, but that sufficient bonding occurs between bases on the two strands to form a stable hybrid complex in set of hybridization conditions (e.g., salt concentration and temperature). Such conditions can be predicted by using the sequences and standard mathematical calculations to predict the Tm of hybridized strands, or by empirical determination of Tm by using routine methods. Tm refers to the temperature at which a population of hybridization complexes formed between two nucleic acid strands are 50% denatured. At a temperature below the Tm, formation of a hybridization complex is favored, whereas at a temperature above the Tm, melting or separation of the strands in the hybridization complex is favored. Tm may be estimated for a nucleic acid having a known G+C content in an aqueous 1 M NaCl solution by using, e.g., $Tm = 81.5 + 0.41(\% G+C)$, although other known Tm computations take into account nucleic acid structural characteristics.

[00109] "Hybridization condition" refers to the cumulative environment in which one nucleic acid strand bonds to a second nucleic acid strand by complementary strand interactions and hydrogen bonding to produce a hybridization complex. Such conditions include the chemical components and their concentrations (e.g., salts, chelating agents, formamide) of an aqueous or organic solution containing the nucleic acids, and the temperature of the mixture. Other factors, such as the length of incubation time or reaction chamber dimensions may contribute to the environment (e.g., Sambrook *et al.*, Molecular Cloning, A Laboratory Manual, 2.sup.nd ed., pp. 1.90-1.91, 9.47-9.51, 1 1.47-11.57 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989)).

[00110] Hybridization requires that the two nucleic acids contain complementary sequences, although mismatches between bases are possible. The conditions appropriate for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of complementation between two nucleotide sequences, the greater the value of the melting temperature (Tm) for hybrids of nucleic acids having those sequences. For hybridizations between nucleic acids with short stretches of complementarity (e.g. complementarity over 35 or less, 30 or less, 25 or less, 22 or less, 20 or less, or 18 or less nucleotides) the position of mismatches becomes important (see Sambrook *et al.*, *supra*, 11.7-11.8). Typically, the length for a hybridizable nucleic acid is at least about 10 nucleotides. Illustrative minimum lengths for a hybridizable nucleic acid are: at least about 15 nucleotides; at least about 20 nucleotides; at least about 22 nucleotides; at least about 25 nucleotides; and at least about 30

nucleotides). Furthermore, the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the region of complementation and the degree of complementation.

[00111] The sequence of polynucleotide need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, a polynucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). A polynucleotide (e.g., gRNA) can comprise at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an gRNA in which 18 of 20 nucleotides of the gRNA are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleotides may be clustered or interspersed with complementary nucleotides and need not be contiguous to each other or to complementary nucleotides. Percent complementarity between particular stretches of nucleic acid sequences within nucleic acids can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656) or by using the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489).

[00112] The protein-binding segment of a subject gRNA interacts with a Cas protein. The subject gRNA directs the bound polypeptide to a specific nucleotide sequence within target DNA via the DNA-targeting segment. The protein-binding segment of a subject gRNA can comprise two stretches of nucleotides that are complementary to one another. The complementary nucleotides of the protein-binding segment hybridize to form a double-stranded RNA duplex (dsRNA). The protein-binding segment of a subject gRNA interacts with the Cas protein, and the gRNA directs the bound Cas protein to a specific nucleotide sequence within the target DNA via the DNA-targeting segment.

[00113] In certain embodiments, a gRNA as described herein comprises two separate RNA molecules. Each of the two RNA molecules of a subject gRNA comprises a stretch of nucleotides that are complementary to one another such that the complementary nucleotides of the two RNA molecules hybridize to form the double stranded RNA duplex (e.g., hairpin) of the protein-binding segment. A subject gRNA can comprise any corresponding crRNA and

tracrRNA pair. In the methods described herein, the gRNA can be used as a complex (e.g. gRNA-Cas complex) of crRNA and tracrRNA or the crRNA and corresponding tracrRNA can be delivered separately. For example, if multiple gRNAs are used for cleavage reaction, individual crRNAs specific for each target site can be delivered separately from a standard tracrRNA that can complex with each crRNA. In such a method, the crRNAs can complex with the standard tracrRNA in order to direct a Cas protein to the target site.

[00114] Guide RNAs can include modifications or sequences that provides for additional desirable features (e.g., modified or regulated stability; subcellular targeting; tracking, with a fluorescent label; a binding site for a protein or protein complex; and the like). Non-limiting examples of such modifications include, for example, a 5' cap (e.g., a 7-methylguanylate cap (m7G)); a 3' polyadenylated tail (i.e., a 3' poly(A) tail); a riboswitch sequence (e.g., to allow for regulated stability and/or regulated accessibility by proteins and/or protein complexes); a stability control sequence; a sequence that forms a dsRNA duplex (i.e., a hairpin); a modification or sequence that targets the RNA to a subcellular location (e.g., nucleus, mitochondria, chloroplasts, and the like); a modification or sequence that provides for tracking (e.g., direct conjugation to a fluorescent molecule, conjugation to a moiety that facilitates fluorescent detection, a sequence that allows for fluorescent detection, and so forth); a modification or sequence that provides a binding site for proteins (e.g., proteins that act on DNA, including transcriptional activators, transcriptional repressors, DNA methyltransferases, DNA demethylases, histone acetyltransferases, histone deacetylases, and the like); and combinations thereof.

[00115] Guide RNAs can be provided in any form. For example, the gRNA can be provided in the form of RNA, either as two molecules (separate crRNA and tracrRNA) or as one molecule (sgRNA), and optionally in the form of a complex with a Cas protein. The gRNA can also be provided in the form of DNA encoding the RNA. The DNA encoding the gRNA can encode a single RNA molecule (sgRNA) or separate RNA molecules (e.g., separate crRNA and tracrRNA). In the latter case, the DNA encoding the gRNA can be provided as separate DNA molecules encoding the crRNA and tracrRNA, respectively.

[00116] DNAs encoding gRNAs can be stably integrated in the genome of the cell and operably linked to a promoter active in the cell. Alternatively, DNAs encoding gRNAs can be operably linked to a promoter in an expression construct. For example, the DNA encoding the gRNA can be in the targeting vector comprising the nucleic acid insert and/or a vector comprising the nucleic acid encoding the Cas protein, or it can be in a vector or a plasmid that is separate from the targeting vector comprising the nucleic acid insert and/or separate

from a vector comprising the nucleic acid encoding the Cas protein. Such promoters can be active, for example, in a pluripotent rat, eukaryotic, mammalian, non-human mammalian, human, rodent, mouse, or hamster cell. Such promoters can be, for example, conditional promoters, inducible promoters, constitutive promoters, or tissue-specific promoters. In some instances, the promoter is an RNA polymerase III promoter, such as a human U6 promoter, a rat U6 polymerase III promoter, or a mouse U6 polymerase III promoter. Examples of other promoters are described elsewhere herein. When a DNA encoding a gRNA is introduced into the cell, the gRNA can be transiently, conditionally, or constitutively expressed in the cell.

[00117] Alternatively, gRNAs can be prepared by various other methods. For example, gRNAs can be prepared by *in vitro* transcription using, for example, T7 RNA polymerase (see, for example, WO 2014/089290 and WO 2014/065596). Guide RNAs can also be a synthetically produced molecule prepared by chemical synthesis.

C. CRISPR RNA Recognition Sequences

[00118] The term "CRISPR RNA recognition sequence" includes nucleic acid sequences present in a target DNA to which a DNA-targeting segment of a gRNA will bind, provided sufficient conditions for binding exist. For example, CRISPR RNA recognition sequences include sequences to which a guide RNA is designed to have complementarity, where hybridization between a CRISPR RNA recognition sequence and a DNA targeting sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex. CRISPR RNA recognition sequences also include cleavage sites for Cas proteins, described in more detail below. A CRISPR RNA recognition sequence can comprise any polynucleotide, which can be located, for example, in the nucleus or cytoplasm of a cell or within an organelle of a cell, such as a mitochondrion or chloroplast.

[00119] The CRISPR RNA recognition sequence within a target DNA can be targeted by (i.e., be bound by, or hybridize with, or be complementary to) a Cas protein or a gRNA. Suitable DNA/RNA binding conditions include physiological conditions normally present in a cell. Other suitable DNA/RNA binding conditions (e.g., conditions in a cell-free system) are known in the art (see, e.g., Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook *et al.*, Harbor Laboratory Press 2001)). The strand of the target DNA that is complementary to and hybridizes with the Cas protein or gRNA can be called the "complementary strand," and the strand of the target DNA that is complementary to the "complementary strand" (and

is therefore not complementary to the Cas protein or gRNA) can be called "noncomplementary strand" or "template strand."

[00120] The Cas protein can cleave the nucleic acid at a site within or outside of the nucleic acid sequence present in the target DNA to which the DNA-targeting segment of a gRNA will bind. The "cleavage site" includes the position of a nucleic acid at which a Cas protein produces a single-strand break or a double-strand break. For example, formation of a CRISPR complex (comprising a gRNA hybridized to a CRISPR RNA recognition sequence and complexed with a Cas protein) can result in cleavage of one or both strands in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the nucleic acid sequence present in a target DNA to which a DNA-targeting segment of a gRNA will bind. If the cleavage site is outside of the nucleic acid sequence to which the DNA-targeting segment of the gRNA will bind, the cleavage site is still considered to be within the "CRISPR RNA recognition sequence." The cleavage site can be on only one strand or on both strands of a nucleic acid. Cleavage sites can be at the same position on both strands of the nucleic acid (producing blunt ends) or can be at different sites on each strand (producing staggered ends). Staggered ends can be produced, for example, by using two Cas proteins, each of which produces a single-strand break at a different cleavage site on each strand, thereby producing a double-strand break. For example, a first nickase can create a single-strand break on the first strand of double-stranded DNA (dsDNA), and a second nickase can create a single-strand break on the second strand of dsDNA such that overhanging sequences are created. In some cases, the CRISPR RNA recognition sequence of the nickase on the first strand is separated from the CRISPR RNA recognition sequence of the nickase on the second strand by at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 250, 500, or 1,000 base pairs.

[00121] Site-specific cleavage of target DNA by Cas9 can occur at locations determined by both (i) base-pairing complementarity between the gRNA and the target DNA and (ii) a short motif, called the protospacer adjacent motif (PAM), in the target DNA. The PAM can flank the CRISPR RNA recognition sequence. Optionally, the CRISPR RNA recognition sequence can be flanked by the PAM. For example, the cleavage site of Cas9 can be about 1 to about 10 or about 2 to about 5 base pairs (e.g., 3 base pairs) upstream or downstream of the PAM sequence. In some cases (e.g., when Cas9 from *S. pyogenes* or a closely related Cas9 is used), the PAM sequence of the non-complementary strand can be 5'-N₁GG-3', where N₁ is any DNA nucleotide and is immediately 3' of the CRISPR RNA recognition sequence of the non-complementary strand of the target DNA. As such, the PAM

sequence of the complementary strand would be 5'-CC N₂-3', where N₂ is any DNA nucleotide and is immediately 5' of the CRISPR RNA recognition sequence of the complementary strand of the target DNA. In some such cases, N₁ and N₂ can be complementary and the N₁- N₂ base pair can be any base pair (e.g., N₁=C and N₂=G; N₁=G and N₂=C; N₁=A and N₂=T, N₁=T, and N₂=A).

[00122] Examples of CRISPR RNA recognition sequences include a DNA sequence complementary to the DNA-targeting segment of a gRNA, or such a DNA sequence in addition to a PAM sequence. For example, the target motif can be a 20-nucleotide DNA sequence immediately preceding an NGG motif recognized by a Cas protein, such as GN₁₉NGG (SEQ ID NO: 8) or N₂₀NGG (SEQ ID NO: 24) (see, for example, WO 2014/165825). The guanine at the 5' end can facilitate transcription by RNA polymerase in cells. Other examples of CRISPR RNA recognition sequences can include two guanine nucleotides at the 5' end (e.g., GGN₂₀NGG; SEQ ID NO: 25) to facilitate efficient transcription by T7 polymerase *in vitro*. See, for example, WO 2014/065596. Other CRISPR RNA recognition sequences can have between 4-22 nucleotides in length of SEQ ID NOS: 8, 24, and 25, including the 5' G or GG and the 3' GG or NGG. Yet other CRISPR RNA recognition sequences can have between 14 and 20 nucleotides in length of SEQ ID NOS: 8, 24, and 25.

[00123] The CRISPR RNA recognition sequence can be any nucleic acid sequence endogenous or exogenous to a cell. The CRISPR RNA recognition sequence can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory sequence) or can include both.

[00124] In one embodiment, the Cas protein is a type I Cas protein. In one embodiment, the Cas protein is a type II Cas protein. In one embodiment, the type II Cas protein is Cas9. In one embodiment, the first nucleic acid sequence encodes a human codon-optimized Cas protein.

[00125] In one embodiment, the gRNA comprises a nucleic acid sequence encoding a crRNA and a tracrRNA. In specific embodiments, the Cas protein is Cas9. In some embodiments, the gRNA comprises (a) the chimeric RNA of the nucleic acid sequence 5'-GUUUUAGAGCUAGAAAUAAGCAAGUUAAAAAU
AAGGUAGGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU-3'
(SEQ ID NO: 1); or, (b) the chimeric RNA of the nucleic acid sequence 5'-GUUUUAGAGCUAGAAAUAAGCAAGUUAAAAUAAGGUAGGUCCG-3' (SEQ ID NO: 2). In another embodiment, the crRNA comprises 5'-

GUUUUAGAGCUAGAAAUAGCAAGUUAAAAU-3' (SEQ ID NO: 3); 5'-GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAG (SEQ ID NO: 4); or 5'-GAGUCCGAGCAGAAGAAGAAGUUUA-3' (SEQ ID NO: 5). In yet other embodiments, the tracrRNA comprises, 5'-AAGGCUAGUCCG-3' (SEQ ID NO: 6) or 5'-AAGGCUAGUCCGU UAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU-3' (SEQ ID NO: 7).

V. Assembly of Polynucleotides

[00126] The methods disclosed herein can assemble at least two nucleic acids under conditions effective to join the DNA molecules to form a substantially intact or seamless double-stranded DNA molecule. Any nucleic acids of interest having overlapping sequences can be assembled according to the methods disclosed herein. For example, any DNA molecules of interest having overlapping sequences can be assembled, including DNAs which are naturally occurring, cloned DNA molecules, synthetically generated DNAs, etc. The joined DNA molecules may, if desired, be cloned (e.g., inserted) into a vector using a method of the invention. Assembling two nucleic acids includes any method of joining strands of two nucleic acids. For example, assembly includes joining digested nucleic acids such that strands from each nucleic acid anneal to the other and extension, in which each strand serves as a template for extension of the other.

[00127] In some embodiments, nucleic acids are assembled with a joiner oligo such that each nucleic acid is assembled to the joiner oligo instead of being assembled directly together. Assembly with a joiner oligo can position nucleic acid bases between the nucleic acids that are being assembled that are not part of the nucleic acids to be assembled, but are part of the joiner oligo. Thus, nucleic acids can be successfully assembled even if extra bases remain between the nucleic acids. Alternatively, a joiner oligo can be used for seamless assembly, wherein no extra bases remain between the nucleic acids to be assembled.

[00128] In some embodiments, the nucleic acids can be prepared for assembly by cleavage with a Cas protein, a restriction enzyme (restriction endonuclease) (e.g., any of the various restriction endonucleases provided elsewhere herein), a meganuclease (e.g., any of the various meganucleases provided elsewhere herein), or any combination thereof. For example, one of the nucleic acids to be assembled can be cleaved with a Cas protein and another nucleic acid to be assembled can be cleaved with a Cas protein, a restriction enzyme, a meganuclease, or any combination thereof. Following cleavage with a nuclease, the digested nucleic acid can be assembled directly to another digested nucleic acid having

overlapping end sequences or assembled to a nucleic acid that has not been digested but has overlapping end sequences. The digested nucleic acid can also be assembled to another nucleic acid by using a joiner oligo.

[00129] In embodiments employing a nuclease agent (e.g., a Cas protein) to produce overlapping end sequences between two nucleic acid molecules, rapid combinatorial methods can be used to assemble the digested nucleic acids. For example, a first and a second nucleic acid having overlapping ends can be combined with a ligase, exonuclease, DNA polymerase, and nucleotides and incubated at a constant temperature, such as at 50 °C. Specifically, a T5 exonuclease could be used to remove nucleotides from the 5' ends of dsDNA producing complementary overhangs. The complementary single-stranded DNA overhangs can then be annealed, DNA polymerase used for gap filling, and *Taq* DNA ligase used to seal the resulting nicks at 50 °C. Thus, two nucleic acids sharing overlapping end sequences can be joined into a covalently sealed molecule in a one-step isothermal reaction. See, for example, Gibson, *et al.* (2009) *Nature Methods* 6(5): 343-345, herein incorporated by reference in the entirety. In some embodiments, proteinase K or phenol/chloroform/isoamylalcohol (PCI) purification is used to remove the nuclease agent (e.g., Cas protein) from the reaction mixture. In some embodiments, the nuclease agent (e.g., Cas protein) can be removed from the reaction mixture by silica gel-based column purification.

[00130] In certain embodiments the methods disclosed herein assemble a vector with a linear polynucleotide. In other embodiments, the methods disclosed herein assemble at least two vectors, such as two BAC vectors. The term “BAC vector” includes any bacterial artificial chromosome. In specific embodiments, the BAC is modified to contain a region with a nucleotide sequence that overlaps with the nucleotide sequence of region of a linear nucleic acid or another vector, for example, another BAC.

[00131] First and second single stranded nucleic acids have overlapping ends when the respective ends are complementary to one another. First and second double stranded nucleic acids have overlapping ends when a 5' end of a strand of the first nucleic acid is complementary to the 3' end of a strand of the second nucleic acid and vice versa. For example, for double stranded overlapping end sequences, the strands of one nucleic acid can have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a corresponding strand of the other nucleic acid. In methods disclosed herein, the 5' end of a strand of a dsDNA molecule to be assembled, shares overlapping end sequences with the 3' end of a strand of the other dsDNA molecule. The term “overlapping end sequences” includes both strands of a dsDNA molecule. Thus, one

strand from the overlapping region can hybridize specifically to its complementary strand when the complementary regions of the overlapping sequences are presented in single-stranded overhangs from the 5' and 3' ends of the two polynucleotides to be assembled. In some embodiments, an exonuclease is used to remove nucleotides from the 5' or 3' end to create overhanging end sequences. In some embodiments, the overlapping region of the first and/or second nucleic acid does not exist on 5' or 3' end until after digestion with a Cas protein. That is, the overlapping region can be an internal region that is subsequently converted to an overlapping end sequence following digestion of the nucleic acid(s) containing the internal overlapping region with a Cas protein. The Cas protein can cleave at a target site (e.g., cleavage site) within the overlapping region or outside of the overlapping region.

[00132] The length of the overlapping region is preferably of sufficient length such that the region occurs only once within any of the nucleic acids being assembled. In this manner, other polynucleotides are prevented from annealing with the end sequences and the assembly can be specific for the target nucleic acids. The length of the overlapping region can vary from a minimum of about 10 base pairs (bp) to about 300 bp or more. In general, it is preferable that the length of the overlap is less than or equal to about the size of the polynucleotide to be combined, but not less than about 10 bp and not more than about 1000 bp. For the joining of 2 or 3 polynucleotides, about 20-30 bp overlap may be sufficient. For more than 10 fragments, a preferred overlap is about 80 bp to about 300 bp. In one embodiment, the overlapping region is of a length that allows it to be generated readily by synthetic methods, e.g., about 40 bp. In specific embodiments, the length of the overlapping region can be about 20-200 bp. The overlaps can be about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1,000 bp in length. In some embodiments, the length of the overlapping region is from 20 – 200 bp. In specific embodiments of the methods disclosed herein at least two polynucleotides can be assembled wherein an overlapping region on at least one of the polynucleotides is generated by contact with a nuclease agent (e.g., a gRNA-Cas complex). For example, endonuclease digestion of a first polynucleotide can create sequences that overlap with the end sequences of a second polynucleotide, wherein the overlapping end sequences are then assembled.

[00133] In the methods disclosed herein, the overlapping sequences can be contacted with an exonuclease to expose complementary sequences (e.g., complementary single strand sequences) between the overlapping sequences. The exonuclease digestion is carried out

under conditions that are effective to remove ("chew back") a sufficient number of nucleotides to allow for specific annealing of the exposed single-stranded regions of complementarity. In general, a portion of the region of overlap or the entire region of overlap is chewed back, leaving overhangs which comprise a portion of the region of overlap or the entire region of overlap. In some methods, the exonuclease digestion may be carried out by a polymerase in the absence of dNTPs (*e.g.*, T5 DNA polymerase) whereas in other methods, the exonuclease digestion may be carried out by an exonuclease in the presence of dNTPs that lacks polymerase activity (*e.g.*, exonuclease III).

[00134] Any of a variety of 5' to 3', double-strand specific exodeoxyribonucleases may be used to chew-back the ends of nucleic acids in the methods disclosed herein. The term "5' exonuclease" is sometimes used herein to refer to a 5' to 3' exodeoxyribonuclease. A "non-processive" exonuclease, as used herein, is an exonuclease that degrades a limited number of (e.g., only a few) nucleotides during each DNA binding event. Digestion with a 5' exonuclease produces 3' single-stranded overhangs in the DNA molecules. Among other properties which are desirable for a 5' exonuclease are that it lacks 3' exonuclease activity, it generates 5' phosphate ends, and it initiates degradation from both 5'-phosphorylated and unphosphorylated ends. It also desirable that the enzyme can initiate digestion from the 5' end of a molecule, whether it is a blunt end, or it has a small 5' or 3' recessed end. Suitable exonucleases will be evident to the skilled worker. These include, *e.g.*, phage T5 exonuclease (phage T5 gene D15 product), phage lambda exonuclease, RecE of Rac prophage, exonuclease VIII from *E. coli*, phage T7 exonuclease (phage T7 gene 6 product), or any of a variety of 5' exonuclease that are involved in homologous recombination reactions. In one embodiment of the invention, the exonuclease is T5 exonuclease or lambda exonuclease. In another embodiment, the exonuclease is T5 exonuclease. In another embodiment, the exonuclease is not phage T7 exonuclease. Methods for preparing and using exonucleases and other enzymes employed in methods of the invention are conventional; and many are available from commercial sources, such as USB Corporation, 26111 Miles Road, Cleveland, Ohio 44128, or New England Biolabs, Inc. (NEB), 240 County Road, Ipswich, Mass. 01938-2723.

[00135] Particularly, in embodiments where the region of overlap is very long, it may only be necessary to chew-back a portion of the region (*e.g.*, more than half of the region of overlap), provided that the single-stranded overhangs thus generated are of sufficient length and base content to anneal specifically under the conditions of the reaction. The term "annealing specifically" includes situations wherein a particular pair of single-stranded

overhangs will anneal preferentially (or exclusively) to one another, rather than to other single-stranded overhangs (e.g., non-complementary overhangs) which are present in the reaction mixture. By "preferentially" is meant that at least about 95% of the overhangs will anneal to the complementary overhang. A skilled worker can readily determine the optimal length for achieving specific annealing of a sequence of interest under a given set of reaction conditions. Generally, the homologous regions of overlap (the single-stranded overhangs or their complements) contain identical sequences. However, partially identical sequences may be used, provided that the single-stranded overhangs can anneal specifically under the conditions of the reactions.

[00136] In certain embodiments, the nuclease agent (e.g., a Cas protein) can create single strand breaks (*i.e.*, "nicks") at the target site without cutting both strands of dsDNA. A "nickase" includes a nuclease agent (e.g., a Cas protein) that create nicks in dsDNA. In this manner, two separate nuclease agents (e.g., Cas proteins) (e.g., nickases) specific for a target site on each strand of dsDNA can create overhanging sequences complementary to overhanging sequences on another nucleic acid, or a separate region on the same nucleic acid. The overhanging ends created by contacting a nucleic acid with two nickases specific for target sites on both strands of dsDNA can be either 5' or 3' overhanging ends. For example, a first nickase can create a single strand break on the first strand of dsDNA, while a second nickase can create a single strand break on the second strand of dsDNA such that overhanging sequences are created. The target sites of each nickase creating the single strand break can be selected such that the overhanging end sequences created are complementary to overhanging end sequences on a second nucleic acid. Accordingly, the complementary overhanging ends of the first and second nucleic acid can be annealed by the methods disclosed herein. In some embodiments, the target site of the nickase on the first strand is different from the target site of the nickase on the second strand. Different target sites on separate strands of dsDNA result in single strand breaks separated by at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 250, 500, or 1,000 base pairs.

[00137] In certain embodiments, the second nucleic acid is also contacted with a first nickase that creates a nick at a first target site on the second nucleic acid and a nickase that creates a nick at a second target site on the second nucleic acid molecule. The overhanging end sequences created by the nicks at two different sites on the second nucleic acid can be complementary to the overhanging end sequences created by nicks at two different sites on the first nucleic acid so that the complementary overhanging end sequences anneal.

[00138] In some embodiments, the nucleic acid sequence of a gene of interest spans across two or more BACs. In such cases, using the methods provided herein, specifically designed nuclease agents can cut the two or more BACs at the desired locations and the resulting nucleic acid fragments joined together to form the sequence of the gene of interest.

[00139] In some embodiments, the overhanging ends created by nicks at different target sites on both strands of a first nucleic acid are not complementary to the overhanging ends created by nicks at different target sites on both strands of a second nucleic acid. In other embodiments, the nucleic acids to be assembled do not have complementary ends such that a separate nucleic acid is necessary to assemble the noncomplementary ends. A joiner oligo can be used to join non-complementary ends of two nucleic acids. A “joiner oligo” includes complementary arms including a polynucleotide or nucleic acid having a complementary sequence to the ends of a different polynucleotide or nucleic acid. In some embodiments, a joiner oligo has an arm complementary to a first nucleic acid on the 5' end, a central portion (spacer), and an arm complementary to a second nucleic acid on the 3' end. Thus, nucleic acids having non-complementary end sequences to each other can be assembled by annealing each nucleic acid to the same joiner oligo following an exonuclease treatment. In specific embodiments, the joiner oligo has a first arm complementary to the 5' or 3' end sequence of a first digested nucleic acid and a second arm complementary to the 5' or 3' sequence of a second digested nucleic acid. The joiner oligo can join non-complementary end sequences that are blunt or have 5' or 3' overhanging sequence.

[00140] The length of the complementary arm sequences of the joiner oligo should be sufficient to anneal to the nucleic acids to be assembled following exonuclease treatment. For example, the length of the complementary arm sequences of the joiner oligo can be at least about 10, 20, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 110, 120, 130, 140, 150 bp or more. In specific embodiments, the complementary arm is 15-120 bp, 20-100 bp, 30-90 bp, 30-60 bp, or 20-80 bp. In one specific embodiment, the length of the complementary arm sequences of the joiner oligo is 40 bp. Each complementary arm of a joiner oligo can be of different lengths. The spacer of the joiner oligo, between the end sequences complementary to the nucleic acids to be assembled, can be at least about 20 bp, 30 bp, 35 bp, 40 bp, 45 bp, 50 bp, 55 bp, 60 bp, 65 bp, 70 bp, 75 bp, 80 bp, 90 bp, 100 bp, 250 bp, 500 bp, 750 bp, 1000 bp, 2000 bp, 3000 bp, 4000 bp, 5000 bp, 8000 bp, 10 kb, 15kb, 20 kb, or more. For example, the spacer of a joiner oligo can include a BAC vector or LTVEC. In some embodiments, the spacer of the joiner oligo can be designed to have sequences specific for detection or sequences suitable for PCR in order to confirm successful assembly. In some embodiments,

the spacer of the joiner oligo can be designed to introduce one or more restriction enzyme sites. In some embodiments, the spacer of the joiner oligo can be designed to introduce a drug resistance gene or a reporter gene. In other embodiments, the spacer can contain at least 20 bp from an end portion of a nucleic acid to be assembled in order to seamlessly assemble the nucleic acids. For example, for seamless assembly the spacer can be about 45 bp.

[00141] In some embodiments, the molar ratio of the nucleic acid to joiner oligo(s) can be from about 1:1 to about 1:200. In some embodiments, the molar ratio of the nucleic acid to joiner oligo(s) is about 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100, 1:120, 1:140, 1:160, 1:180, or 1:200. In specific embodiments, the molar ratio of the nucleic acid to joiner oligo(s) can be from about 1:6 to about 1:20. In one embodiment, the molar ratio is about 1:6. In another embodiment, the molar ratio is about 1:20.

[00142] In specific embodiments, a joiner oligo is used to seamlessly assemble at least two nucleic acids. “Seamless” assembly refers to assembly of two nucleic acids wherein no intervening nucleic acid bases are present between the adjacent ends of the nucleic acids to be assembled. For example, seamlessly assembled nucleic acids have no nucleic acid bases present that are not a part of the nucleic acids to be assembled. In order to seamlessly assemble two nucleic acids, the spacer of a joiner oligo should include nucleic acid sequence identical to an end portion of either the first or second nucleic acid to be assembled. This end portion should be removed from the nucleic acid prior to assembling with the joiner oligo. For example, the end portion can be cleaved by a nuclease agent (e.g., a gRNA-Cas complex) at least 20bp from the end of the nucleic acid, such as at least 40bp or at least 45bp from the end of the nucleic acid. Alternatively, the end portion can be cleaved by a nuclease agent (e.g., a gRNA-Cas complex) at least 2, at least 4, at least 6, at least 8, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 37, at least 40, at least 42, at least 45, at least 48, at least 50, at least 55, at least 60, at least 65, at least 70, at least 80, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150 bp from the end of the nucleic acid to be assembled.

[00143] In one embodiment, the joiner oligo can comprise from the 5' end to the 3' end: about a 15-120 bp overlap to the 5' nucleic acid, about 20-50 bp of a 3' end region of the 5' nucleic acid, and about a 15-120bp overlap to the 3' nucleic acid. In one embodiment, the joiner oligo can comprise from the 5' end to the 3' end: about a 15-120 bp overlap to the 5' nucleic acid, about 20-50 bp of a 5' end region of the 3' nucleic acid, and about a 15-120 bp overlap to the 3' nucleic acid. Thus, when the joiner oligo is assembled to the first and second

nucleic acid, the spacer from the joiner oligo reconstitutes the section removed from the nucleic acid prior to assembly. See, FIG. 5 and FIG. 6. The term “reconstitutes” includes replacement of the end portion of the nucleic acid that was cleaved in order to provide a complete assembled nucleic acid when assembled to the joiner oligo. For example, reconstituting the cleaved nucleic acid replaces the cleaved portion of the nucleic acid with a nucleic acid included in the spacer of the joiner oligo having the identical sequence to that of the cleaved portion.

[00144] The joiner oligo can be assembled to a first and second nucleic acid molecule simultaneously or sequentially. When assembled simultaneously, the joiner oligo can be contacted with a first and second nucleic acid in the same reaction mixture such that the resulting assembled nucleic acid comprises the first nucleic acid, joiner oligo, and second nucleic acid. When assembled sequentially, the joiner oligo is contacted with the first nucleic acid in an assembly reaction that produces an assembled nucleic acid comprising the first nucleic acid assembled to the joiner oligo, but not the second nucleic acid. Such an assembled nucleic acid can then be contacted with the second nucleic acid in a separate assembly reaction that produces an assembled nucleic acid comprising the first nucleic acid, joiner oligo, and second nucleic acid. In other embodiments, the joiner oligo is contacted with the second nucleic acid in an assembly reaction that produces an assembled nucleic acid comprising the second nucleic acid assembled to the joiner oligo, but not the first nucleic acid. Such an assembled nucleic acid can then be contacted with the first nucleic acid in separate assembly reaction that produces an assembled nucleic acid comprising the first nucleic acid, joiner oligo, and second nucleic acid.

[00145] Any number of joiner oligos can be used in the methods herein to assemble nucleic acid molecules. For example, 1 joiner oligo can be used to assemble 2 nucleic acid molecules, 2 joiner oligos can be used to assemble 3 nucleic acid molecules, 3 joiner oligos can be used to assemble 4 nucleic acid molecules, 4 joiner oligos can be used to assemble 5 nucleic acid molecules, or 5 joiner oligos can be used to assemble 6 nucleic acid molecules. The number of joiner oligos can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more depending on the number of nucleic acid molecules to be assembled.

[00146] In some embodiments, the joiner oligo comprises a gBlock DNA. A “gBlock” is a linear double stranded DNA fragment. The gBlock can be from about 50 bp to about 2000 bp. The gBlock can be from about 50 bp to about 100 bp, from about 100 bp to about 200 bp, from about 200 bp to about 300 bp, from about 300 bp to about 400 bp, from about 400 bp to about 500 bp, from about 500 bp to about 600 bp, from about 600 bp to about 800

bp, from about 800 bp to about 1000 bp, from about 1000 bp to about 1250 bp, from about 1250 bp to about 1500 bp, from about 1500 bp to about 1750 bp, or from about 1750 bp to about 2000 bp.

[00147] Assembly of two or more nucleic acids with a gBlock can be screened, for example, by PCR assays described elsewhere herein (e.g., Example 10). In some cases, the gBlock does not comprise a selection cassette. Such a method allows for rapid joining of two or more nucleic acid molecules that can be screened by a simple PCR assay. The gBlock can comprise any nucleic acid sequence of interest. In some cases, the gBlock can comprise a target site for a nuclease agent or a target site for any of the various meganucleases or restriction enzymes provided herein. In other embodiments, a gBlock can comprise a selection cassette. In some embodiments, the gBlock comprises a DNA sequence of interest. In one embodiment, the gBlock comprises a human DNA sequence.

[00148] The nucleic acids to be assembled or any of the various joiner oligos can also comprise a selection cassette or a reporter gene. The selection cassette can comprise a nucleic acid sequence encoding a selection marker, wherein the nucleic acid sequence is operably linked to a promoter. The promoter can be active in a prokaryotic cell of interest and/or active in a eukaryotic cell of interest. Such promoters can be an inducible promoter, a promoter that is endogenous to the reporter gene or the cell, a promoter that is heterologous to the reporter gene or to the cell, a cell-specific promoter, a tissue-specific promoter or a developmental stage-specific promoter. In one embodiment, the selection marker is selected from neomycin phosphotransferase (neo^r), hygromycin B phosphotransferase (hyg^r), puromycin-N-acetyltransferase (puro^r), blasticidin S deaminase (bsr^r), xanthine/guanine phosphoribosyl transferase (gpt), and herpes simplex virus thymidine kinase (HSV-k), and a combination thereof. The selection marker of the targeting vector can be flanked by the upstream and downstream homology arms or found either 5' or 3' to the homology arms.

[00149] In one embodiment, the nucleic acids to be assembled or any of the various joiner oligos comprise a reporter gene operably linked to a promoter, wherein the reporter gene encodes a reporter protein selected from the group consisting of LacZ, mPlum, mCherry, tdTomato, mStrawberry, J-Red, DsRed, mOrange, mKO, mCitrine, Venus, YPet, enhanced yellow fluorescent protein (EYFP), Emerald, enhanced green fluorescent protein (EGFP), CyPet, cyan fluorescent protein (CFP), Cerulean, T-Sapphire, luciferase, alkaline phosphatase, and a combination thereof. Such reporter genes can be operably linked to a promoter active in the cell. Such promoters can be an inducible promoter, a promoter that is endogenous to the report gene or the cell, a promoter that is heterologous to the reporter gene

or to the cell, a cell-specific promoter, a tissue-specific promoter manner or a developmental stage-specific promoter.

[00150] Following the annealing of single stranded DNA (e.g., overhangs produced by the action of exonuclease when the DNA molecules to be joined are dsDNA or overhangs produced by creating nicks at different target sites on each strand), the single-stranded gaps left by the exonuclease are filled in with a suitable, non-strand-displacing, DNA polymerase and the nicks thus formed are sealed with a ligase. A "non-strand-displacing DNA polymerase," as used herein, is a DNA polymerase that terminates synthesis of DNA when it encounters DNA strands which lie in its path as it proceeds to copy a dsDNA molecule, or that degrades the encountered DNA strands as it proceeds while concurrently filling in the gap thus created, thereby generating a "moving nick" (nick translation).

[00151] In some embodiments, overlapping end sequences have sufficient complementarity between the overlapping regions to anneal the single-stranded complementary ends of each polynucleotide. Following annealing of a single strand of a first polynucleotide to the complementary strand of a second polynucleotide, the 3' end of the first polynucleotide can be extended based on the template of the second polynucleotide strand and the 3' end of the second polynucleotide strand can be extended based on the template of the first polynucleotide strand. By extending the complementary 3' end of each polynucleotide, the polynucleotides can be assembled. Following assembly, nicks between the extended 3' end of a strand from one fragment and adjacent 5' end of a strand from the other fragment can be sealed by ligation. More specifically, the hydroxyl group of the extended 3' end of the first polynucleotide to the phosphate group of the 5' end of the second polynucleotide and ligating the hydroxyl group of the extended 3' end of the second polynucleotide to the phosphate group of the 5' end of the first polynucleotide.

[00152] The ligation reaction can be performed by any of a variety of suitable thermostable DNA ligases. Among the suitable ligases are, for example, Taq ligase, Ampligase Thermostable DNA ligase (Epicentre Biotechnologies), the Thermostable ligases disclosed in U.S. Pat. No. 6,576,453, Thermostable Tfi DNA ligase from Bioneer, Inc.,

[00153] A suitable amount of a crowding agent, such as PEG, in the reaction mixture allows for, enhances, or facilitates molecular crowding. Without wishing to be bound by any particular mechanism, it is suggested that a crowding agent, which allows for molecular crowding and binds to and ties up water in a solution, allowing components of the solution to come into closer contact with one another. For example, DNA molecules to be recombined can come into closer proximity; which facilitates the annealing of the single-stranded

overhangs. Also, it is suggested that enzymes can come into closer contact with their DNA substrates and can be stabilized by the removal of water molecules. A variety of suitable crowding agents will be evident to the skilled worker. These include a variety of well-known macromolecules, such as polymers, e.g., polyethylene glycol (PEG); Ficoll, such as Ficoll 70; dextran, such as dextran 70; or the like. Much of the discussion in this application is directed to PEG. However, the discussion is meant also to apply to other suitable crowding agents. A skilled worker will recognize how to implement routine changes in the method in order to accommodate the use of other crowding agents.

[00154] A suitable amount of a crowding agent, such as PEG, in the reaction mixture allows for, enhances, or facilitates molecular crowding. For example, crowding agents can help DNA molecules to be recombined can come into closer proximity; this thus facilitates the annealing of the single-stranded overhangs. Also, it is suggested that enzymes can come into closer contact with their DNA substrates and can be stabilized by the removal of water molecules. A variety of suitable crowding agents will be evident to the skilled worker. These include a variety of well-known macromolecules, such as polymers, e.g., polyethylene glycol (PEG); Ficoll, such as Ficoll 70; dextran, such as dextran 70; or the like. In general, when PEG is used, a concentration of about 5% (weight/volume) is optimal. However, the amount of PEG can range, e.g., from about 3 to about 7%. Any suitable size of PEG can be used, e.g., ranging from about PEG-200 (e.g., PEG-4000, PEG-6000, or PEG-8000) to about PEG-20,000, or even higher. In the Examples herein, PEG-8000 was used. The crowding agent can, in addition to enhancing the annealing reaction, enhance ligation.

[00155] Reaction components (such as salts, buffers, a suitable energy source (such as ATP or NAD), pH of the reaction mixture, etc.) that are present in an assembly reaction mixture may not be optimal for the individual enzymes (exonuclease, polymerase, and ligase); rather, they serve as a compromise that is effective for the entire set of reactions. For example, one suitable buffer system identified by the inventors, sometimes referred to herein as ISO (ISOthermal) Buffer typically comprises 0.1 M Tris-Cl pH 7.5; 10 mM MgCl₂, 0.2 mM each of dGTP, dATP, dTTP and dCTP, 10 mM DTT, 5% PEG-8000, and 1 mM NAD.

[00156] In the methods disclosed herein, at least two nucleic acids are contacted with a Cas protein and other enzymes under conditions effective to assemble the nucleic acids to form an assembled double-stranded DNA molecule in which a single copy of the overlapping region is retained. The described methods can be used to join any DNA molecules of interest, including DNAs which are naturally occurring, cloned DNA molecules, synthetically

generated DNAs, etc. The joined DNA molecules may, if desired, be cloned into a vector (e.g., using a method of the invention). In some embodiments, the nucleic acids to be assembled are codon optimized for introduction and expression in a cell of interest (e.g., a rodent cell, mouse cell, rat cell, human cell, mammalian cell, microbial cell, yeast cell, etc...).

[00157] DNA molecules of any length can be joined by methods disclosed herein. For example, nucleic acids having about 100 bp to about 750 or 1,000, or more, can be joined. The number of nucleic acids that may be assembled, in one or several assembly stages according to the methods described therein, may be at least about 2, 3, 4, 6, 8, 10, 15, 20, 25, 50, 100, 200, 500, 1,000, 5,000, or 10,000 DNA molecules, for example in the range of about 2 to about 30 nucleic acids. The number of assembly stages may be about 2, 4, 6, 8, 10, or more. The number of molecules assembled in a single stage may be in the range of about 2 to about 10 molecules. The methods of the invention may be used to join together DNA molecules or cassettes each of which has a starting size of at least or no greater than about 40 bp, 60 bp, 80 bp, 100 bp, 500 bp, 1 kb, 3 kb, 5 kb, 6 kb, 10 kb, 18 kb, 20 kb, 25 kb, 32 kb, 50 kb, 65 kb, 75 kb, 150 kb, 300 kb, 500 kb, 600 kb, 1 Mb, or larger. The assembled end products may be at least about 500 bp, 1 kb, 3 kb, 5 kb, 6 kb, 10 kb, 18 kb, 20 kb, 25 kb, 32 kb, 50 kb, 65 kb, 75 kb, 150 kb, 300 kb, 500 kb, 600 kb, 1 Mb, or larger, for example in the range of 30 kb to 1 Mb.

[00158] In some embodiments, the assembled nucleic acids form a circle and/or become ligated into a vector to form a circle. The lower size limit for a dsDNA to circularize is about 200 base pairs. Therefore, the total length of the joined fragments (including, in some cases, the length of the vector) is at least about 200 bp in length. There is no practical upper size limit, and joined DNAs of a few hundred kilobase pairs, or larger, can be generated by the methods disclosed herein. The joined nucleic acids can take the form of either a circle or a linear molecule.

[00159] The methods described herein can be used to assemble a linear fragment with another linear fragment, a linear fragment with a circular nucleic acid molecule, a circular nucleic acid molecule with another circular nucleic acid molecule, or any combination of linear and circular nucleic acids. A “vector” includes any circular nucleic acid molecule. In certain embodiments, the vector assembled by the methods disclosed herein is a bacterial artificial chromosome (BAC). The vector (e.g., the BAC) can include a human DNA, a rodent DNA, a synthetic DNA, or any combination thereof. For example, the BAC can

comprise a human polynucleotide sequence. When joining a mixture of DNA molecules, it is preferable that the DNAs be present in approximately equimolar amounts.

[00160] The nucleic acid used for assembly by the methods disclosed herein can be a large targeting vector. The term “large targeting vector” or “LTVEC” includes vectors that comprise homology arms that correspond to and are derived from nucleic acid sequences used for homologous targeting in cells and/or comprise insert nucleic acids comprising nucleic acid sequences intended to perform homologous recombination targeting in cells. For example, the LTVEC make possible the modification of large loci that cannot be accommodated by traditional plasmid-based targeting vectors because of their size limitations. In specific embodiments, the homology arms and/or the insert nucleic acid of the LTVEC comprises genomic sequence of a eukaryotic cell. The size of the LTVEC is too large to enable screening of targeting events by conventional assays, *e.g.*, southern blotting and long-range (*e.g.*, 1kb-5kb) PCR. Examples of the LTVEC, include, but are not limited to, vectors derived from a bacterial artificial chromosome (BAC), a human artificial chromosome or a yeast artificial chromosome (YAC). Non-limiting examples of LTVECs and methods for making them are described, *e.g.*, in US Pat. No. 6,586,251, 6,596,541, 7,105,348, and WO 2002/036789 (PCT/US01/45375), and US 2013/0137101, each of which is herein incorporated by reference.

[00161] In some embodiments, cassettes can be inserted into vectors that can later be removed. Various forms of cassettes can be constructed to allow for deletion in specific cell or tissue types, at specific developmental stages, or upon induction. Such cassettes can employ a recombinase system in which the cassette is flanked on both sides by recombinase recognition sites and can be removed using a recombinase expressed in the desired cell type, expressed at the desired developmental stage, or expressed or activated upon induction. Such cassettes can further be constructed to include an array of pairs of different recombinase recognition sites that are placed such that null, conditional, or combination conditional/null alleles can be generated, as described in US 2011/0104799, which is incorporated by reference in its entirety. Regulation of recombinase genes can be controlled in various ways, such as by operably linking a recombinase gene to a cell-specific, tissue-specific, or developmentally regulated promoter (or other regulatory element), or by operably linking a recombinase gene to a 3'-UTR that comprises a recognition site for an miRNA that is transcribed only in particular cell types, tissue types, or developmental stages. A recombinase can also be regulated, for example, by employing a fusion protein placing the recombinase under the control of an effector or metabolite (*e.g.*, CreER^{T2}, whose activity is

positively controlled by tamoxifen), or by placing the recombinase gene under the control of an inducible promoter (*e.g.*, one whose activity is controlled by doxycycline and TetR or TetR variants). Examples of various forms of cassettes and means of regulating recombinase genes are provided, for example, in US 8,518,392; US 8,354,389; and US 8,697,851, each of which is incorporated by reference in its entirety.

[00162] The vectors used for assembling as disclosed herein (*e.g.*, LTVEC) can be of any length, including, but not limited to, from about 20kb to about 400kb, from about 20kb to about 30kb, from about 30kb to 40kb, from about 40kb to about 50kb, from about 50kb to about 75kb, from about 75kb to about 100kb, from about 100kb to 125kb, from about 125kb to about 150kb, from about 150kb to about 175kb, about 175kb to about 200kb, from about 200kb to about 225kb, from about 225kb to about 250kb, from about 250kb to about 275kb or from about 275kb to about 300kb, from about 200kb to about 300kb, from about 300kb to about 350kb, from about 350kb to about 400kb, from about 350kb to about 550kb. In one embodiment, the LTVEC is about 100kb.

[00163] The methods provided herein for assembling nucleic acids can be designed so as to allow for a deletion from about 5kb to about 10kb, from about 10kb to about 20kb, from about 20kb to about 40kb, from about 40kb to about 60kb, from about 60kb to about 80kb, from about 80kb to about 100kb, from about 100kb to about 150kb, or from about 150kb to about 200kb, from about 200kb to about 300kb, from about 300kb to about 400kb, from about 400kb to about 500kb, from about 500kb to about 1Mb, from about 1Mb to about 1.5Mb, from about 1.5Mb to about 2Mb, from about 2Mb to about 2.5Mb, or from about 2.5Mb to about 3Mb.

[00164] In other instances, the methods provided herein are designed so as to allow for an insertion of an exogenous nucleic acid sequence ranging from about 5kb to about 10kb, from about 10kb to about 20kb, from about 20kb to about 40kb, from about 40kb to about 60kb, from about 60kb to about 80kb, from about 80kb to about 100kb, from about 100kb to about 150kb, from about 150kb to about 200kb, from about 200kb to about 250kb, from about 250kb to about 300kb, from about 300kb to about 350kb, or from about 350kb to about 400kb. In one embodiment, the insert polynucleotide is about 130 kb or about 155kb.

[00165] Linear nucleic acids can be assembled with each other or to vectors by the methods disclosed herein. The linear molecule can be a vector that has been digested by an endonuclease (*e.g.*, Cas protein) or any synthetic, artificial, or naturally occurring linear nucleic acid. In certain embodiments, the linear nucleic acid is created such that the end sequences overlap with a region of another nucleic acid. The overlapping end sequences of a

linear nucleic acid can be introduced by any method known in the art for generating customized nucleic acid sequences. For example, the end sequences can be a portion of a synthetically produced molecule, can be introduced by PCR, or can be introduced by traditional cloning techniques.

EXAMPLES

[00166] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (*e.g.* amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

Example 1: BAC digest with CAS9 followed by assembly with a selection cassette

[00167] An artificial crRNA and an artificial tracrRNA were designed to target specific sequences in the MAID 6177 (116 kb LTVEC) for assembly with a 3 kb PCR product (UB-HYG). The PCR product contained 50 bp overlaps with the vector. First dissolve crRNAs and tracrRNA to 100 uM in Duplex Buffer (30 mM HEPES, pH 7.5, 100 mM Potassium Acetate). In order to anneal the RNAs, add 10 ul of 100 uM crRNA and 10 ul of 100 uM tracrRNA to 80 ul of annealing buffer. Heat RNAs in a 90 °C temp block then remove block from heater and cool on bench. Final concentration of RNA is about 10 uM.

[00168] In order to digest the BAC, clean maxiprep BAC DNA is used and the BAC digested according to the following mixture.

<u>1X</u>	
BAC DNA (500ng)	Xul
BSA (100x)	0.5ul
RNA	2ul (1 ul of each tracr:crRNA hybrid)
Cas9 (4.5mg/ml)	1ul
10x Buffer	1.5ul
H ₂ O	to 15ul

Digest for 1 hour at 37° then de-salt for 30 min. The final reaction buffer contains: 20 mM Tris 7.5; 100-150 mM NaCl; 10 mM MgCl₂; 1 mM DTT; 0.1 mM EDTA; 100 ug/ml BSA; for a final volume of 15 ul.

[00169] In order to assemble the BAC and insert, digest a plasmid or perform PCR to create an insert. For PCR reactions, run a small aliquot on a gel and look for a single product, if the product has a single band then do PCR cleanup instead of gel extraction. A 1:1-1:6 molar ratio for the BAC:Insert is desired. Usually, 50 ng of the purified insert will work. The following reaction mix can be used:

BAC Digest	4ul
Insert	1ul
Assembly Mix	15ul

[00170] Add the DNA and Mix on ice or directly in a PCR machine at 50 °C. Incubate at 50°C for 1 hour. Add 0.5uL of Proteinase K (20mg/ml) and incubate at 50°C for 1 hour. Desalt for 30 min and electroporate 8 ul of the reaction into DH10B cells. 10 ul of the BAC Digest can be run on a pulse-field gel to check digestion efficiency. Use RNase-free water and buffers.

[00171] The assembly reaction is carried out as follows: Iso-Thermal Buffer: 3 mL 1M Tris-HCL (pH 7.5); 150 ul 2M MgCl₂; 60 ul 100 mM each: dGTP, dATP, dTTP, dCTP; 300 ul 1M DTT; 1.5 g PEG 8000; 300 ul 100 mM NAD. The iso-thermal Buffer is stored in 320 ul aliquots at -20 °C. The Master Mix is prepared as follows: 320 ul iso-thermal Buffer; 0.64 ul T5 exonuclease (stock conc=10 U/ul); 20 ul Phusion DNA polymerase (stock conc=2 U/ul); 160 ul Taq DNA Ligase (stock conc=40 U/ul); 699.36 ul H₂O; mix together, and aliquot at 15 ul or 30 ul and store -20°C. Use 15 ul master mix (MM) in a total volume of 20 ul reaction.

[00172] The tracr RNA sequence used in the example is:

CAAAACAGCAUAGCAAGUUAAAUAAGGUAGCUAGUCCGUUAUC (SEQ ID NO: 9).

This CRISPR RNA (crRNA) contains: (1) about 20 nucleotides of RNA complementary to a target sequence and (2) a tail sequence (GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 10)) that will anneal to the tracrRNA.

[00173] These steps are outlined in FIG. 1.

Example 2: Sewing together two overlapping BACs: Humanized HLA-DQ + Humanized HLA-DR in mouse MHC II locus (H2-A/H2-E)

[00174] An artificial crRNA and an artificial tracrRNA were designed to target specific sequences in the humanized HLA-DQ BAC for assembly with a humanized HLA-DR BAC. The vectors contained ~70bp overlaps with each other created by Cas9 cleavage at two sites on each vector (See, FIG. 2). Dissolve crRNAs and tracrRNA to 100 uM in Hybe Buffer. To anneal the RNAs, add 10 ul of 100 uM crRNA and 10 ul of 100 uM tracrRNA to 80 ul of Annealing buffer. Place RNAs in a 90 °C heat block then remove block from heater and cool on bench. Final concentration of RNA is about 10 uM.

[00175] In order to digest the BAC, clean maxiprep BAC DNA can be used. Each BAC can be digested individually according to the following mixture:

BAC DNA 2.5 ug	Xul
BSA (100x)	0.5ul
RNA	4ul (2ul of each tracr:crRNA hybrid)
Cas9 (4.5mg/ml)	1ul
10x Buffer	5ul
H ₂ O	to 50ul

The BAC vectors should be digested at 37° C for 1 hour and then heat inactivated for 20 min at 65 °C. Desalt for 30 min. The digested DNA was purified via phenol/chloroform/isoamylalcohol (PCI) extraction and then resuspended in 35 ul TE buffer.

[00176] In order to assemble the vectors, use 2.5 uL of the BACs for the assembly reaction as follows:

Digested BACs	5 ul (total)
Assembly MIX	15 ul

[00177] Add the DNA and Mix on ice or directly in a PCR machine at 50 °C. Incubate at 50 °C for 1 hour. Desalt for 30 min and electroporate 8 ul of the assembled DNA into DH10B cells. Use RNase-free water and buffers.

[00178] The tracr RNA sequence used in the example is:

CAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGGUCCGUUAUC (SEQ ID NO: 9).

This CRISPR RNA (crRNA) contains: (1) about 20 nucleotides of RNA complementary to a target sequence and (2) a tail sequence (GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 10)) that will anneal to the tracrRNA.

[00179] These steps are outlined in FIG. 2.

Example 3: Assembling of 2 Cas9-cleaved fragments from 2 different plasmids using linkers

[00180] In order to construct a targeting vector, pMJ8502x was cleaved with 2 identical crRNAs to drop out 400 bp fragment and 2283 bp Amp backbone. (FIG. 7). Qiagen columns were used to purify the entire reaction. R6KZenUbiNeo was then cleaved with 2 different crRNAs to separate into Neo resistance (1086 bp) and backbone (5390 bp). Qiagen columns were used purify the entire reaction. (FIG. 7). Cleavage Reaction: 1170 ng DNA, 30 ul Buffer, 4 ul annealed RNA (@100 uM), 1.7 ul Cas9 (@0.89 ng/ul), H₂O to 60ul. The mixture was incubated at 37 °C for 1 hour and purified on a Qiagen column before eluting in 30ul elution buffer.

[00181] The cleaved fragments were then assembled with two linkers to result in a seamless assembly according to the following reaction mixture: 0.5 ul linker1 (5 ng), 0.5 ul linker2 (5 ng), 2 ul Neo cleavage (~60ng), 2 ul Amp cleavage (~60ng), 15 ul Assembly Master Mix. The mixture was incubated at 50 °C for 1 hour, and the reaction was dialyzed against H₂O. 10 ul of the reaction was electroporated into electrocompetent Pir cells before plating on Carb/Kan plates. PCR across junction showed 6/8 selected colonies were correct and was confirmed by sequencing.

Example 4: Replacement of a portion of a BAC with a cassette using linkers

[00182] In order to construct a knock out mouse targeting vector, 40 kb of a BAC targeting vector was replaced with a selection cassette flanked by recombination recognition sites. (FIG. 8) 2 linkers were designed to delete a region of interest from mBAC and to insert the selection cassette, one for 5' and one for 3'. The linkers had 40 bp overlap to mBAC and 40 bp overlap to a selection cassette. First, 39.5 kb of the 206 kb targeting vector (mBAC) was cleaved according to the following reaction: 500 ul reaction (bring up with H₂O): add 1 ul Cas9 (@0.89 ug/ul), 2 ul each RNA duplex (@50 uM), 250 ul buffer, 220 ul (12.5 ng) BAC maxi prep, and incubated at 37 °C for 1 hour. The digested DNA was purified via phenol/chloroform/isoamylalcohol (PCI) extraction and then resuspended in 55 ul TE buffer. After PCI cleanup of the mBAC cleavage, assembly was done at 50 °C for 1hr, and 10 ul of the reaction was electroporated into DH10B cells. (FIG. 9). Sequencing across junctions confirmed correct assembly. (FIG. 10). Linker 1 (joiner oligo 1) is seamless from mBAC sequence to Cassette sequence (SEQ ID NO: 12). Linker 2 (joiner oligo 2) is seamless from Cassette sequence to mBAC sequence (SEQ ID NO: 13).

Example 5: Assembling two BAC vectors using linkers (Joiner Oligos)

[00183] Stitching of 2 mBACs by Cas9/isothermal assembly was utilized to make a targeting vector that contains homology arms to a mouse genomic region and restriction sites for inserting a human gene by BAC ligation. This targeting vector was used in a BAC ligation to make a humanized targeting vector. The mBAC was cleaved according to the following reaction: 12.5 ug DNA, 2 ul each annealed RNA (@50uM), 10 ul Cas9 (@0.89 ug/ul), 250 ul buffer, H₂O to 500 ul. The mixture was incubated at 37 °C for one hour; cleaned up by phenol/chloroform/isoamylalcohol (PCI) extraction; and resuspended in 20 ul TE. The two mouse BACs were then assembled together with linkers (FIG. 11) according to the following reaction: 6 ul (2 ug) bMQ-208A16 cleavage, 5.6 ul (2 ug) bMQ-50F19 cleavage, 0.25 ul each linker (@50 uM), 4.3 ul (100 ng) selection cassette (Ubi-Hyg) cassette, 12 ul high concentration assembly master mix, 11.35 ul H₂O. The reaction mixture was incubated at 50 °C for 1 hour and dialyzed against H₂O at 30°C. 10 ul or 30 ul of the dialyzed reaction was used to transform DH10B cells. Sanger sequencing confirmed all junctions. Illumina Sequencing reconfirmed all junctions (FIG. 12 and SEQ ID NO: 17). Linker 1 is seamless from mBAC to Cassette (SEQ ID NO: 14). Linker 2 is not seamless from cassette to mBAC. It incorporates a human spacer sequence as per the project design. Linker 3 is not seamless from mB2 to mB3. It incorporates a unique sequence that was used for PCR verification. This area was removed when linearized for ES electroporation (SEQ ID NO: 15).

[00184] FIG. 13 illustrates an example of using 4 joiner oligos (linkers) to insert large human gene fragments onto an mBAC using four linkers and isothermal assembly.

Example 6: Reagents and reactions mixtures for cleavage and assembly

[00185] Crispr RNA (crRNA) (ordered as ssRNA) contains: (1) 20 nucleotides of RNA that is complementary to a target area to cleave; (2) and a tail that will anneal to the tracr RNA: <20nt crisprRNA>GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 10).

[00186] Tracr RNA (ordered as ssRNA):

GUUGGAACCAUUCAAAACAGCAUAGCAAGUAAAAUAAGGCUAGUCCGUUAU
CAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUU (SEQ ID NO: 11).

[00187] All RNA is resuspended to 100 uM in H₂O. 2.5 ul of each crRNA and tracrRNA is combined with 5 ul of annealing buffer (final concentrations: 10 mM Tris pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA). The mixture is then incubated at 95 °C for 5 minutes and slowly cooled to room temperature over 1 hour. Cas9 2X cleavage buffer contains 40

mM HEPES pH7.5 (Final= 20 mM); 300 mM KCl (Final= 150 mM); 1mM DTT (Final= 0.5 mM); 0.2mM EDTA (Final= 0.1 mM); 20 mM MgCl₂ (Final= 10 mM).

[00188] Large Scale Cas9 Cleavage Reaction: Add in order at room temperature: H₂O to 500 ul, 250 ul 2x cleavage buffer, 12.5 ug DNA, 2ul of each RNA (50 uM concentration), 10 ul Cas9 (0.89 mg/ml concentration), and incubate at 37 °C for 1 hour.

[00189] This reaction can be scaled as needed, for example: H₂O to 50 ul, 25 ul Buffer, 125 ng DNA, 2 ul each RNA (5 uM concentration), 1 ul Cas9 (0.89mg/ml concentration), and incubate at 37 °C for 1 hour.

[00190] The assembly reaction is carried out as follows: Iso-Thermal Buffer: 3 mL 1M Tris-HCL (pH 7.5); 150 ul 2M MgCl₂; 60 ul 100 mM each: dGTP, dATP, dTTP, dCTP; 300 ul 1M DTT; 1.5 g PEG 8000; 300 ul 100 mM NAD. The iso-thermal Buffer is stored in 320 ul aliquots at -20 °C. The Master Mix is prepared as follows: 320 ul iso-thermal Buffer; 0.64 ul T5 exonuclease (stock conc=10 U/ul); 20 ul Phusion DNA polymerase (stock conc=2 U/ul); 160 ul Taq DNA Ligase (stock conc=40 U/ul); 699.36 ul H₂O; mix together, and aliquot at 15 ul or 30 ul and store -20°C. Use 15 ul master mix (MM) in a total volume of 20 ul reaction.

[00191] Alternatively, a high concentration master mix (GA MM HC) can be made as follows: 320 ul iso-thermal buffer; 0.64 ul T5 exonuclease (stock conc=10 U/ul); 20 ul Phusion DNA polymerase (stock conc=2 U/ul); 160 ul Taq DNA Ligase (stock conc=40 U/ul); mix together and aliquot at 6 ul or 12 ul and store -20 °C. Use 6 ul of the master mix in a total volume of 20 ul reaction.

[00192] For all assembly reactions, the concentration of DNA should be determined (e.g., by Nano Drop) and a 1:6 molar ratio (vector to insert(s)) is used. For standard concentration, 15 ul of the assembly master mix is used. DNA and water are added to a final volume of 20 ul in a 200ul PCR tube. Reaction is carried out in a thermocycler at 50 °C for 1 hour. The reaction can then be stored at -20 °C. For high concentration, 6 ul of the high concentration assembly master mix is used. DNA and water are added to a final volume of 20 ul in a 200 ul PCR tube. The reaction is carried out in a thermocycler at 50 °C for 1 hour. The reaction can then be stored at -20 °C. Upon completion of the reaction, 10 ul is dialyzed against water for 30 min and electroporated into appropriate electro-competent cells (e.g., DH10B or Pir+ cells).

[00193] Cas9/Isothermal Assembly Reaction: For the Cas9 digest 2.5 ug of each DNA (e.g., BAC DNA), 4 ul of 10 uM guide/tracr RNAs each, and 5 ul of Cas9 protein (0.89 mg/ml) are digested for 2 hours at 37°C. The reaction is heat inactivated at 65°C for 20 min,

phenol chloroform extracted (e.g., to remove Cas9 protein), washed once with 70% ethanol, and DNA resuspended in 35 μ l water. The Isothermal Assembly is performed with 5 μ l of the DNA mixed together with 15 μ l of the master mix (MM) as described elsewhere herein and incubated at 50 °C for 1 hour. The reaction is desalted for 30 min and 8 μ l of the reaction can be electroporated into cells.

Example 7: Cas9/Isothermal Assembly to insert human sequence into a BAC vector

[00194] In order to construct a humanized targeting vector, MAID 6236 was cleaved with a gRNA-Cas complex to generate a cleaved fragment with overlapping sequences. VI568 was also cleaved with a gRNA-Cas complex to generate sequences overlapping with the fragment of MAID6236. Cas9/ Isothermal assembly was performed as described above resulting in insertion of the humanized locus into the vector (VI599). This process is outlined in FIG. 14.

Example 8: Cas9/Isothermal Assembly Using a gBlock Without Selection

Cas9 digest and assembly can also be performed without selection, for example, by utilizing gBlock DNA fragments. In order to test the possibility of adding double stranded DNA into a locus without a selection cassette, gBlock DNA fragments were synthesized and inserted into the construct. As outlined in FIG. 15 A and B, a Cas9/gRNA was designed to target two sites within the TCR beta locus to delete a 4.4 kb fragment. A gBlock was designed to introduce a meganuclease recognition site into the construct. The gBlock was able to insert into the construct without using a selection marker. FIG. 15 A shows the insertion of a PISceI gBlock and FIG. 15B demonstrates the insertion of a MauBI gBlock.

The final constructs were confirmed for successful insertion of each of the gBlocks by PCR junction screens using the primers indicated in Table 1. The protocol for the junction screens is as follows: The PCR reaction contained: 1 μ L DNA, 0.5 μ L Primer 1, 0.5 μ L Primer 2, 1 μ L DMSO, 4 μ L dNTPs, 2.5 μ L 10x buffer, 0.5 μ L Ex-Taq, and 15 μ L Water. The Reaction was carried out in a thermocycler at 95 °C for 3 minutes, 95 °C for 30 sec, 55 °C for 30 sec for 25 cycles, followed by 72 °C for 30 sec, and 72 °C 5 min. The junction sequences were confirmed by sequencing.

Table 1: Primers for junction screening of MAID1715 with either PI-SceI gBlock or MauBI gBlock

MAID1715+PI-SceI Gblock		
Primer name	Sequence	Junction size
(m380)5' 302p18 detect	GGAAAGCCACCCCTGTATGCT (SEQ ID NO: 18)	796 bp
3'down detect 302p18(m41)	CTTGGCCAACAGTGGATGG (SEQ ID NO: 19)	
Cas9 Primer name	Sequence	DNA Target sequence
1715 target-5'	CUAAAAUGAUUCUCAUCUGC GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 20)	CTAAAATGATTCTCATCTGC(AGG) (SEQ ID NO: 22)
1715 target-3'	GCUCUCAACUUCACCCUUUC GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 21)	GCTCTCAACTTCACCCTTTC(TGG) (SEQ ID NO: 23)
MAID1715+MauBI Gblock		
Primer name	Sequence	Junction size
(m380)5' 302p18 detect	GGAAAGCCACCCCTGTATGCT (SEQ ID NO: 18)	759bp
3'down detect 302p18(m41)	CTTGGCCAACAGTGGATGG (SEQ ID NO: 19)	
Cas9 Primer name	Sequence	DNA Target sequence
1715 target-5'	CUAAAAUGAUUCUCAUCUGC GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 20)	CTAAAATGATTCTCATCTGC(AGG) (SEQ ID NO: 22)
1715 target-3'	GCUCUCAACUUCACCCUUUC GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 21)	GCTCTCAACTTCACCCTTTC(TGG) (SEQ ID NO: 23)

Example 9: Cas9/Isothermal Assembly to insert human sequence into a BAC vector using Joiner Oligos

[00195] FIG. 16 provides an example of direct humanization using Cas9/isothermal assembly and joiner oligos. The human fragment and the mouse deletion are dropped out by Cas9 (each BAC uses 2 crispr RNAs). The human fragment and mouse backbone are linked together in a Gibson Assembly reaction with 3 linkers (joiner oligos) and a selection cassette.

[00196] FIG. 17 provides an example of indirect humanization using Cas9/isothermal assembly and joiner oligos for assembly into a large targeting vector (LTVEC). The human fragment on the hBAC is cleaved out by Cas9 using 2 crispr RNAs. The donor comprises up and down joiner oligos and a selection cassette. After hBAC cleavage by Cas9, the fragment is “captured” by Gibson Assembly using a synthetic donor with incorporated complimentary overhangs. Targeting vector construction is completed by Gibson Assembly or BHR.

Example 10: Introducing a Point Mutation By Cas9/Isothermal Assembly

[00197] FIG. 18 provides an example of utilizing Cas9/Isothermal Assembly to introduce a point mutation. A donor is made by traditional cloning. A selection cassette is inserted into a synthetic DNA fragment that contains linker overlaps and the point mutation. The mBAC is cleaved with Cas9, the sequence is removed from the mBAC and the mBAC is Gibson Assembled to the donor resulting in a construct (LTVEC) comprising the point mutation and the selection cassette.

Example 11: BAC Trimming by Cas9/Isothermal Assembly

[00198] FIG. 19 provides an example of BAC trimming using the Cas9/isothermal assembly method. The area needed to be removed from the LTVEC is trimmed using Cas9. In this example, the BAC trimming removes the Ori sequence. The Ori is replaced in a Gibson Assembly reaction using 2 linkers (joiner oligos).

Example 12: Other Methods for BAC digest with CAS9 followed by assembly

[00199] Other methods can be used in the methods provided herein including the following: Synthetic or in vitro-transcribed tracrRNA and crRNA were pre-annealed prior to the reaction by heating to 95 °C and slowly cooling down to room temperature. Native or linearized plasmid DNA (300 ng (about 8 nM)) was incubated for 60 min at 37 °C with a purified Cas9 protein (50-500 nM) and a tracrRNA:crRNA duplex (50-500 nM, 1:1) in a Cas9 plasmid cleavage buffer (20 mM HEPES pH 7.5, 150 mM KCl, 0.5 mM DTT, 0.1 mM EDTA) with or without 10 mM MgCl₂. The reactions were stopped with 5X DNA loading buffer containing 250 mM EDTA, resolved by 0.8 or 1% agarose gel electrophoresis and visualized by ethidium bromide staining. For the Cas9 mutant cleavage assays, the reactions were stopped with 5X SDS loading buffer (30% glycerol, 1.2% SDS, 250 mM EDTA) prior to loading on the agarose gel.

[00200] An artificial crRNA and an artificial tracrRNA were designed to target specific sequences in the MAID 6177 (116 kb LTVEC) for assembly with a 3 kb PCR product (UB-HYG). The PCR product contained 50 bp overlaps with the vector. An isothermal one-step assembly was used based on the use of an isolated non-thermostable 5' to 3' exonuclease that lacks 3' exonuclease activity as follows. A reaction was set up containing the following: 100 fmol each dsDNA substrate, 16 µl 5X ISO buffer, 16 µl T5 exonuclease (0.2 U/µl, Epicentre), 8.0 µl Taq DNA ligase (40 U/µl, NEB), 1.0 µl Phusion™ DNA polymerase (2 U/µl, NEB), and water to 80 µl. The 5× ISO (ISOthermal) buffer was 25%

PEG-8000, 500 mM Tris-Cl, 50 mM MgCl₂, 50 mM DTT, 5 mM NAD, and 1000 μ M each dNTP (pH 7.5).

[00201] This gave a final concentration of 1.25 fmol/ μ l each dsDNA (or 45 fmol/ μ l each ssDNA) that was to be assembled, 5% PEG-8000, 100 mM Tris-Cl pH 7.5, 10 mM MgCl₂, 10 mM DTT, 200 MM each dNTP, 1 mM NAD, 0.02 U/ μ l T5 exonuclease, 4 U/ μ l Taq DNA ligase, and 0.03 U/ μ l PHUSION DNA polymerase.

[00202] Methods used 1.64 μ l (0.2 U/ μ l) of T5 exonuclease for substrates that overlap by 20-80 bp, and for substrates that have larger overlaps (e.g., 200 bp), 1.6 μ l (1 U/ μ l) of T5 exonuclease was used. T5 exonuclease was used as a 1:50 dilution (in T5 exonuclease storage buffer) from the 10 U/ μ l T5 exonuclease (Epicentre) concentrated enzyme stock. The reaction was then incubated at 50°C for 15 minutes.

Example 13: Other Methods for Sewing together two overlapping BACs

[00203] Other methods can be used in the methods provided herein including the following: Synthetic or in vitro-transcribed tracrRNA and crRNA were pre-annealed prior to the reaction by heating to 95 °C and slowly cooling down to room temperature. Native or linearized plasmid DNA (300 ng (about 8 nM)) was incubated for 60 min at 37 °C with a purified Cas9 protein (50-500 nM) and a tracrRNA:crRNA duplex (50-500 nM, 1:1) in a Cas9 plasmid cleavage buffer (20 mM HEPES pH 7.5, 150 mM KCl, 0.5 mM DTT, 0.1 mM EDTA) with or without 10 mM MgCl₂. The reactions were stopped with 5X DNA loading buffer containing 250 mM EDTA, resolved by 0.8 or 1% agarose gel electrophoresis and visualized by ethidium bromide staining. For the Cas9 mutant cleavage assays, the reactions were stopped with 5X SDS loading buffer (30% glycerol, 1.2% SDS, 250 mM EDTA) prior to loading on the agarose gel.

[00204] An artificial crRNA and an artificial tracrRNA were designed to target specific sequences in the humanized HLA-DQ BAC for assembly with a humanized HLA-DR BAC. The vectors contained ~70bp overlaps with each other created by Cas9 cleavage at two sites on each vector (See, FIG. 2). An isothermal one-step assembly was used based on the use of an isolated non-thermostable 5' to 3' exonuclease that lacks 3' exonuclease activity as follows. A reaction was set up containing approximately the following: 100 fmol each dsDNA substrate, 16 μ l 5X ISO buffer, 16 μ l T5 exonuclease (0.2 U/ μ l, Epicentre), 8.0 μ l Taq DNA ligase (40 U/ μ l, NEB), 1.0 μ l Phusion™ DNA polymerase (2 U/ μ l, NEB), and water to 80 μ l. The 5 \times ISO (ISOthermal) buffer was 25% PEG-8000, 500 mM Tris-Cl, 50 mM MgCl₂, 50 mM DTT, 5 mM NAD, and 1000 μ M each dNTP (pH 7.5).

[00205] This gave a final concentration of about 1.25 fmol/μl each dsDNA (or 45 fmol/μl each ssDNA) that was to be assembled, 5% PEG-8000, 100 mM Tris-Cl pH 7.5, 10 mM MgCl₂, 10 mM DTT, 200 μM each dNTP, 1 mM NAD, 0.02 U/μl T5 exonuclease, 4 U/μl Taq DNA ligase, and 0.03 U/μl PHUSION DNA polymerase.

[00206] Methods used 1.64 μl 0.2 U/μl T5 exonuclease for substrates that overlap by 20-80 bp, and for substrates that have larger overlaps (e.g., 200 bp), 1.6 μl 1 U/μl T5 exonuclease was used. T5 exonuclease was used as a 1:50 dilution (in T5 exonuclease storage buffer) from the 10 U/μl T5 exonuclease (Epicentre) concentrated enzyme stock. The reaction was then incubated at 50° C. for 15 minutes.

Example 14: Other Methods for assembling an insert with a BAC vector

[00207] Other methods can be used in the methods provided herein including the following: Dissolve crRNAs and tracrRNA to 100 uM in Hybe Buffer (10X buffer: 20 mM Tris 7.5, 100-150 mM NaCl, 10 mM MgCl₂, 1 mM DTT, 0.1 mM EDTA, 100 ug/ml BSA). In order to anneal the RNAs, add 10 ul of 100 uM crRNA and 10 ul of 100 uM tracrRNA to 80 ul of annealing buffer. Heat RNAs in a 90 °C temp block then remove block from heater and cool on bench. Final concentration of RNA is about 10 uM.

[00208] In order to digest the BAC, clean maxiprep BAC DNA is used and the BAC digested according to the following mixture.

<u>1X</u>	
BAC DNA 500ng	Xul
BSA	0.5ul
RNA	2ul (1 ul of each tracr:crRNA hybrid)
Cas9 (4.5mg/ml)	1ul
10x Buffer	1.5ul
H ₂ O	to 15ul

Digest for 1 hour at 37° then de-salt for 30 min.

[00209] In order to assemble the BAC and insert, digest a plasmid or perform PCR to create an insert. For PCR reactions, run a small aliquot on a gel and look for a clean product, if the product is not clean then do PCR cleanup instead of gel extraction. A 1:1-1:6 molar ratio for the BAC:Insert is desired. Usually, 50 ng of the purified insert will work. The following reaction mix can be used:

BAC Digest	4ul
Insert	1ul

28 Apr 2017
2015280120

Assembly Mix 15ul

[00210] Add the DNA and Mix on ice or directly in a PCR machine at 50 °C. Incubate at 50°C for 1 hour. Add 0.5uL of Proteinase K (20mg/ml) and incubate at 50°C for 1 hour. Desalt for 30 min and electroporate 8 ul of the reaction into DH10B cells. 10 ul of the BAC Digest can be run on a pulse-field gel to check digestion efficiency. Use RNase-free water and buffers. The final reaction buffer contains: 20 mM Tris 7.5; 100-150 mM NaCl; 10 mM MgCl₂; 1 mM DTT; 0.1 mM EDTA; 100 ug/ml BSA; for a final volume of 15 ul.

[00211] The tracr RNA sequence used in the example is:

CAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCGUUAUC (SEQ ID NO: 9).

This CRISPR RNA (crRNA) contains: (1) about 20 nucleotides of RNA complementary to a target sequence and (2) a tail sequence (GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 10)) that will anneal to the tracrRNA.

[00212] Throughout the description and claims of the specification, the word “comprise” and variations of the word, such as “comprising” and “comprises”, is not intended to exclude other additives, components, integers or steps.

[00213] A reference herein to a patent document or other matter which is given as prior art is not to be taken as an admission or a suggestion that that document was, known or that the information it contains was part of the common general knowledge as at the priority date of any of the claims.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for assembling two or more nucleic acids, comprising:
 - (a) contacting a first nucleic acid with a first nuclease agent, wherein the first nuclease agent comprises a Cas protein and a guide RNA (gRNA) (gRNA-Cas complex), a zinc finger nuclease, or a Transcription Activator-Like Effector Nuclease (TALEN), wherein the first nuclease agent cleaves the first nucleic acid at a first target site to produce a first digested nucleic acid with an overlapping end sequence shared by a second nucleic acid;
 - (b) contacting the first digested nucleic acid and the second nucleic acid with an exonuclease to expose complementary sequences between the first digested nucleic acid and the second nucleic acid; and
 - (c) assembling the two nucleic acid fragments generated from step (b).
2. The method of claim 1, wherein step (c) comprises:
 - (i) annealing the exposed complementary sequences;
 - (ii) extending the 3' ends of the annealed complementary sequences; and
 - (iii) ligating the first and the second nucleic acids.
3. The method of claim 1 or 2, wherein the two or more nucleic acids are double stranded.
4. The method of any one of claims 1-3, wherein step (a) further comprises contacting the second nucleic acid with a second nuclease agent, wherein the second nuclease agent cleaves the second nucleic acid at a second target site to produce a second digested nucleic acid with the overlapping end sequence, and
wherein the second nucleic acid of step (b) is the second digested nucleic acid.
5. The method of any one of claims 1-4, wherein the first nuclease agent comprises the Cas protein and the gRNA, wherein the Cas protein is a Cas9 protein, the gRNA comprises a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA), and the first target site is immediately flanked by a Protospacer Adjacent Motif (PAM) sequence.
6. The method of claim 5, wherein the Cas9 protein comprises a RuvC domain and a HNH domain, at least one of which lacks endonuclease activity.

7. The method of any one of claims 1-6, wherein the overlapping end sequence ranges from 20 bp to 200 bp long.

8. The method of any one of claims 1-7, wherein the first nucleic acid, the second nucleic acid, or both nucleic acids are derived from a bacterial artificial chromosome.

9. The method of claim 8, wherein the bacterial artificial chromosome comprises a human DNA, a rodent DNA, a synthetic DNA, a human polynucleotide sequence, or a combination thereof.

10. A method for assembling two or more nucleic acids, comprising:

(a) contacting a first nucleic acid with at least one nuclease agent, wherein the at least one nuclease agent comprises a Cas protein and a guide RNA (gRNA) (gRNA-Cas complex), a zinc finger nuclease, or a Transcription Activator-Like Effector Nuclease (TALEN), wherein the at least one nuclease agent cleaves the first nucleic acid at a first target site to generate a first digested nucleic acid;

(b) contacting the first digested nucleic acid with a second nucleic acid, a joiner oligo, and an exonuclease,

wherein the joiner oligo comprises:

- (i) a first complementary sequence that is complementary to the first digested nucleic acid;
- (ii) a spacer; and
- (iii) a second complementary sequence that is complementary to the second nucleic acid;

wherein the exonuclease exposes the first and second complementary sequences; and

(c) assembling the joiner oligo with the first digested nucleic acid and the second nucleic acid.

11. The method of claim 10, wherein assembling in step (c) comprises:

- (i) annealing the first complementary sequence of the joiner oligo to the first digested nucleic acid and the second complementary sequence of the joiner oligo to the second nucleic acid; and
- (ii) ligating the joiner oligo to the first digested nucleic acid and the second nucleic acid.

12. The method of claim 11, wherein step (i) further comprises extending the 3' end of the first digested nucleic acid and/or the second nucleic acid.

13. The method of any one of claims 10-12, wherein the first complementary sequence of the joiner oligo is between 15 and 120 complementary bases, and the second complementary sequence of the joiner oligo is between 15 and 120 complementary bases.

14. The method of any one of claims 10-13, wherein the two or more nucleic acids are double-stranded.

15. The method of any one of claims 10-14, wherein the spacer of the joiner oligo comprises non-complementary nucleic acids.

16. The method of any one of claims 10-14, wherein the first digested nucleic acid is seamlessly assembled to the second nucleic acid.

17. The method of claim 16, wherein the at least one nuclease agent is designed to cleave an at least 20 bp fragment from the end of the first nucleic acid at which the seamless assembly will occur,

wherein the spacer of the joiner oligo comprises a sequence identical to the at least 20 bp fragment, wherein no nucleic acid bases are present between the first complementary sequence and the at least 20 bp fragment, and no nucleic acid bases are present between the second complementary sequence and the at least 20 bp fragment,

such that assembly of the first digested nucleic acid with the joiner oligo and the second nucleic acid reconstitutes the at least 20 bp fragment and seamlessly assembles the first nucleic acid and the second nucleic acid.

18. The method of claim 17, wherein the at least 20 bp fragment is double-stranded.

19. The method of any one of claims 10-18, wherein the spacer is between about 20 bp to about 120 bp.

20. The method of any one of claims 10-19, wherein step (a) further comprises:

(i) contacting the second nucleic acid with a second nuclease agent, wherein the second nuclease agent cleaves the second nucleic acid to produce a second digested nucleic acid comprising a nucleotide sequence that is complementary to the second complementary

sequence of the joiner oligo, wherein the first digested nucleic acid is assembled to the second digested nucleic acid; or

(ii) contacting the second nucleic acid with a restriction enzyme or meganuclease, wherein the restriction enzyme or meganuclease cleaves the second nucleic acid to produce a second digested nucleic acid comprising a nucleotide sequence that is complementary to the second complementary sequence in the joiner oligo, wherein the first digested nucleic acid is assembled to the second digested nucleic acid.

21. The method of any one of claims 10-20, wherein the joiner oligo is assembled to the first nucleic acid and the second nucleic acid in the same reaction.

22. The method of any one of claims 10-20, wherein the joiner oligo is assembled to the first nucleic acid and the second nucleic acid sequentially.

23. The method of any one of claims 10-22, wherein the at least one nuclease agent comprises the Cas protein and the gRNA, wherein the Cas protein is a Cas9 protein, wherein the gRNA comprises a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA), and wherein the first target site is immediately flanked by a Protospacer Adjacent Motif (PAM) sequence.

24. The method of claim 23, wherein the Cas9 protein comprises a RuvC domain and a HNH domain, at least one of which lacks endonuclease activity.

25. The method of any one of claims 10-24, wherein the first nucleic acid, the second nucleic acid, or both nucleic acids are derived from a bacterial artificial chromosome.

26. The method of any one of claims 10-25, wherein the first nucleic acid, the second nucleic acid, or both nucleic acids comprise a human DNA, a rodent DNA, a synthetic DNA, or a combination thereof.

27. The method of any one of claims 16-26, wherein the joiner oligo comprises a linear double stranded DNA fragment.

28. The method of claim 27, wherein the linear double stranded DNA fragment does not comprise a selection cassette.

29. The method of claim 27 or 28, wherein the joiner oligo is from about 50 bp to about 400 bp.

30. The method of claim 29, wherein the joiner oligo is from about 100 bp to about 300 bp.

31. The method of any one of claims 10-30, wherein the first complementary sequence of the joiner oligo is between 20 and 80 complementary bases and the second complementary sequence of the joiner oligo is between 20 and 80 complementary bases.

32. The method of any one of claims 10-31, wherein the method is for seamlessly assembling the two or more nucleic acids,

wherein the two or more nucleic acids are double-stranded nucleic acids,

wherein the cleaving in step (a) removes a double-stranded fragment from the end of the first nucleic acid at which the seamless assembly will occur,

wherein the joiner oligo in step (b) is a linear double-stranded DNA that is from about 50 bp to about 400 bp,

wherein the spacer in the joiner oligo comprises a sequence identical to the fragment, wherein no nucleic acid bases are present between the first complementary sequence and the sequence identical to the fragment, and no nucleic acid bases are present between the second complementary sequence and the sequence identical to the fragment, and

wherein the assembly in step (c) reconstitutes the fragment.

33. The method of any one of claims 1-32, wherein the first nucleic acid, the second nucleic acid, or both nucleic acids are at least 10 kb.

34. The method of any one of claims 1-33, wherein at least three nucleic acids are assembled.

1/19




FIG. 1

2/19




FIG. 2

3/19




FIG. 3

4/19

Cloning efficiencies for Cas9/Gibson Assembly method

Construct	Cas9 used	Method for removing Cas9	total # colonies	# (%) correct clones
6177(BDIC) + HYG Cas9-6xHis		Proteinase K	3	3 (100)
HLA-DQ + HLA-DR 6xHis-MBP-Cas9		Proteinase K, phenol/chloroform	1	1 (100)
		SDS, heat inact, phenol/chloroform	1	1 (100)
		Heat inact, phenol/chloroform	16	16 (100)

Time required for BAC cloning steps §

Method	Time
BHR	~ 1 week
BHR + BAC Ligation	>2 weeks
2 BHRs + BAC ligation	~ 5 weeks
Cas9/Gibson Assembly	2 days

§ starting from BAC maxiprep DNA
 ending with *E. coli* colonies
 BHR: bacterial homologous recombination

FIG. 4

5/19





FIG. 5

6/19

Design crRNA to target 5' upstream from area of interest:



The removed portion will be reconstituted by a joiner oligo during assembly

Joiner oligo has {1} overlapping sequence with 5' cleaved DNA, {2} DNA to reconstitute removed DNA, and {3} overlapping sequence with 3' cleaved DNA





FIG. 6

7/19



Running higher than expected

FIG. 7

8/19




FIG. 8

9/19




FIG. 9

10/19

Linker 1 (SEQ ID NO: 12)

200

卷之三

THESE ARE THE WORDS WHICH WERE SPOKEN BY THE PROPHET JESUS TO HIS DISCIPLES, AS HE WAS LEAVING THEM. HE SAID, "DO NOT Grieve, for I AM WITH YOU ALWAYS, TO THE END OF THE AGE."


LINKER 2 (SEQ ID NO: 13)

卷之三

Constitutive elements of the *hsp70* promoter are required for the induction of *hsp70* mRNA by heat shock in *S. pombe*.

FIG. 10

11/19

**FIG. 11**

12/19




FIG. 12

13/19





FIG. 13

14/19



15/19




FIG. 15

16/19




FIG. 16

17/19




FIG. 17

18/19




FIG. 18

19/19




FIG. 19

2015280120 23 Dec 2016

SEQUENCE LISTING

<110> Schoenherr, Chris
McWhirter, John
Momont, Corey
Macdonald, Lynn
Murphy, Andrew
Warshaw, Gregg S.
Rojas, Jose F.
Lai, Ka-Man Venus
Valenzuela, David M.
Montagna, Caitlin

<120> Nuclease-Mediated DNA Assembly

<130> 057766-461002

<140> PCT/US2015/037199
<141> 2015-06-23

<150> US 62/036,983
<151> 2014-08-13

<150> US 62/016,400
<151> 2014-06-24

<150> US 62/015,809
<151> 2014-06-23

<160> 25

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 80
<212> RNA
<213> Artificial Sequence

<220>
<223> Synthetic chimeric gRNA

<400> 1
guuuuagagc uagaaaaugc aaguuaaaau aaggcuaguc cguuaucAAC uugaaaaagu 60
ggcaccgagu cggugcuuuu 80

<210> 2
<211> 42
<212> RNA
<213> Artificial Sequence

<220>
<223> Synthetic chimeric gRNA

<400> 2
guuuuagagc uagaaaaugc aaguuaaaau aaggcuaguc cg

42

<210> 3
<211> 30
<212> RNA

2015280120 23 Dec 2016

<213> Artificial Sequence	
<220>	
<223> Synthetic crRNA	
<400> 3	
guuuuagagc uagaaauagc aaguuaaaau	30
<210> 4	
<211> 33	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic crRNA	
<400> 4	
guuuuagagc uagaaauagc aaguuaaaau aag	33
<210> 5	
<211> 26	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic crRNA	
<400> 5	
gaguccgagc agaagaagaa guuuua	26
<210> 6	
<211> 12	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic tracrRNA	
<400> 6	
aaggcuaguc cg	12
<210> 7	
<211> 50	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic tracrRNA	
<400> 7	
aaggcuaguc cguuaucAAC uugaaaaagu ggcaccgagu cggugcuuuu	50
<210> 8	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> a target locus that is linked to a guide RNA (gRNA)	

<220>
<221> misc_feature
<222> 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21
<223> n = A,T,C or G

<400> 8
gnnnnnnnnn nnnnnnnnnn ngg 23

<210> 9
<211> 41
<212> RNA
<213> Artificial Sequence

<220>
<223> Synthetic tracrRNA

<400> 9
caaaacagca uagcaaguua aaauaaggcu aguccguuau c 41

<210> 10
<211> 22
<212> RNA
<213> Artificial Sequence

<220>
<223> Synthetic crRNA region complementary to tracrRNA

<400> 10
guuuuagagc uaugcuguuu ug 22

<210> 11
<211> 89
<212> RNA
<213> Artificial Sequence

<220>
<223> Synthetic tracrRNA

<400> 11
guuggaacca uucaaaacag cauagcaagu uaaaauaagg cuaguccguu aucaacuuga 60
aaaaguggca ccgagucggu gcuuuuuuu 89

<210> 12
<211> 145
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic -Confirmation of seamless assembly from
mBAC to cassette

<400> 12
ttgtgtgaat ataataatat cagtgccttct ttacttccaa aactggacag cgcatcaaac 60
atcagaaaaca acagtatcag ctcctgtccc aactaccatg ggtaccgatt taaatgatcc 120
agtggtcctg cagaggagag attgg 145

<210> 13
<211> 205
<212> DNA
<213> Artificial Sequence

23 Dec 2016

2015280120

<220>
<223> Synthetic -confirmation of seamless assembly from cassette to mBAC

<400> 13
cagccccctag ataacttcgt ataatgtatg ctatacgaag ttatgcttagc tcggcacac 60
tgtcagcttc ctgtgtttcc taggccatga taagatgcag caaagttct gcaatgcaca 120
atgaggcagc cgtcggaata gatttgagaa agtcatgatg atgcaatgtg cacactcttc 180
ctttgtattt atctctatcc accat 205

<210> 14
<211> 138
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic -confirmation of seamless assembly from mBAC to cassette

<400> 14
acttttagggt ttgggtggtt tttaaagccc tatttccagt atgtggaaat gagccaaccc 60
aggacagctt ccgctggatc gtggacagct tctatggccg tcgacgtgta cactcgagat 120
aacttcgtat aatgtatg 138

<210> 15
<211> 147
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 15
tccaaacgac agcagaacta actgagagga gagcacagta gcccccaaa attgctttga 60
gaggctctat aaaaccttag aggctattta aatttaatg gccggcccg cggccaggcg 120
gccgccaggc ctaccacta gtcaatt 147

<210> 16
<211> 9
<212> PRT
<213> Unknown

<220>
<223> Synthetic

<400> 16
Leu Ala Gly Leu Ile Asp Ala Asp Gly
1 5

<210> 17
<211> 49631
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<220>
<221> misc_feature

2015280120 23 Dec 2016

<222> (22396) ... (22533)
<223> Linker 1

<220>
<221> misc_feature
<222> (22494) ... (25426)
<223> Cassette Sequence

<220>
<221> misc_feature
<222> (25427) ... (25595)
<223> Human Spacer Sequence

<220>
<221> misc_feature
<222> (25596) ... (40791)
<223> BMQ-208A16 sequence

<220>
<221> misc_feature
<222> (25387) ... (25672)
<223> Linker 2

<220>
<221> misc_feature
<222> (40792) ... (40858)
<223> Unique additional sequence of linker 3

<220>
<221> misc_feature
<222> (40752) ... (40898)
<223> Linker 3

<220>
<221> misc_feature
<222> (1) ... (22395)
<223> bmq-50F19

<220>
<221> misc_feature
<222> (40899) ... (49631)
<223> bmq-50F19

<400> 17
gctggagtgt ggtcaggcaa catccccaaa gggatggaga tgccgggacg acacctttag 60
ggaggcagtgt gctctggtcc gggattccgg tgctggccat ccctcaccag ccacagcggt 120
tggcgcagga gggatcgccg cgccgcctggg gctagggggc gaactggacc gactttcct 180
agttcgcccta gctgtccga ccgctgccc gccgagatgt taaaagcaca ggcgagttct 240
aacttgcgcg ctcattcttt cagcgcgggg gaatcggtcg agggccctgc gtggcgctgg 300
cttccaccct cgcggccagg gggcaggcgc gggaggccgg cttcggctcc gtgcccctgc 360
aaacttccca agaccttcct tctccccccc acctcaccgg ccagttcaat aaaatctacc 420
cttaaaggca gacttgctt caaatccacg gcacccatta tgtgttttgt gtgaaacgct 480
atcaacattt aaaactctat tgtcccaagg gtcccaaatac cctgtaaatc ttccaccaggc 540

ctggactcat tttcatctga aaagcctgtt tagttgaat agaaaagcaa tcaggcgccc 600
ctctcgctct cgttggaatg tcaattaaaa tgcagattc tcagagctct ttagcgcccc 660
aagaagtggg acaaaaacagg atatttcagg ctgacacaatg aaagaaatgc tacaatgaag 720
tgggggtggcg atgtgcaccc caaactgctt ggagtagccca ctgaaagagt aggtcaggga 780
ttatggtctt acttacgaca gcttatattt ttggggttt gttgtttt gggccccccc 840
ttgggtgtccc cccccccat gagcccatga cagctccctt ccctattcag ccccgtggag 900
aagtaaggga gccttgaacc agggtagaga ggctacattt agtattaacc tggagtggtt 960
gacttctccc aggagtaatc cacttgagaa caaaatgcca attgctctgc ccgctgaggt 1020
atccctggAAC tacccttaa ggttagcaga cccgtcgac cggccccc ccccaagggc 1080
ttgccttaaa ttaacctgcc ttcttgagg acaggggaga gtgtgtaaac gtgtataaca 1140
ctgcgcaagc tcaccagccg ggcctttcg gccgggtccc ttgcctgtc tttggaggca 1200
gacttgtgtg gagatgaccc caaggggcgg gtggccgtga agagccatcc gtcagagtga 1260
gggtgaggac tcctccctcg taggctgaga agagagtatc ctttcagggg gaaaaataaaa 1320
cacgctgggg ctttctctgg ggttcagcct ccaggaagga ttatggtatt gaaggcagga 1380
agctgggatt gtggccgcca gcagcatgt gggcctgtgt tcccaacacg gacgcttggg 1440
acctaattat cctgccttagg aggtcgctca gcactttgt ccactccggg gaggagctgt 1500
gcagacctgc tgccgtcaact tctgcctta cagaggttt aggagggggc tcctgtgggg 1560
gctgggactt cgaagaacga acgttcaagt tgagtcaagc tggggcaactg gccatcttcc 1620
tcattcagct ggagctgagg tactcctggg tagtggctag tagagacagt gggcccagca 1680
ctctgcttca agacctactg ggacctgaga ttgcaaagtt gctggagagg ggagtttacc 1740
tgcattctga aagttcttag gaaatcaacg agaatgttt tgcaactttcc tttgacttggt 1800
atgttagaaat agacaaggaa ttatctttt tgactcttgg ctttaagaag aaagaagact 1860
tgggggaaca aaaatcctc cagccaaacta aaaacactgg gcacctaact gctcatatac 1920
ccctggctt tggtagc tataccattc tacctgtgt taaaaaaaca accaaacagc 1980
agcttcctat tcccctcttg gagatggta gtcctctctg ccttagtctc agtgaaggct 2040
gaaaggaaca gatttttaga cggaggttct ggcagtgtcg aaatcctgtg tcataattga 2100
aagcatcaaa agcgcacggg attagaattc ttttcttctt tctctcttt tcattaaaac 2160
gctcaccat ccccaagtctc ataaaatggg catcccagca tccaaagccc atggtttgc 2220
gcatgcctt cctgcattt gttcagcag attctctaa gctcgtcat tctgactcaa 2280
agattagtca ctgaagacac tgaacaaaca taaagttatt tgcactgtgg taagttttt 2340
tttttggaa attctctgtc ttggatctag taaattgagt gcccccttgc aactgatact 2400
tgggaggtt agccaatagg ttgcgtatt gaaagttccc aggcaatca cataccagg 2460
cagcttgcattc gtatcatcac cattactaat aaaatctga attattcatc aagggttgta 2520
tctttacccc tttgcgtcg gttgcagata ttttagttt atgcctgtac actgccttgc 2580
agtcagtggg agggattca ggcttgaat ccccccgggtt gattaaactc actctttgt 2640
agtggctgtc tggcggaaaga ttgaaataca cgcctgcatt cgaaaatgaa ttctgacaag 2700
tgtaaactgg tggaatgtt tttgaagcct tcctgagatt ctttgattct gttggcttcc 2760
tttcttctg agaaccgttc tgaagcggagg acgtccgcgt cagctcagct gaaatgcgg 2820
tctcagagca gacccttcct ccagtcaagc tcttaaggc cagctggaaat aagagacgtt 2880
aatgaggctg gccatgccaa gcccagcggtt ttaaactcag gttttctgc agttgccctt 2940
gaaaggaatg aaggtcaagt tgcttcagca accttcgcgc tttgatagtg gacggaagg 3000
cacgctgcag agctgggtgg ctgggtccca cagtgtatgg ttatcttgcg tctcttaaaa 3060
gtaagcttaa aaaaaaaaaaatttgcctac tgcaatgtt ggactgcctt gggaaacac 3120
gggacgctga ggtgaggatg gaaggctttt ccgataatga gaaagaatgt gtttgcgaat 3180
gtattgagag gctgagaaat ggttttatcc catctgggtt taagcaatgtt ggcacttggg 3240
gaaaaaaactg aatctggctg aatctcttc tttcagtgcc agccacacgca gcagcagcag 3300
cagcagtggg agcaggaaca gcagtaacaa cagcaacacg agcacagccg cctcagagct 3360
ttggctcctg agccccctgt gggctgaagg cattgcaggt agcccatggt ctcagaagaa 3420
gtgtgcagat gggattaccg tccacgtgga gatatggaaag aggaccaggg attggcactg 3480
tgaccatgtt cagctggggg cgcttcattt gcctggctt ggtcaccatg gcaaccttgc 3540
ccctggcccg gccccttcctc agtttagttt aggataccac ttttagaaccga aaggttaagt 3600
tcatgcgtgc catttttaagg gtaccaatgc gttttggga tttgtctggg ggaagtggtc 3660
tttaagtggg aggctgtttt cagccggctg ccattatgagt agtctctctc cgcattat 3720
cgagcttag aagggagggt ttgtctccc aggcatgagt ggagtgggtt ggtttgcct 3780
gttctttgtt ctgggttag ggaagcagtg gcagttctt ttttagccagt gccttacagc 3840
actctggagg ggacgtaccc tggcagggtt actgtggct tctgcagttt ctctctagat 3900
tgagggaaaa gccttgaatc acactatctt ttggctaaag gaaataggca gcctctgaaa 3960
gctgactttt ttttctttt tccgcattgt ttaagagaaa agaaggtctt gaaagttgagc 4020
atggagagcc gtgcctatgtt ggtcggtt ttaagctgtt gtaagctttt tttgtctttca 4080
cccgccatca cagagtgggc aggttcatg ttggaaagat tggaaagtga atttgcac 4140
agtcttcccc catctggggaa aaagccagat ttcaacttagt gttttggctt tgacacttgc 4200

cagtagccct gtgccacact tatagacagt ttggctactt acatagttag ggtggtcattg 7920
 aaaagacaac taagtcctt tcatcaggct ccgtcttaac tttccattt ctgattgaat 7980
 ccctggatc gatccagcag ggtgtcttg cttggtcagc agcttaggagt tattttgggg 8040
 gaagggatgc tgcaggctat tttacagata attatgggtt tcctgtgcag aactgtccct 8100
 gttagggctg gagcaagtga tgattctgtg attaagagca cttcctccctt ttgcagagga 8160
 ccagtgttgg gtccccaaca cccacaggga agtactcctg attgtctta tctccaggtg 8220
 ctgggggcca gcgcctctga cctactgtt cctgcaggtg cccttctcat gtgggctgcc 8280
 ctggccctta ctgtctttgt ggcttcgtag agaatgatgg gaaaaaattc caagatggta 8340
 gtcccactgg tgactaaagg tggttagtag tagtttttc taaaataca gttggtgagc 8400
 aagatagtgg tgcacacctt taatcccaac actagggagg cagaagcggg tggttcttg 8460
 agattgaggg tagcctggc tacagagtga gtgcaggac tacacacaca cacacacgca 8520
 cacacacacc ccagaaagct tgaagttgta gttttacgaa agtgtattta accgtcagga 8580
 ctaactatga tctttcttt gggctggtag ctgatggttt ggtttttttt ttttagatg 8640
 ggcatctccc acagcctggc ttgggatttg cctttagct caggtcggtc tagaactttc 8700
 aatcccccta cctcaacttc cactcctaattt tgcggcat cttgaagag catgtgtctt 8760
 gatttctgt aattttgaaa aacttggcct cggtttttat ggcttactta tctttatgtg 8820
 tatctttatg tggtttgcct gcatgtatgt atgtgtacca tgcataatgtt tagtgcttgc 8880
 agagaccaga agaggacttg cggtcccctg gaaatagagt tatctacgtg gttttgagct 8940
 agcacccagt ggtcttcact tccccctgtt ctctccagcc cttggattaa atgtgaaatg 9000
 tgctgtttgc ttgcttgaag ccaccatagg cagtgcacagg ctttggaccc tttcttacact 9060
 ctgagaataa atgaaagtcc acttgcttgc tcttggctgg gtcaagtcag ggagctaaac 9120
 tattcacatac ctcccttta acttcttgc caactaaaga atcatgaatc ccaagccgtt 9180
 tctggacaga gagaattcca ggttatggt accatgtttt atgaggatgt taaaatagc 9240
 tcttaaggag gatgttgaca gattcaggaa ggagaacccg gcctcatgtt tatttgggtg 9300
 ttatTTatgt agcatgttcc tgagacatct caatccttag cactaaggaa gtcaacacat 9360
 tggttcctaa ccctggaaact tggttttcac ttcttatacc tgacagttt caaataactgg 9420
 ttccccccccc cccccatgtt tggccaagtg tttaaaggt atctaacacc gaaaatggcc 9480
 aattttgggtg gctgttatag atcaaaagga gatctttag actagagatc tctgtcaagt 9540
 ttattctctt tggaaaccct tcaagttcac attgagagct gacagttggc tagccctaga 9600
 gtcatgtggc ttgcttcaag ccgcctctcc cccattccac ctcaacccct tggactgcca 9660
 ctaagactgt tgcttagctg attgttagcag gtaccttgc gaatgtgtaa cctgtataga 9720
 ttatgtgtt cagattaaa accactcagg tctttaaga ctaaggatc tgatccgaca 9780
 ttgacttaa aatttttaatg agaaaactaag taaagttgtt ttgaatagta tgcgttgcgt 9840
 ttctggagg tacagtctca taggaatatcg cccttgggtg ctgagttga atgtgcctac 9900
 tatctacttg accttagtca agtgagataa cctgggtgaa attccaaatg aatatctgtc 9960
 taaattgcac agattgaata cacactggac tgcgttccctt ggcggcgtgtt aggcgcaggg 10020
 taagtgtca tttccctccca cccccacact ttgtcaaaact aaataaaacc cacatctcaa 10080
 agacctaata tgatgttgc ttgttaatct ataatgataa atgtcagatt ttcagacctt 10140
 aggcccttcctt ttatccaact cttttttgc cctcgggtt ttgcaagccc cctgggtttt 10200
 agacatgtga ccctttatct gcttacagtc taggtgttca aggttgactt tttttttttt 10260
 tcttctgtta aggaagtcaa ccgtagccac ccagcacata gtgagaatat gtcatggtca 10320
 tgggtatatt ttggcaggag agtcctctgt ttgagggttt caaataatcg atgtaggcca 10380
 gtgaagggtt gtagagaggt tggtgtgagc ttgggtgggt gtgtgggtg ttagcttgggt 10440
 tgggtgtgtt ggtatgttta tagtgtgtc tgccctgtcc aagccagtga agaaccatc 10500
 caccattgca ggtgtgtcgtt gtctttgtcc atcttctctt gtaatgccac catccatttg 10560
 cctggccagggt gagcttaggtg ctgggtttcc ggtgggtgtt atggcaggaa gttcacagaa 10620
 ctgtgtctggg gtccagacta gtggaaagagc tggacattca tgcgttgcgtt tcctctaaga 10680
 ggggcttgggt atggcaggagg cttaggggtga gatcgtgtcc ttcaactcag tccttgggt 10740
 aatgtatgggtt tccatgaaga caccttagct cctgtctttt gctccgtgcc ttgtgataag 10800
 atgctgaagg tgcagatgtc gagagcgcac ggcctttatt aagtgcctgt aagcggctca 10860
 catgtgttag ggtatgttgc aaattgcctt ttcccaacaa acaggcagat cccaggatcc 10920
 catttcattga ataaaatttt tgcaattctt agagatgtc tgggttccgg acacacccatc 10980
 atgaccaca cacccaccct ttaggtgaac taatttgggg aagatggatt tcacagctca 11040
 ttccctccccc ctcagcaaga ggtatagat tgcgttgggtt gttaggcacc cctcttgc 11100
 tttttttttt tttcccccacttggact ttaaacttca gaggacaggc tgggtgggtt 11160
 tggttctccct tcacccccc acacccactt ccttaagtcc ttgttgcgtt agttcaggc 11220
 aataaaaaattt ttcttagcact tatattctgt agttctgggt cgatgttaggg agttggtcca 11280
 taccctctgc taccgtgggg accagtggga cacagcacag agtccttagac gctgacttat 11340
 gctgagtcac tggagaaaag ctcagaacaa gaagggccac cttgcttgc cctgactgtt 11400
 cctccatcggtt aggtttccct ttcctcggtt cctccagacc ttagcttcat tgcgttgc 11460
 ttttgataggc atttcaagct ttcctttca gcatttcttcc ctttttgc 11520

aatcaaaggc cacctggact ggactacctg gaactccttc aggctgtgg catgaaaagg 11580
acaggtgtgg aggccttcc gggaaacttt ttctccagag attagggact cacctatctt 11640
ctctccatct ctatctcc tcctctcccc caggaggaaa aagaaaagaa aaaaattcca 11700
agaacgagaa gtgtggccct aggggcaaaa gaagccagga aatgaagccg tttaaaagc 11760
cagcaaagct cactttggtg actttaaaaa aaaaaaaagt gacctctgg cgcaagctggg 11820
tatggaggtg acagtgactg actaggatac tgatcttgc agaggtcatt tigtgaaatgg 11880
gtggggatgc tcagagacag caggtatgaa gtaaggcaag gtcactgctg aaggaaaaga 11940
cccaccacca tcagctccc tcagagctgt acagccttt catataacga ccacttccca 12000
ggctggtaga gagaagatgg catctctaga tgcgtttt tagtctcagg gtaatttagtt 12060
cccttgagt cagttccca acttattggc tgattgggtt acctagagtc tcatgttagcc 12120
cttgaacgtc caattcttct gtctctaccc cctgagtgct ggaattacag gcaggcacca 12180
cttagccag ttccatctc atctttgtt tagaaaagtg ttccacccctt aagggggtggc 12240
cagttctgagg aagctgcacc gcgcgttagc ttccccttga cgtctctttc ctggcacttc 12300
actctgtatgg ctttcttgcc tagccatcat ggaggcaagg aaatggccag ggctgagagg 12360
ccagaaaacc cctgctctc ttgggcagag taatgtatgac ttccctgcct ggcacagtg 12420
cacacccctgt cctcgaaaag ccacaatgtt tgggcaccc gcctggatct tcctagactc 12480
agtggctgag tctgaaggga gccactttc agatttgctt gctttctgaa agccttcct 12540
ccaggcaaaag ctgaggctctg tggggcagga gaggaagggtt aaccatgggt ctgccatctt 12600
aatttgaac ttccaaggcag atgtggctt cagtcctctt ggatggcatc cccaggcaga 12660
ggcagagagt cctgtgttca tccgtccgtc cgtccccccc aacgaaaaac actacagaaa 12720
agtgtatctt ctggctctgg cctacccttc taggtctgtt ggtgttaacc agctgggatg 12780
gtgtggccccc ccgctccaga acgatccctg ccctctcctg aaagcagctt tctgtgaggt 12840
cattgctgtc cagcaacttg cggaccattc ctccagcaga gattccctt cagcttccat 12900
gcaggcctga gctaactgag ccccagcaac aggatcaaac ccattccaag aggaaggcca 12960
tctgttccctc agcctccagc tgctggccct tcatttgcaa ttggctggg agctttggag 13020
gggtcaggtc ctggggacac atctgcagtc tctgaatggt gttataactg gggcctgtct 13080
gagcagagaa aggccaagcc cttaaataaa acttgctgaa caataaaaaa ccaaagggtt 13140
agagtcaagag aagcaggagg cagcttgcctt tagttttttt cttttttttt tggttttgta 13200
gccaggcac ttgaaaacta tttttttttt cagaaagtac ttaccaagcg gagaaggggag 13260
gggctgtct gacaaggaa aatgtcatat aggatttggg catcgatctg ccccttaagg 13320
gaatttagagg gcaaataatct ccacttgagt gtatgccatt tattgaatat ttacctcagt 13380
gtcaaagagg ttagctgtt ccagatgcag ttgttaaaga gccacaggca gcatgaagtc 13440
ctctcgaact tgcctctgga atgcagttca gccttgggaa caccagccaa tctccctagt 13500
tcattgcaag caggtccccca agctgtagct gctttaggtc ctgtggttct tggcctgtc 13560
tgttagttgg ttttagggcc cttttttctt gcatccgggg gcctatgata acttagccta 13620
atgctctagg gactttctat agggaccagg ctgtaatcgg gcgtgtgact tcattgagtg 13680
gatgaatggc atttatgcag gtgttgccca cttttttttt attgacaggg tctctccctg 13740
actggaaact taccacatag gttaaagctgg ctggtgagca ggctccctgg agatgtctt 13800
gtctcattca ctacatctag gtttttttgg tttttttttt ttgtttttttt gttttttttt 13860
gtttttttttt tttttttttt ggtgggttct gaggaattaa agtgatgctt 13920
gcaaggcaag aactttatgg actgagctat ctgtcagcta tctgtcagcc cagccccca 13980
aggtacaata acctgtggc cttttggctc actggtttct tgaagcaggt attaggcctg 14040
gtctgtatga gacggagcct tcaggacccctg cagatgttta gttccacttg agaactttgc 14100
aggaatccctc gtcagggaa ggcgtgtata taagatgtga cagatttatt cacttgaaag 14160
aaagccctgg ttggagtc gaggcatgca agtggatatt ctcatggggc catcttaacc 14220
ctctgctgac tcatctactg acctgtttaga atcaggctgt gaccataaa accaagcccc 14280
aggtggctcc cgctgggtg aatatgtctg cagagcttca ggttagagcat ttggcctact 14340
gtgcacagag tttttctct cagtgtgctc ctcacatcag gtcagttag ggcacttaaca 14400
gaaagccttg gttccctct ttgtccacc gtttgcctt agctggctt tctgggtct 14460
cagggacaga gggggccgtt cagtagcacc acgttcattt tggacagcag caagccttaa 14520
gctttggctt ttggacaaag gtttcttag gttggcgtgc catcctcagc tggagggcca 14580
ggagcacccca gccagagcac tcaggccatt caggaggctg accctgggtg gaggtcctt 14640
tgcacgataa acctcggtca ttgcgttcat tttccttctt cccaccttct cagaatgtct 14700
ccacgagaca gttgggttag aatgaatatg tctgcgtgtt ctacgtggat aaaacatagg 14760
ctgtgacatc atggggatgg ggtgacggca tttgttcataa tgggaaactg gaaatctt 14820
agaagagaca tttaggtttt gaaaactgca caggagccct tcaggttagag aaacagttt 14880
ggtacagggc acagggacag gggacagagg acagacatac cgtctggcta ggcaagccac 14940
catgtgaatg aacggggggaa agagggaaa ctgggggaat gtggactcg gtaatgtatgt 15000
aaagattcc tagagagaca ctcattatag ttggggtaca ttccattcag gccttgcct 15060
ctttaggagc ccctatagca ttcccttgatg ttgttagctac gaggagcagc aacctggccc 15120
caaaagagat tcaacagact ttcccagtgg cttttgtctg cctgtggatc cagccctaga 15180

tggcaagggtt tgggactagt gtgtcctaag gagtcctgca gaccttgggg agcctgtgct 15240
 ttctcttgca agtgcgcctt caggacgcag gaggcctggg cctggctggc cagacctcg 15300
 atacagacgc ctctttgtgc ctctgagcca cgagtgcgtgg gtactttgac ataacttgc 15360
 atgccagttt ctacttcctg ggtgcatagg aatctaattgg ctgagttctc tgggacatgc 15420
 tctctcagaa caaaaagggtt cattttccag ttcttgctca agcaaagcat caacagctag 15480
 gggatttgg tagctgcgc gatttgatct ctcctcgcgt cttgggtggcc cagtggaaat 15540
 ttcagtcttg ggagtgtatg aatttgagtg cttatgttgc accaggcgc accgtgcattt 15600
 ggacactatc gtcgcatgac aggattgggg gggagagagg tgcgggtggg taaggagcta 15660
 agctgcccgc gctttgagtc taggtacccg gtgacacaat gattctttagg ccctttgcc 15720
 ttttctgcat ttttattttc tcctgggctc aggacataatt tgtttcaaac tggagggctg 15780
 tccaccctgt ttctcaaagc caaacctaaa ttacgagggg tgcgcctaaa tatgaaat 15840
 gtaatggttc ccatattgaa acatttgcta ccttctagtc ctctccgatg ggcggcttga 15900
 gccagcccaag agtttctggg gctgtccgac tactgcagct gaggtagcta ttgggtgggg 15960
 ttagtctaacc aggaacgtgt ctgaagagat gctccagcta ttgggtgtaa acaaagagcc 16020
 tgggcagccct gtcacccctc tcctctccc tagcctcacc atcctgcctt cccccacccc 16080
 cttttttat gcagccgtat ttcttgaggt tgaaaacttc catctttgtc ctgtatgggt 16140
 gttggccccc tcctctctt caggatgagt tgtacagagg ccttataagg atgctatcag 16200
 gatgtgcaag ttggcacact ggtaaaggaa aaactttgaa agagtaggag ctgcagcagc 16260
 cagctctggg atgtcgtctt tttgtctggg gacaaggcta gctaggccgc tcttcttcct 16320
 gactccacca aaggacccca ttgtccttaa tatctttat actgaactct ggtgccagct 16380
 ccatgctgac agtgcacatgc aaaaatatgt acaggagagg ctcttccaag gtcccagtc 16440
 tgccaggtgt caccgggttc taaaaggcta ggtggacatt ccagtaccat gtgcctgca 16500
 ttctgggtgt ctttgattt aagttacaaa gaaccttca agttctgtac cctgttctat 16560
 gcccagtgac cacagctcac caggccatg gagtggcagg gcatcttataat ggctcgagg 16620
 gcagagtggtt tcaacccttt gccactcacc ttgttatgaa ccagtgtcct gtgactttgc 16680
 atgacattt ggcagtcga tccccatttc ccgtcaagac tttggcagt cctgtggctt 16740
 tgctgtttat ttgtcttgta ttagatggca ctgtctgggaa gaacgcccggg ccatggatt 16800
 gtcctcgtcc cagggttcct gtgcagtcct actgggctag aggagtgcgtt ggaggtgggg 16860
 acagcttagc tggcagccc cgtcccttga caggacatgc ctgctgaagc tgccttcct 16920
 cctccaccct ctcctcccc ttccctcct gcctcctc tcctcttc tcctcatcgt 16980
 ccccttctt cttgtacgt ccctttctg ggtgaatcta ctctgattct gcttgcct 17040
 ttccagaaga atgtgtttt ggtatctgatt gtgcctgtt gggagccccc ctaagtgggg 17100
 ctgtttgagg taccctactg tatcttaac tcagatcctt tagacgctga ctaaaagaat 17160
 cattctgggg acaccctaga agtggcttgg tttgtgtgcga ggtgatttgcgtt tgcccagag 17220
 gtgggtggca gaagtggctc ttctccctg cgtatgggg aagctccat gtgatctgt 17280
 ggagacgatt ggccaggggca ggacttggac gcccattctgt tctctgtttt cagttggcg 17340
 ccatttcaga aaccacaggg gaaaagttt taggcaaaca tgataaaaat tgacagtctg 17400
 aagtgcgtct atgcgtggct tggcaactta aagcattacc tgaagcagct tctaacttcc 17460
 agacgctcta gtcgaacccgg gaaccccaag atggccatcc tggggcgct gggaaagatt 17520
 tcgtttgtgc gcagtggaggt gtcttagtct cggcccccattt tacttcttgcg aggctccctt 17580
 tcttagggtgc ctccacgaat agcaagggtgt catacccttc ccccttagt tacaggaagg 17640
 taaaatacaag ctgtcacttag tgacatcagg tgaggtccca cccagagggtt gtgacactt 17700
 tggatctgta gaaggacttg gagaagggtc aggaagattt tgcctcgtt tcccttcgc 17760
 ctgggtctga agccctctc atttcttaat cccttattacc tcccaggaa tagtggctt 17820
 agaatctttt gggaaagaaag agggctcatg gcagggttaac agtcagccac gtgtgcggaa 17880
 ttttaaagac agaatctcact tacatagccc aggtggctt tgactgcctt cactcagtag 17940
 cttagtaggc ggttaaactct gaagccgatg caggcttgcg acttatgatc ttcttaaccc 18000
 accatgtgccc accataccccc accactgttg atgtttcat tattggattt gatgctgtga 18060
 aggaacccct ttatctttt gttgtttgt tttctgagta tcagagtagt cagtcactg 18120
 aaaatatgac cagtatatacg gaaaactgtctg gcatgtctca agggtttgcg acctgtgggt 18180
 agaaaacacag ctaaggctcc acacaggaga gcctctggcc actgtttgtt ttgtcgcagg 18240
 tagaaaacacg tgagcagagc ctcccagaa agtaaatacg tgccttgcg tggcagagaa 18300
 gtttaggtaa caatgacatgt gtatggccca gctcccatgc atctttccaa gtttccattt 18360
 aattatgaaa aatgtatgag aacagacttt ctgtctgcgg aaacccctga aagagcattt 18420
 ggtgcctctg ctcgttagctt ctggaaacttt ctcccccactg tgctgtgcag agtgcagagg 18480
 gtggaaacttg gaagcgtgtg ctccggtaag ccacggcattt agaaatgtt aatccaggaa 18540
 atgttgatataat tgctataaaa gagactgttt ggatttccca gggagttcct tgcctgtgt 18600
 caattgtcac gtgttacaca gagcagcttgc gcaagggtcg gcaaggaggtt gcctgtgtgg 18660
 agaggccatc tgagtggtgg agacagggtt ggtgtggcg gacagtcct tggtgcctt 18720
 gccccttata ggacactatg aggtggttac aatatggagt tgtaacacca caggactt 18780
 aagagcaggc agtgatttttggg aggagccatg cccgaaggctt ggtgaaggat ttaggcacag 18840

aagagaagcc tttagctctc aagtctccag ggctaggcgg gagcaggatg gcatctttc 18900
 agcatgccac ttgggttcca tggcttagt gccctggcc gtgatgtatc tcatgtgtga 18960
 tccatttgc aggagctacc aactgcattt gtgcctggg atgctgttgg gttggcttt 19020
 tcttctcacc cccttattat aatccctgc tctcctgtt ctccccctc tacggtattt 19080
 gaccccttcc tttcttctg cccttctt tccctgttacc accaatctc cctactccct 19140
 aggatcacca aggaggaggt aacattgtt tctgctgacg ctgctgaccc ctaagtgggg 19200
 cctcttgaga gaaggctact agggagttgt gcattctgc tatccaaggc agatacctt 19260
 gaggaggcct tggcgtagg atggctgtat ttcataagata cttatcttc tgacgtgtt 19320
 gcagatgata ctctatactg tccccaaagc cagtcgtt cctggaaac tagagagttt 19380
 cccatttgc ccatgccaaac ctggcctcac cattgactga gtgagatggg agcccatcag 19440
 tgaaagtctt gagataaaaa atccagttgtt ttctgaagac agtggagcac cacagttata 19500
 gcttgagaac aacggcggat gactgacatt gttgtggct ggaagatcaa gtatacagcc 19560
 ggtggctccc aggcacccctt cgtataatgc cttcttgtat gttgtgggtt ggggatctt 19620
 tggctgagag gctatgcagg gcagagagga aatgagccca gtgtccctgt acccaggggca 19680
 gtgtccctt accaaacatc cagtcgtt ctcctacctga gaccctt cttctgtgtt 19740
 cctcacagca tggtgataca gtatggtaga attggtccag catggtccag tagtgcagct 19800
 aaatttcaat gagtcttggg cttttgttga tgggggtgg aggaagggtt tctccgttga 19860
 tggtagac tttaaggctc catcattttt aacattgtac gaatcttggg tttaaagatg 19920
 ttaagaccag actggcagat ggtatgagac ttaggttcaa atgaaacccc cttttccct 19980
 ctttatttctt cttccatcatc cttaaaaata tgaaccctt gtttactt gtttgctgt 20040
 ttttatttatttctt tctcaatgtt agtgtgtgt tttttttttt tttttttttt 20100
 gtgagtgcattt gtagacaaat cagccatgtt gtgtaaaggtt cagagtgcag tctggtagag 20160
 tcaattccctt cttccatcatc taccttttta agggtttctt ggaaccaaac ttggcttttag 20220
 gcaagcatgc cttccatcatc ggagccatca ttccagaact gcctctccctt cattcaactt 20280
 gccaactcagg tcagtcgcctt cttggtttta atggcagggg aaaggcctga gctgagaccc 20340
 ttccaacttgc attctcaatgc tctttcaaaac ttgggttctgt tttttttttt 20400
 ctacttcttgc gaggagactc ctatcccctc ctgcaacaga agctgaaaca ctttcgggt 20460
 gggggccacgc tatcaatgtt tggggcttgc agaccatgag aatacatacc caagtatgt 20520
 gactctggtc tgccgtata acacaaaagc agccttagac aatacatacc caagtatgt 20580
 tttagttagg cactgcttca agaagtctt gtttacaaaaa gcaagtggct gacttgcctt 20640
 tcaggccatg ctttgcgttgc ttctgtgttgc cacggggctt gtttccatgt 20700
 aacggctacc tacctgcctc acccttaaga cttccatcatc cacttcctat tttctctgag 20760
 gtttttctt acttttcat tttttttttt 20820
 ctaccctccatc ttgtgttgc tttttttttt 20880
 taaacagagg gcacatgaga taaacaagcc tttttttttt 20940
 ttgtttcttgc cccctgtttt ttgtgttgc tttttttttt 21000
 gtgtgggttgc ggtgggggtttt ttgtttccatc aacttctgtt ttcttcctt tttttttttt 21060
 acttttgc tttttttttt 21120
 ggggtcccttgc gttttttttt 21180
 agatgttttgc tttttttttt 21240
 ttgtttcttgc tttttttttt 21300
 tggaaacctgc cttttttttt 21360
 ccattcacatc tttttttttt 21420
 ggggtcccttgc tttttttttt 21480
 tttttttttt 21540
 gtgtttttttt 21600
 agttttttttt 21660
 tttttttttt 21720
 ttccagccatc tttttttttt 21780
 tcaggaggatc tttttttttt 21840
 gcaatgttgc tttttttttt 21900
 atctggctcc tttttttttt 21960
 tttttttttt 22020
 ttgtttttttt 22080
 tttttttttt 22140
 acaatcaatc tttttttttt 22200
 gttttttttt 22260
 gggcaaaatgttgc tttttttttt 22320
 tttttttttt 22380
 gtggattttttgc tttttttttt 22440
 gaaatgagcc aacccaggac agttccgttgc tttttttttt 22500

gtgtacactc gagataactt cgtataatgt atgctatacg aagtttatcg catggcctcc 22560
gcggccgggtt ttggcgccctc ccggggcgcc cccctcc acggcgagcg ctgcccacgtc 22620
agacgaaggg cgacgcgac gtcctgatcc ttccggccgg acgctcagga cagcggcccg 22680
ctgctataa gactcggcct tagaaccctt gtatcagcag aaggacattt taggacggga 22740
cttgggtgac tctagggcac tggtttctt tccagagac ggaacaggcg aggaaaagta 22800
gtcccttctc ggcgattctg cggagggatc tccgtgggg ggtgaacgcc gatgattata 22860
taaggacgca cggggtgtgg cacagctagt tccgtcgac ccgggattt ggtcgcggtt 22920
cttggttgtg gatcgctgtg atcgtcactt ggtgagtagc gggctgctgg gctggccggg 22980
gccttcgtgg ccgcggggcc gctcgggtgg acggaagcgt gtggagagac cgccaaggc 23040
tgtagtcgtt gtcgcgagc aagggtgccc tgaactgggg gttggggggc ggcagcaaa 23100
atggcggctg tccccgagtc ttgaatggaa gacgcttggg aggccccgtg tgaggtcg 23160
gaaacaaggt ggggggcatg gtggggggca agaaccctaa gtcttgaggc cttcgcta 23220
gcggggaaagc tcttattcgg gtgagatggg ctggggcacc atctgggac cctgacgtga 23280
agtttgcac tgaactggaga actcggttt tcgtctgtt cggggggccg agttatggcg 23340
gtgccgttgg gcaagtgcacc cgtacccctt ggagcgcgcg ccctcgctg tgcgtgacgt 23400
caccgggttctt gttggcttat aatgcagggt gggggccacc gccggtaggt gtgcggtagg 23460
cttttcctcg tcgcaggacg caggggtcgg gccttagggta ggctctcctg aatcgacagg 23520
cgccggaccc ctgggtgaggg gagggataag tgaggcgtca gtttcttgg tcgggtttat 23580
gtacctatct tcttaagtag ctgaagctcc ggtttgaac tatgcgctcg gggttggcga 23640
gtgtgtttt tgaagtttt taggcaccc ttgaatgtt atcatttggg tcaatatgtt 23700
attttcagtg ttagactagt aaattgtccg ctaaattctg gccgtttt gctttttgt 23760
tagacgtgtt gacaattaat catcgccata gtatatcgcc atagtataat acgacaaggt 23820
gaggaactaa accatgaaaaa agcctgaact caccgcgacg tctgtcgaga agtttctgtat 23880
cgaaaaagttc gacagcgtgt ccgacccgtat gcagctctcg gagggcgaag aatctcg 23940
tttcagcttc gatgttaggg ggcgtggata tgcctgcgg gtaaatagct ggcggatgg 24000
tttctacaaa gatcggtttag tttatcgca ctttgcacatcg gccgcgctcc cgattccgga 24060
agtgcgttgc attggggaaat tcagcgagag cctgacccat tgcatctccc gccgtgcaca 24120
gggtgtcacc tgcaagacc tgcctgaaac cgaactgccc gctgttctgc agccggtcgc 24180
ggaggccatg gatgcgattt ctgcggccga tcttagccag acgagcgggt tcggcccatt 24240
cggaaccgcaa ggaatcggtc aatacactac atggcgatgt ttcatatgcg cgattgctga 24300
tccccatgtg ttcactggc aaactgtgtat ggacgacacc gtcagtgcgt ccgtcg 24360
ggctctcgat gagctgatgc tttggccga ggactgcccc gaagtcggc acctctgtca 24420
cgccggatttc ggctccaaca atgtcctgac ggacaatggc cgcataacag cggtcattga 24480
ctggagcgag gcatgttgc gggattccca atacgaggc gccaacatct tcttctggag 24540
gccgtgttgc gcttgtatgg agcagcagac ggcgtacttc gagcggaggc atccggagct 24600
tgcaggatcg ccgcggctcc gggcgtatata gtcggcatt ggtcttgc accctatca 24660
gagcttgggtt gacggcaatt tcgatgtgc agcttgggcg caggtcgat ggcacgcaat 24720
cgccgatcc ggagccggga ctgtcgccg tacacaaatc gcccgcagaa ggcggccgt 24780
ctggaccgt ggctgtgttag aagtactcgc cgatagtggg aaccgacgccc ccagcactcg 24840
tccgaggcga aaggaatagg gggatccgc gtaagtctgc agaaattgtat gatctattaa 24900
acaataaaga tgcactaa aatggaaatgg tttctgtca tacttgcgta agaagggtga 24960
gaacagagta cttacatttt gaatggaaagg attggagctt cgggggtggg ggtgggggtgg 25020
gattagataa atgcctgctc ttactgtaa gctcttact attgctttat gataatgttt 25080
catagttgg ttcactaaat taaacaagca aaaccaaatt aaggccagc tcattcctcc 25140
cactcatgtat ctatagatct atagatctc cgtggatca ttgttttctt ctgtattccc 25200
actttgtgg tctaagtact gtggttcca aatgtgtcag ttcatagcc tgaagaacga 25260
gatcagcagc ctctgttcca catacacttc attctcagta ttgtttgcc aagttctaat 25320
tccatcagac ctgcacccgtc agcccttagc cccggataac ttgcgtataat gtatgtata 25380
cgaagttatg ctgtacta taacggccctt aaggtagcga gctagccac ctggccttga 25440
gaatggtcgt cgcctttgg ttcccttgg tgcgtatgtc tgcgtcagtc tgggtgtct 25500
actctatggc ctgttatct gttccctcc tcgtgtatctg caatctagcg cctggaaagag 25560
aaaaggagat tacagcttc ccagactacc tggagatagc tatttactgc atagggggtct 25620
tcttaatcgc ctgcgttgcgt gtgcacgtca tctttgcgg aatgaagacc acgaccaaga 25680
agccagactt cagcagccag ccagctgtgc acaagctgac caagcgcatt cccctgcg 25740
gacaggttaac agaaagttaga taaagagttt gaagaaattt actccctcc cccacccagc 25800
cagctttgg atcttcttc ctctgtatccc ccccttaact tctgtgagct ccagaactgc 25860
aggcaattct aatctgcccac tgcgtggagg ttcaactgtc ggttggact aaagagcatt 25920
aagtcaaat gctgctctgg gcttggtagg ctggctctgg ttttaaagga caagagtgt 25980
aagactggag ctgcccagtg ggtatggcag aggaggccat gcccctgcg cccctcaagc 26040
tcacggctcc ttggggagaa caagcatttgc gtctggctcc attgcttctg tatgaggcca 26100
gtatgttgcgg ttcagttttt acccttcata ggaaagagag ttaattttc ttgtattac 26160

tatttaagt agagatcaga aacagaggat ggaggtatac ctgaactaat gcttcataa 26220
aagtggctcg ttagtgcatt taaactgggt tttggctgat tttgtctgg ttttaaaacg 26280
ctgtatgcgt atagtttatt gttacagggt tggctaggaa ttcaagtata ggttggattgt 26340
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 26400
atttaggtta taagtacatg tggcagggt cctgtggaga caaaaagaga gtgtcaggc 26460
caactgtgt agagtttac acgtatagggt gtaggaattt aactctggc ttctagaagt 26520
gcagcaagca ctcttaacc actgagccag ttctccagcc cccagatacg atgattgcta 26580
tgttagaacag ggagaaaatt accttaacc tttagctgat tctttatgg ctggcttgg 26640
gggaggtaaag gcaatagaac cttccctgtg ccataaaaaca aagccctca aaggtggata 26700
aggaaaaaat gcttgacttc tgtacttgc cctggattcc aagagccagg catgtgtggg 26760
tgtaaatctt tatgataaga ttccggactt gattctgata agattgtcac tattttttt 26820
aaatttagcaa tggaaatgaa caacctggcc tggctatgg ggaggtgcac cttagtgttt 26880
gttaaaaactg catattcatt agttcaacc cttagaaattt ttatattgtt cttcttgaat 26940
ggatctgtaa gagtctgtat tttaaacact ttctcggtt atactgtgtt ataccttaag 27000
aatctctggg ttcaacccaa ccctgcctt cctggggccct ttctgtggac aaggtggaa 27060
ctagcagggtc agtagtggct tggacacagg gccttggctg ttctcaaccc acgttcacac 27120
tacaggctga gcagggtcctt gtcaacgtcc ttgaagcctc gtttccaaca ggttgggtt 27180
gcagagggtt aagatataat ttggagcata tgtcagatgc agcctttggc cagctgtga 27240
atgtggagtc aaaaaggctc agttgggtt ctttaatcc tgagaatgtt gtgctacttt 27300
gagtgacacc actgtcattt gtgggaccat agaagctaga tggtgctgaa gttaaagttt 27360
gttgccctgaa tgagttgtt gaagagtctt taataaaaact cttaccttgc tagatagtgt 27420
taaggctca ggctgaatgg ccactccctt ggccactcct ttggctactc cttcacagcc 27480
tctcctgatc tcttagccctt gggccattt taacatctgg actctggctt agggagttt 27540
ataaaaggaa gcaatgtcct gtctcattt ttttataat agagaaaaga agtaaaatcc 27600
ataagttgag gtagataggc cattgaccct taatttattt atcattttaa aaactgtatgt 27660
gtgtgtgtgt gtgttatac atgtgtgtt gagctcttgg aaagctggaa gagagcaactg 27720
gatccctcaag agctggaggg ccggtagtt tgagctctt gatgtgggtc tgggactaga 27780
actcgggtcc tctgcaagag cagcaagcgc tcctaatcac tgagccatct atctctccag 27840
cctgcatacc tttaaagaa aactctttt atttctccat ttccatattt cattccatc 27900
tttttacatt tataattttt atttataat ttatgttagt tggcacgtg tgcgtttgt 27960
tggggcattt cacatggcat agcaaggta gtgaagggtt ttttgaatg gttggccagg 28020
gacaacttac atgggagcca gcacccattt ctaccacgtg attcccaatg atcaaacagg 28080
tcaggttcag tcaggtcatc gtagtgcattt accgattttt ttgactccat cgcttttaaa 28140
gaaaaaaaaga attaacaccc attacagcgc tcttccttt gttcatgtt aaaaagacag 28200
aggccctggg gttcccgagg acatggattt agcatgtt ctttctgtt tgccaactg 28260
agtttctca ttttctgtcc acctaagctt tccattttt ttgtttttt attccctgtt 28320
tgaccggagg gaaaagttgt tttttttt tttcattttt cttcccttct tcttgattt 28380
attgttattt actgaatgtca cagtttctt tagtgcattt gcctaaatca ggactcttgg 28440
gctgggagtg tggctcaggc tggcatgtc cgccttagtt gtccaaaggct cagttatcacc 28500
aaagaaaata attaagccag tttcggttca gagaaaaggct gcccatttgc cactggctgc 28560
aaggtagtg aaggctttt tggaaatgtt cttcatgtt acgctggata acaaatgtgt 28620
gaggcccagg ctctctgtcat gaggaaaggct ctgggagata aatgggttga aaggtactg 28680
ataataccccc agcatttccctt agaagtcatg gggaaatgtt gtactaactg cctctccca 28740
aaggatttcc caaagcttag gccactggga ggaggaggag gaggaaaagg aggagaagga 28800
ggaggggaga tgcttatcat gagtctggat aaagagggtt ttgggctgtt gctggaggcc 28860
tgcatgttggg ttaatgtacatg agtgaattttt tcagggtatgc caagcatgccc ttacctggcg 28920
acagatgagc ctgtaatcatg atgtctggag gacgggtgc cccaggact aagaggctag 28980
gttttattttt gtgttaggccc aagcttctat atgatgcagg atccatgccc tggcccttgc 29040
ccaggacggc gaggaggcgc atagcctctc tccatttactt ccattttgtt cttgtttta 29100
gaacgagaaa agttgtttt tttatttcatg ctgtttttt ccatgtgcac aagcgcgtgc 29160
tcggaaatgtg tggtagtgc tacagaaatgtt gtgtgtggc caaatgataa ctttgggtt 29220
cattccctca gtcggcttcca ctccttactt tttgtgtgtt tatgtgtgtt tggtagtgc 29280
tgtgtgtgtt ctaagtttctt cacctgtttt cctgtactt ccaagtaagc taggttatct 29340
ggtctgttagt ccccaagggtc ccaatttgc ctccttctcc tcctctgtt taggatttca 29400
agtgtcggtt cccaaaggctt actcttctt ttttttctgtt gacagggtt cttgtgttag 29460
ccctggctgtt cctggaaactt actctgttgc ccaggctggc cttgtacttca gaaatccggcc 29520
tgcctctgtcc tccaaatgtt gggattaaat gcatggatca ccaccggccg gttttttttt 29580
ttttttttt tttttttt taatataatgtt ctttagggattt gctctcaggat caagggaggc 29640
aggcgttttg atccttctt ctccttgcagg tttgtttcc tggcccttgc acgtttttttt 29700
caaggcattttt actttaaaaa ggttagggctt tttttttttt ggggtggaggg ggtgggggg 29760
gttttctgtt tcaaataat tttttatgtt ctttttagtta aacattaattt tgggagaca 29820

tttgtgcttgg agtaagatac gcaacttttt ggtgggacag cctggtaggt agcctgtggg 29880
atctctaaagg aggagtcatc tctctcaccc aaggcttagga ctgggcactt tgtaagcgct 29940
tgcgcacttgc cctctacttc ttgttaccta gtgttaaatg gcaatagtca gtctagagaa 30000
gggcacccatgg tgacccaact ggaccatcag tggtaactgg gcagtggtct ttgtgtactt 30060
ctgagttccaa gtggaaagat ttgccttctg tgatttccac aagtccttg ttggggaggt 30120
gggcgtatgtg ttagtgcaga gcgggggtgga ggaagcctt ttctgtggag tgcttgttt 30180
tggaggagct ttccctggta gttcagctt ctttctggag ccagaagttt gcttagggca 30240
agatggagat ccatctgtct gtgtccagat gagtgcata gctacccgat ccccccagtct 30300
cacacaggac ttagtgcagt ttgttccag cctcagccat tgacatgggt agctgagaaa 30360
accagagagc aatttcataa tgcgtttag acccatggg attcagggtg ggctgggggg 30420
aacacttaat tccagagctg ttctcaggcc aatgtattcg tggctttaga gtatatgaaa 30480
ctcagtgaaa gtgagtgctg actgcttagc atcccagcac cgtgacctgg aatctccatc 30540
gtacgaggtg tagtcgatcc agagttgcag tgcgttggg ctggaaaca tttgggcagc 30600
tggatagttg tggatgaccc gagtggagtc ttgcgttcc tagggatcga tcgccttcct 30660
tgtcccccagt ttggcctgtc tttctctca gcccctgaaa gacatgctgc cttggctgag 30720
atccacccta gacttttgc gatgagctat aagttaggttca agaacacctg agtcaggtac 30780
ttttactgtt gtacacagggc attcaagagt ccagaggagg tagaagctgt ctaaggggca 30840
gtgtgagcaa ttacctagat ttgttatgg aaggaaaaac aaaacaaaac aaaacaaaac 30900
caaaaaactc cactcccgaga aactctctga agcttgggt ggtgcaggtt tttctgttg 30960
ccatagaggt gtgtggggct agacttaaga tagaacacac tggccctctg ttctgtatgt 31020
gaaggctcca tctgctgcct gggagtcgga ggggtgtctca agtctgctgt agtccaagggg 31080
catgtgtcaa ttctcaggaa taaagacaaa cttgactcac cttcccccgt actgtcttg 31140
cttccgcctg cgctgttgc tggaggtcc cctctgaatg ttcaagttca tccagcataa 31200
agggagacgg ctatgacttgc ttggctctt aaaaagaaaa ggggagaaaa cccacttcct 31260
ccgttaatct cccatatgtt cccgtggaaat atatgaaaag cacattttagt taaaagctt 31320
atttatggca cttgtttaaag agatcccgcc atgttaaggct gccgaattgg agactgtgaa 31380
gagtgtcggtt ctttctaaaaa accgcctgc aagatttggg gtggggatg ggggtggggc 31440
ggagcaacag ttactacag tggtagcgtt tattgtttat aagtgaactt ctaacagtg 31500
gatgtttta agtgcgttga aaggaaaact caaaaatggaa agtttctaga ttaaggattg 31560
agaactatct gaggagggaa gttataagta caagagaaaaa agaagaaaagg aagtctgtaa 31620
tacagtgggtg tggaggaacct tccaagggtgg gcgggtggggc cacaattcag agggaaaggag 31680
ccccctgaaaaa gccaggctcc tccaggacc cctgctgggg attttgccaa gccctccaga 31740
caggttgcct ttctcaggag aggccagttga agagaaagcc agtcatgctt tatacgcccc 31800
gagaggattt taaaagtata gtaaaacgc tggaggtaga attaagatgg acctctgttag 31860
acagggagag cagagtgtat gctcagagac ttgcgtatt ttcttaccct tccccactct 31920
gggtgtttt tacaaggta tttccaggc ttgtacattt aacctgaatc tgcaactgtgt 31980
attgaacaaa attcccacac atgaaggcag ttttacatt tgataccat gtgcagcaac 32040
gactgccaag gttttttttt ttttcttcc gtattagttt agttttttt tttttttttt 32100
tctcccggtt ttccattttgc aaaatgttgc cttaaaacc ttgtggaggt gctctgttg 32160
gggggtggta tgcgtatggg aaacttgcac cccaggccctg tgctgtgc tctgtttggg 32220
tcaaagggtcc tccacagagt agttgatgtc agactggatg gtaaatctct ctgttttag 32280
gtaaccctta agtcatggtc accagggga cttgtctgt ctatggttt ttcttctcc 32340
tctaattccct acattaaaaa tatataatgt ttgtcttact ggaactccag gctatcctgg 32400
ctggcagttt agggcccat ttgtttaatc agactcgca ttcaagggtga tgccatctaa 32460
aatcagaaca aactcacctt gtagagcaga ctggtagct atggctgtcc cagctcagca 32520
ataagcactt gatgctgtct tcattctgtc ctgctactc tgagaccacc tgagactcac 32580
atagaccccc ggaatctgac ttgtactca cggtaccatt gaccaggatg tagcctgcca 32640
gggcacatcttgc ccctgggtt atcaccaggt cacacattga aggtgcggaa aacatcacaa 32700
aacagcctgg ggtggggggg acaaaaaaaa agtgcctatcg ggcgtcttc tagttctaa 32760
actgaagtct gcataattca accctgtgcc ttctttctt gctgttcata ttatatttt 32820
tccaaatgtctt attttggctt aagaaaagaat gtctactaaa acacaaagga aacacaagac 32880
cagggtaata aatctatata gatgttagaaa gttctagaat aagacctgtt tcctacctg 32940
ctccctatttgc ttgtatcttc actctcttc cgaagggtgac cactgctaa tccttagata 33000
tctttccaga aaacattttcc tgcgttgcct ccaagtctt gatctcttc cccaaagggg 33060
accatggctt aacccttaga tattcctcca gaaaatgcct gtggtcacaa cccatcctgt 33120
aaggccttat gtgctgagta ctgactccca aggacaggcc acagaagctg cgatgtgcca 33180
ctagcctctg gccattacca tcattcagaa ctgtggtctt ctgagatttc tcagcatccc 33240
ctcctcactg gtcttagcac acagtgggtc ctaacaacta agcttaggaac tttagggtcc 33300
agtgtatgcag aggcaagctg atgatggccc tataaagagt atcctggctt cacacagtt 33360
ctgttgctc ttgtctccct ggggtctgtt ttgtctcatt actgggcaga ctttacttgc 33420
tttggctgtt gcttcttgc tcgttattatc ttgtgtgaat ttactata ttctacttgc 33480

gagatgattt ttgccttattt gtgtggaaag actgcccggaa agatcttaaa aattaaaaaa 33540
aattacatgc ctttgcaag cataacttgt gaggctgatt cagaatgagt caggtgggtg 33600
gttccacaga agactatgg accagctcca ttccagaatc ttctgagtcc ttgtctgt 33660
gatggagctc acgatgttt tggggccagt ggaaaatgga catcttgatg ttgtcaggaa 33720
acttctggtt tctgatgcag cctgctcacc acagtttaggc tggacaccat gcggacagt 33780
gaaggggctt gggagttatc ttttgcctg ctggatgga atgccttattc tggacaagg 33840
caagtgggtt cttagggcac tcgcgtgtt cctgctcacc ttcccctgct tgctctgcg 33900
tttgccttag agattggat ccttgaatgt atggctctt attacagaat taccagggtc 33960
cttctcttc ttcttcttt ttttaatta aaaaaaaagc atcaatttt gttgtggcac 34020
aaggagaaa tgcctgtct gcatagtata atgtatatac agcttcttct tgggtacggg 34080
tgagatggct caatggacaa aggcaattac gctgatgacc aagcctgacg ctctgtagtc 34140
aatcttcaga gcctatgtgg taggaaaaga gaactgaccc tcagaagttg tcctctgacc 34200
tccacactga tatgcacaca aacacatgca cacagataca tttttttca tttaaaaga 34260
aaatcacctt tctccttccc aaaagatact tagaaggttc agaaaagtcc ttatgtgtat 34320
tttaaataat aagatttcat atcaaaaattt gcttactgtat tttaacattt ctttggggg 34380
tttttttct tttgaggggg ggaggatagg gtctctggg ttgagcttag tgggtagcca 34440
aggataacca tcactgactt taatactgca aacactttt tcatttctt ttaagggtag 34500
ttgggtttcc aaagagcaga agggcttgcc aatgggacag tcagtcctgg gaacaacata 34560
ggaccttggg ttctctgtat gagagtcttag gatccacatg ggagagttcc tttggcttta 34620
tctttccag ctggattttag gagttttgtat actcagcagg ggattgtcac ccatgtggg 34680
gctggaaagcc tgggtgtctt gctgagtgcc tcttgcctaa cctcacaccc atgtctccgg 34740
gaccaaagcc tccgttgcgg tctgagttga aagcgtatc cagcagccca ccatcacacc 34800
aagattgtgt agtcataccca aggacacaggc tttgtgtggg ctctgggtat atttcttcc 34860
gcagaaatca gccaaggaga gacgggtgtt ttcaagata gacactgggt ctgacacagt 34920
ctgctataca tcaaggcaaa cttggtaag ccctgtgtgc tgctgggtga gagaggaccc 34980
ttccccgtgt gctctgagt aaagtatctt ttctttaacc ctgggtctcc ttttatttact 35040
gctctgctt ctgaagctaa agtgacaaga gtcagcccat tttcaactata tgggtctggc 35100
atcatcaagt ttcaagaggc ctggggagag atggagaata gcctcccggt gcctgaaact 35160
ctggatttct tgaataaaaag acctttgagt taccagaatg cccttccctt gtgtcttagt 35220
taggattta ttgctgcaaa gagacaacac aatgttaactt aaaaaaattt ttttatttgg 35280
ttatgtatata gagtgcacca tgactctt cagagacact agaagaggc atcagatccc 35340
attacagatg gttgtgagcc accatgtgtt tgctggaaat tgaactgagg acttctcaaa 35400
gagcagttgg tgctcttaac tactgagtca tctctccagc ccccaactgca actcttataa 35460
agaaaacacac ttaattgggg cttgcttaca gtttcagagg ttttagttcat tattgtcatg 35520
gtggaaagca tggcagcttc ctggcagaca cagtgctggg gagagaagaa gctgagagtt 35580
ctacatctt acccacaggc agcagaaggg gattgtgtgc cataactctt gaggttttag 35640
caaaggaaac ctcaaaagccc gccccacag tgagaaactc cctccaacaa gcccacatgt 35700
tctctagcaa gcccacaccc cctaatacg cctatggggc aggtattcaa accaccacac 35760
catacatatc ttacagctt ttccttgaga tctttcttta tactttggag gcaatggcag 35820
cacggatgac ctcaactgtt agatgtttgtt gaatccctcc ctgctgactt gatttggat 35880
gtgtttttat ttatgggtc tggacattgt acatgagaca agcatctgtt aattgagccc 35940
agccttgag tttagtgcattt ataggctgag caaaaaaacta taatgaagtc agtagagtt 36000
gtctgcacat tttaagtgg ctgtcttaaa acaattaagg taaggggctg gagagatgt 36060
tcctcgctt agagcactgg ctgctcttcc agaggacctg gttcagttc ccagcaccca 36120
tatggcagct cacaactgtc tataccctca gttccagttc gacatcctca catagacata 36180
catgcaggca aaacaccaat gtacattaaa aaaaacacct aattttttaa aagttcagat 36240
gaaaagaaga aatactatga ttaaacttctt agaaacattt ctatttgcattt acttgaccc 36300
ccaaggtaaa ggatcctgtt acttcttccatt tttggccctt tattttgtt ttttgggtt 36360
ttttgtttgtt ttgtttgtt ttttgtttgtt tgtttagttt agtttctgt ttttgggtt 36420
gtccttccctt gttccttcc cctttctttt taaaacttcc taaaacttcc ttttgggtt 36480
tcacttccag cttcctcttga tggagccagc attacatctt ctggttttgc ttttgggtt 36540
aggtttccggc cgagtccagc tcctccatgtt actccaaaccc cccgtgggtt aggataacaa 36600
cgcgtctgtc ctcaacagcg gacaccccgat tgcttagcagg ggtctccgag tatgagttgc 36660
cagaggatcc aaagtggaa ttcccagat ataagtaatg actctccctc tgggagggtc 36720
gttgcgtgc tttccctgggat ctgagcgcag gtcttgggtt tgggagttc caccctgtgc 36780
ttggtaatca gggacctgtt tcttggtaat cagggacctt cgaactgtaa actgtaaact 36840
gtaaactgca gcaagatggt gcaatttaca gagctgtctgg tgccacagggtt aggctaccag 36900
cctgtccctt tgaggtggaa gaccaacattt agctctgggat agtgaggatc ctggaaggct 36960
ggcagcttcc ttcttgcattt attagcgtt aaacagctt agagtaacag aaggtggaaa 37020
aatgggtctt ttctgcattt aagacacagg aatacgctt cagcttgcattt gaagacaact 37080
cgtctgcctt ttttgcattt ttcttgcattt cttccttgcattt ttgttagtq tatgttttaac 37140

acacacagcg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tatacagaga 37200
 ttcagaaaca caaagacaag cttcccaag tctgggtatg gccagctcta gttgaaagtt 37260
 gaaggaagct taggccccct tggagcttcg tgcacacta ttccaggat tttggttccc 37320
 aacttagaga tcttacata tattcaatac cagggccgag gaactgtctg ttagtcatc 37380
 ttatgtcagt ggaaagaatt tccagttct ttatatactg cagtaaaag agcattcatt 37440
 cattcctca ttcatccgg gaatgtttag tggacatttt tgggtgagg tatgaaagaa 37500
 aacacaaaga atggcttctt tacctataga attttgagaa aggaaggat gtttctctt 37560
 acccttgcca gcctccttagc tgggtgtat tataaaaata gctgggtcg tgcacatt 37620
 cctatgtcta caaggctgga ctggggagtt gtgcctat gctaaaaact tgcagcttc 37680
 gggttgagcc tggcttgg gccacctgtg acaccacagt caacagtgtg agtctgttt 37740
 gcccagcagc tcccaccccg gggtaaaaaa gtgtggaaaa tctgagcgct atgcatttc 37800
 aagcagtgtt tagcacaaat gtaggtggag cacattccca atgaatgaag gctatTTAGA 37860
 aatggtttat taggtggag gcaggagta cacaagaga ggttggat ggtttagt 37920
 acaggggcaa taggacataa attagccatt ttccaaacgca aatgtttatt ttctgccaag 37980
 atgttcaatt taatTTAGT tcttgcactgg aaagggggcg cttcagcag agcaagtgc 38040
 ggtatccatt ttctttcct tttttagt tttaaaagcg ttgcgtgctt actgcaaattg 38100
 ctgtttactg aggacagctc aatacttgc tggactggc ttatggttt ttgggggg 38160
 tttttttaa aacaaaacaa aacaaaacaa aacaaaacac cccgaaaagc atactcaggc 38220
 tggagaggtt tctctctgg ctaaaggcaga cactgcccgt taaaggacca gagttcggtt 38280
 cccagcaccc atgatgtgta gtcacaaacc tctgtacta cagatctgg gaatctgtt 38340
 gggctctta ggtgcctgtc ctcacatgcc cataccctct ccccgaaaac acacatacac 38400
 ataatcaaga ataaattgaa aaaaaataaa aataaaaaac acactctaa gtattaattc 38460
 caaagacttc cctgttcctt tggcttctgg aacatctaa ataatgtcag gtcatttgc 38520
 tgggtgtat aaaacttaca tgcttagaaa tgtaacttgc gctgttttctt atttttttt 38580
 ttccttgc tttttttttt actttggta gtgataagga atcctaaact tatgtcaaaa aggtatcg 38640
 cctgattttt agaagttttt ctaatgaga cacgataaaat tatttggaaac gtgctgaaga 38700
 ttccttaccct gcaactggc aatcgatgta accataaaat ctaccggat tgaataatag 38760
 tgatttgaga gttgccactt tacagggaca gaaaataaga acagactttc actttttttt 38820
 tcacctctgc gacattttaa attataataa ttttatttgc tcaagacca aagctcccta 38880
 tggctggcat gcagggagcc tgaccaccgc gctagcaagg acaccttcca taaagaaaaa 38940
 gaaaataaaat cgagaggaca aatgtgaaat ttaatagttcc ctccaacagt aattgacgtt 39000
 ctggaaaaac atcactaaga aaatgcctg cgtgtgtatc ggaggctcat tggttccata 39060
 tgcattgc tggaaagattt ttatatttgc ttcttgcattt tccctccctg tgccctcg 39120
 ccagactcgc ggtgtgttac tcccgtattt acacattttg gctgacgctg ggcaaaacccc 39180
 tgggggaagg ttgttcggg caagtagtca tggctgaaac agtggaaatc gataaagaca 39240
 aacccaagga ggcggtcacc gtggcagtga agatgttggaa aggtgagtgg gggatgggc 39300
 ggtcggggag gaggggtct tatcaggagc gagcgttccct tttgtgacat gtgaactctg 39360
 cagggacgtg gggtaagaga gcacatactt gacctggcg ttgaggggtt ttcaggata 39420
 aatgagcaaa tgagatggag gatttacctt gagctgtgtg tacttaaaaa gaaaagccag 39480
 ttttagcaga agttgttagt tgcgggcgc aaccggctc taactccta gaaaagggtc 39540
 ccgattctct tctttctgt gtgttcatgg gtttagaaag ttttaggggtt ttatTTAGT 39600
 ggttaaattt tggaccctt ctttaacat acaaataagg agaggttagt gttggagtgg 39660
 caactggaga cagaatgtca aatgtggat tcaaagagtc gcttagaagc caaaaaggag 39720
 caaacaattt gaactgtatgc agaatcccag ggacatgtaa acaataatgc cagctataa 39780
 atgcccgc ttttttttgc ttttttttgc ttttttttgc tttttttttt ttttagggga 39840
 gggggggggg ggggtctgg gaatttattcc acaacccctt taacacagct tgatgtgac 39900
 gcccaaggag cttaaattgc tttcaactat taacttattcc ttgcattggg attctttat 39960
 cgaagagata aaggaaaagg tcacattata aatcctgtt gttggaaatc tcagaaagga 40020
 gaaaggagcc atgttcaatg tttccctggc ttgtggcag agaagtctgt cccggccctg 40080
 tggatgtgg catgttctca ggagtccgac cttttctctc ttgtatggaa cacttaccac 40140
 atccctccctt gatgcagaca acaaaggggc aggacatggt tcattttgtc agtttagtt 40200
 attgacctga gactcccagt gaaatctggg atgttccctt ctttggagac tgataccagg 40260
 aaggagataa caagtatcgg ggcaccaggc cagaggcagc ctttggatcc tactggaaagc 40320
 tggatgtgg gaaggatcg gcatcatact gctttccaca gaaaccttgg ttttggatcc 40380
 cttggagctt gtcggaaagg gaggtttagg gttggccct tcccttttgc caagatcacc 40440
 caccatcctt ttcatcgtgg tcagaggaca tgcctttca acatttttgc tgacagccag 40500
 agatggctg aggtgttgg aagacaagtg tactgagcc tttgttgc tttttttttt 40560
 tcttccctct tctctgttatt ggtcaggata gattttggaa tacctgttgc tttttttttt 40620
 ttttaaccct ttttttttgc ttttagctca gattttttttt ttcttaagttat ttctgtattt 40680
 aatttagctt gtcacagaac acttgcgtgg tttttttttt gttttttttt tttttttttt 40740
 cattacaaga atccaaacgca cagcagaact aactgagagg agagcacagt agcggccgca 40800

aattgcttg agaggctcta taaaacctta gaggctattt aaatttaaat ggccggcccg 40860
 acggccaggc ggccgccagg cctaccact agtcaattcg ggaggatcga aacggcagat 40920
 cgcaaaaaac agtacataca gaaggagaca tgaacatgaa catcaaaaaa attgtaaaac 40980
 aagccacagt tctgactttt acgactgcac ttctggcagg aggagcact caagcctcg 41040
 cggaaagaaaa taaccaaaaaa gcatacaaag aaacgtacgg cgtctctcat attacacgccc 41100
 atgatatgct gcagatccct aaacagcagc aaaacgaaaaa ataccaagtgc cctcaattcg 41160
 atcaatcaac gattaaaaat attgagtctg caaaaggact tgatgtgtgg gacagctggc 41220
 cgctgcaaaa cgctgacgga acagtagctg aataacaacgg ctatcacgtt gtgttgc 41280
 ttgcggaaag cccgaaagac gctgatgaca catcaatcta catgtttat caaaaggctcg 41340
 gcgacaactc aatcgacagc tggaaaaacg cgggcccgtgt cttaaagac agcgataagt 41400
 tcgacgcca cgatccgatc ctgaaagatc agacgcaaga atggtccggc tctgcaac 41460
 ttacatctga cggaaaaatc cggttattct acactgacta ttccggtaaa cattacggca 41520
 aacaaagcct gacaacagcg caggtaaatg tgtcaaaatc tgatgacaca ctcaaaatca 41580
 acggagtggc agatcacaaa acgatttttgc acggagacgg aaaaacatata cagaacgttc 41640
 agcagtttat cgatgaaggc aattatacat ccggcgacaa ccatacgtg agagaccctc 41700
 actacgttga agacaaaggc cataaatacc ttgtattcga agccaacacg ggaacagaaaa 41760
 acggataccca aggcgaagaa tctttatata acaaagcgtt ctacggcggc ggcacgaact 41820
 tcttccgtaa agaaagccag aagcttcagc agagcgttca aaaaacgcgtat gctgagttag 41880
 cgaacggcgc cctcgttatac atagagttaa ataatgatta cacattgaaa aaagtaatga 41940
 agccgctgtat cacttcaaac acggtaactg atgaaatcga ggcgcgcaat gtttcaaaa 42000
 tgaacggcaa atggtaacttgc ttcactgtt cacgcgggtc aaaaatgacg atcgatggta 42060
 ttaactcaaa cgatatttac atgcttgggtt atgtatcaaa ctcttaacc ggccttaca 42120
 agccgctgaa caaaacaggg ctgtgtctgc aaatgggtct tgatccaaac gatgtgacat 42180
 tcacttactc tcacttcgca gtgccgcaag ccaaaggcaaa caatgtgggtt atcacaagct 42240
 acatgacaaa cagaggcttc ttcgaggata aaaaggcaac atttgcgcca agcttcttaa 42300
 tgaacatcaa aggcaataaa acatccgtt tcaaaaacag catcctggag caaggacagc 42360
 tgacagtcaa ctaataacag caaaaagaaaa atgcccgtatc ttcatggca ttttcttta 42420
 tttctcaaca agatggtaa ttgacttagt ggtagatcca caggacgggt gtggcgcca 42480
 tgatcgcgtt gtcgatagtg gtcgatgtt gtcgatgtt gtcgatgtt gtcgatgtt 42540
 agcggctggc cagtgtccg agaacgggtt cgcataaaaa ttgcatcaac gcatatagcg 42600
 cttagcagcac gccatagtga ctggcgatgc tgcggatgc gacgatatacc cgcacggaggc 42660
 ccggcgttac cggcataacc aagcctatgc ctacagcatc cagggtgacg gtggcgagga 42720
 tgacgttgcg cgcattgtt gatttcatc acgggtcctg actgcgttag caatttaact 42780
 gtgataaaact accgcattaa agcttacatc tgataagctg tcaaacatga gaattgatcc 42840
 ggaaccctta atataacttc gtataatgtt tgctatcga agttattagg tccctcgact 42900
 atagggtcac cgtcgacagc gacacacttgc catcgatgc agcccggtt acgtgcccggc 42960
 acggccctggg taaccaggta tttgtccac ataaccgtgc gcaaaatgtt gtggataagc 43020
 aggacacacgc agcaatccac agcaggcata caaccgcaca ccgaggttac tccgttctac 43080
 agtttacgac gacatgtcaa tactgcccgtt tgacaggcat tgatggaaatc gtagtctcac 43140
 gctgatagtc tgatcgacaa tacaagtggg accgtggtcc cagaccgata atcagaccg 43200
 caacacgagt gggatcgtgg tcccagact ataatcagac cgacgatcgt agtgggaccg 43260
 tggtcccaga ctaataatca gaccgacgtt acgagtggga ccgtgggtcc agactaataa 43320
 tcagaccgac gatacgtgtt ggaccgtgtt cccagactaa taatcagacc gacgatacga 43380
 gtgggaccat ggtcccgac taataatcgtt accgacgata cgagtgggac cgtggccca 43440
 gtcgttattt cagaccgacg atacgagtgg gaccgtggc ccagactaat aatcagaccg 43500
 acgatcgtgg tgggaccgtt gtcggactt aataatcgtt ccgacgatac gagtgggacc 43560
 gtggtcccgg tctgattttc agaccgacg tacaagtggg acagtgggccc cagagagaat 43620
 attcaggcca gttatgtttt ctggcctgtt acaaaggaca ttaagtaaag acagataaaac 43680
 gtagactaaa acgtggcgtc atcagggtgc tggctttca agttccttaa gaatggcctc 43740
 aattttctct atacactcgtt tggaacacg agacgtgtcc aggttaagca ccatttttac 43800
 gcccttatac aataactgtcg ctccaggagc aaactgtatgt cgtgagctt aactgttct 43860
 tgatcgtcgtt gacgttttaa gcacagaatg taaaagagtg ataacttctt cagctcaaa 43920
 tatcacccttca gcttttttct gctcatgtt gttatgtcc tgctgcttaa gtaattcctc 43980
 ttatctgtt aaggctttt gaagtgcattt acctgaccgg gcagatagtt caccgggtg 44040
 agaaaaaaa gcaacaactg atttaggcaaa tttggcgggtt tgatcgtcgtt ggtataataat 44100
 cttagtggaa atatttccg catcggccat cgcacggataa ttccagcaaa attcattctg 44160
 caatcggctt gcataaacgtt gaccacgtt ataacgttcc gttggcgat aatcgatc 44220
 caatctggat aatcgaccca tctgctcatc atccagctcg ccaaccgaaa caccataatc 44280
 acatttcggta agtgcagcagc cttagcgtt ggcactccca tcggcaattt ctatgacacc 44340
 agataactctt cgaccgaacg ccgggtgtctg ttgaccgtt agtagaaaaag aagggtatgag 44400
 atcatccatg gctccctcgtt taagcgttcc gtcgttccatc accatacccg 44460

agaggcttc tcaacactat caccggag cacttcaaga gtaaacttca catccgacc 44520
acatacaggc aaagtaatgg cattaccgcg agccattact cctacgcgcg caattaacga 44580
atccaccatc gggcagctg gtgtcgataa cgaagtatct tcaaccgtt gagtatttag 44640
cgtatgttt ggaataacag ggcacgcctt cattatctaa tctccagcg tggttaatc 44700
agacgatcga aaatttcatt gcagacaggt tccaaatag aaagacatt tctccaggca 44760
ccagttgaag agcgttgc tccaaatag aaagacatt tctccaggca 44760
ttaccaactt catccgttcc acgtacaaca ttttttagaa ccatgcttcc ccaggcatcc 44880
cgaatttgct cctccatcca cggggactga gagccattac tattgtgtt tttggtaaagc 44940
aaaatacgta catcaggctc gaacccttta agatcaacgt tcttgcgcg atcacgaagc 45000
atatcgaaaa actgcagtgc ggaggtgttag tcaaaacaact cagcaggcgt gggacaatc 45060
agcacatcag cagcacatac gacattaatc gtgcccatac ccaggttagg cgcgtgtca 45120
ataactatga catcatagtc atgagcaaca gtttcaatgg ccagtcggag catcagggt 45180
ggatcgggtgg gcagtttacc ttcataat ttgcccatta actcagttt aatacgggtc 45240
agagccagac aggaaggaat aatgtcaagc cccggccagc aagtgggctt tattgcataa 45300
gtgacatcgt cttttcccc aagatagaaa ggcaggagag tgcgttctgc atgaatatga 45360
agatctggta cccatccgtg atacatttag gctgttccct gggggcgtt accttccacg 45420
agcaaaacac gttagccctt cagagccaga tcctgagcaa gatgaacaga aactgagg 45480
ttgttaacgc cacctttatg ggcagcaacc cggatcaccc gtggaaatac gtcttcagca 45540
cgtcgcaatc gcgtaccaaa cacatcacgc atatgattaa ttgttcaat tgcgttacca 45600
acacgttgct caaccctgtcc tcgaatttcc atatccgggt gcggttagtgc ccctgccttc 45660
tcggcatctc tgatagccctg agaagaaacc ccaactaaat cgcgtcctt acctatttctc 45720
cagcgcggg ttatccctt cgcgttccggg ctgtcatcat taaactgtgc aatggcgata 45780
gccttcgtca ttcatgacc agcgtttagt cactggttaa gtgttccat gagtttcat 45840
ctgaacatcc ttaatcatt gcttgcgtt ttttattaa atcttgcatttactgcaat 45900
gcaacaacaa aatcgcaaaag tcatcaaaaa accgcaaaagt tgttttaaat aagagcaaca 45960
ctacaacaaagg agataagaag agcacatacc tcagtcattt attatcacta ggcgtcgcc 46020
cagccgtgtt accgagcata gcgagcgaac tggcgaggaa gcaaaagaaga actgttctgt 46080
cagatagctc ttacgctcg cgcgaagaaga aatatccacc gtggggaaaaa ctccaggtag 46140
aggtacacac gggatagcc aattcagagt aataaaactgt gataatcaac cctcatcaat 46200
gatgacgaac taaccccgta tatcaggtca catgacgaag gggaaagagaa gggaaatcaac 46260
tgtgacaaac tgccctcaaa tttggcttcc ttaaaaatta cagttcaaaa agttagagaa 46320
aatccatgca ggctgaagga aacagcaaaa ctgtgacaaa ttaccctcag taggtcagaa 46380
caaatgtgac gaaccaccct caaatctgtg acagataacc ctcagactat cctgtcgtca 46440
tggaaagtgtat atcgcggaaag gaaaatacga tatgagtcgt ctggcggcct ttcttttct 46500
caatgtatga gaggcgcatt ggagttctgc tttgtatctc attaacacag acctgcagga 46560
agcggccgccc gaagtccaggc atacgctgtt aactttgagg cagctggtaa cgctctatga 46620
tccagtcgtat ttccagagag acgtgcctt agccatccgg cttacgatac tgacacagg 46680
attcgtataa acgcattggca tacggattgg tgatttctt tgtttcaacta agccgaaact 46740
gcgtaaaccg gttctgttaac ccgataaaga agggaaatgag atatgggtt atatgtacac 46800
tgtaaagccc tctggatggc ctgtgcgcac gtttgcataaa ccaaggaaaaa gattcatagc 46860
ctttttcatc gccggcatcc tcttcaggcc gataaaaaac cacttcctt cccgcgaaac 46920
tcttcaatgc ctgcccgtata tccttactgg cttccgcaga ggtcaatccg aatatttcag 46980
catatttagc aacatggatc tcgcagatac cgtcatgtt cttgtagggtg ccatcagatt 47040
ttctgtatctg gtcaacgaaac agatacagca tacgtttttg atccgggag agactatatg 47100
ccgcctcagt gaggtcggtt gactggacga ttgcggggtt attttacgt ttcttgcgt 47160
tgataaccgc tggttccgccc atgacagatc catgtgaagt gtgacaagtt ttttagattgt 47220
cacactaaat aaaaaagagt caataagcag ggataacttt gtgaaaaaaac agcttcttct 47280
gagggcaatt tgtcacaggg ttaaggcata tttgtcacaag acaggactgt catttgaggg 47340
tgatttgtca cactgaaagg gcaatttgc tcaacacccct ctctagaacc agcatggata 47400
aaggcctaca aggccgtcta aaaaagaaga tctaaaaact ataaaaaaa taattataaa 47460
aatatccccg tggataagtg gataacccca agggaaagtt tttcaggcat cgtgtgtaa 47520
cagaatataat aagtgtgtt ccctgtgtt tcctcgctca ctcgagggtt tcgcctgtc 47580
gctcaactgc ggcgagcact actggctgtt aaaggacaga ccacatcatg gttctgtgtt 47640
cattagtttgc ttctgtccat tgctgacata atccgctcca cttcaacgtt acaccgcacg 47700
aagatttcta ttgttccgtt aggcataatc aaatcggtt ctttaccgtt tgccgttgc 47760
atgacagaac actacttctt ataaacgcgtt cacaggctcc tgagattat aatgcggatc 47820
tctacgataa tggagattt tcccgactgt ttcgttgcgt tctcgtgtt taacagccag 47880
cttctctgtt taacagacaa aaacagcata tccactcgt tccacatttcc catataaaagg 47940
ccaaggcatt tattctcagg ataattgttt cagcatcgca accgcattcag actccggcat 48000
cgccaaactgc acccggtgcc gggcagccac atccagcgca aaaaccttcg tgtagacttc 48060
cggtgaactg atggacttat gtcccatcgac gcttgcaga actttcagcg gttatccggc 48120

atacagcatg tgcacatcgcat aggaatggcg gaacgtatgt ggtgtgaccg gaacagagaa 48180
 cgtcacaccc tcagcagcag cggcgcaac cgcctccca atccagggtcc tgaccgttct 48240
 gtccgtcact tcccagatcc gcgctttctc tgcgttctt gtgcgacggc tacgcccgtc 48300
 catgagctta tcgcaataa atacctgtga cggaaagatca cttcgagaa taaataaaatc 48360
 ctgggtgtccc tggatacc gggaaaggcct gggccaactt ttggcgaaaaa ttagacgttg 48420
 atccggcacgt aagaggttcc aactttcacc ataatgaaat aagatcacta ccggggcgtat 48480
 tttttgagtt atcgagattt tcaggagcta aggaagctaa aatggagaaa aaaatcactg 48540
 gatataccac cggttatata tcccaatggc atcgtaaaga acatttttagt gcatttcagt 48600
 cagttgctca atgtacctat aaccagaccc ttcaagcttga tattacggcc tttttaaaga 48660
 ccgtaaagaa aaataaggcac aagttttatc cggcctttat tcacattttt gcccgcctga 48720
 tgaatgctca tccggagttc cgtatggcaa taaaagacgg tgagctgggat atatgggata 48780
 gtgttacccc ttgttacacc gttttccatg agcaaactga aacgtttca tcgctcttgg 48840
 gtgaataccca cgacgatttc cggcagttc tacacatata ttgcgaagat gtggcgtgtt 48900
 acgggtaaaaa cctggccstat ttccctaaag gttttattga gaatatgttt ttcgtctcag 48960
 ccaatccctg ggtgagttc accagtttg atttaaacgt gccaatatg gacaacttct 49020
 tcgccccctg ttccaccatg ggcaaatatt atacgcaagg cgacaaggtg ctgatgcccgc 49080
 tggcgattca gtttcatcat gccgtttgtt atggcttcca tgcggcaga atgcttaatg 49140
 aattacaaca gtactgcgtt gatggcagg gcggggcgtt attttttaa ggcagttatt 49200
 ggtgcctta aacgccttggt tgctacgcct gaataagtga taataagcgg atgaatggca 49260
 gaaattcgat gataagctgtt caaacatgag aattggcgtt cggcgccca aagcttgcatt 49320
 gcctgcagcc gcgtaacctg gcaaaatcgg ttacgggtt gtaataaaatg gatccctgc 49380
 gtaaggcgccc cacatttcat taccttttc tccgcacccg acatagataa taacttcgtt 49440
 tagtatacat tatacgaagt tatcttagtag acttaattaa ggatcgatcc ggcgcgccaa 49500
 tagtcatgccc cgcgcgcac cggaaaggagc tgactgggtt gaaggctctc aagggcattcg 49560
 gtcgagctt acattgttagg actatattgc tctaataat ttgcggccgc taatacgaact 49620
 cactataggg a 49631

<210> 18
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 18
 ggaaagccac cctgtatgtc

20

<210> 19
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 19
 ctggccaac agtggatgg

19

<210> 20
 <211> 42
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Synthetic

<400> 20
 cuaaaaugau ucucaucugc guuuuagagc uaugcuguuu ug

42

<210> 21

23 Dec 2016

2015280120

<211> 42
<212> RNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 21
gcucucaacu ucaccuuuc guuuuagagc uaugcuguuu ug 42

<210> 22
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 22
ctaaaaatgat tctcatctgc agg 23

<210> 23
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic

<400> 23
gctctcaact tcacccttgc tgg 23

<210> 24
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic- a target locus that is linked to a
guide RNA (gRNA)

<220>
<221> misc_feature
<222> 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21
<223> n = A,T,C or G

<400> 24
nnnnnnnnnnnnnnnnnn nngg 23

<210> 25
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic- a target locus that is linked to a
guide RNA (gRNA)

<220>
<221> misc_feature

<222> 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23
<223> n = A,T,C or G

<400> 25
ggnnnnnnnn nnnnnnnnnn nnngg

25